<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-orange ">
                        40.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=40.0 class=" progress-orange ">40.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-red ">
                        0.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=0.0 class=" progress-red ">0.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-orange ">
                        50.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=50.0 class=" progress-orange ">50.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-red ">
                        0.0%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=0.0 class=" progress-red ">0.0%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">40%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content"> Improve the Generator&#39;s performance on simple questions related to the &#39;Others&#39; topic, as it currently performs poorly compared to complex and double questions. Additionally, enhance the Router&#39;s ability to accurately identify simple questions to ensure they are directed to the appropriate components for optimal responses.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"b1b796c1-4d4d-4896-b0fe-9756b8167f63":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p1469","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p1471","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p1478","attributes":{"factors":["APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE for HIV-1 PrEP","ATRIPLA Warnings and Side Effects","Others","The provided text appears to be a table of pharmacokinetic data for various antiviral drugs, including protease inhibitors (e.g., Atazanavir), integrase inhibitors (e.g., Simeprevir), and NS5A inhibitors (e.g., Sofosbuvir/Velpatasvir). The table shows the changes in pharmacokinetic parameters for each drug when coadministered with Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor.\\n\\n   The data includes the mean percentage change of various pharmacokinetic parameters, such as AUC (Area Under the Curve) and Cmax (Maximum Concentration), for each drug when coadministered with EFV at different doses. Some drugs show increased concentrations (e.g., Sofosbuvir/Velpatasvir), while others show decreased concentrations (e.g., Tipranavir/Ritonavir).\\n\\n   The table also includes the dose of each drug and EFV, as well as any additional information such as meal requirements or duration of administration. It is important to note that all interaction trials were conducted in healthy volunteers.\\n\\n   This data can be useful for pharmacists, physicians, and other healthcare professionals when prescribing these drugs to patients, as it helps them understand potential drug interactions and adjust dosages accordingly to ensure safe and effective treatment."]}},"x_scale":{"type":"object","name":"LinearScale","id":"p1479"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p1480"},"title":{"type":"object","name":"Title","id":"p1476","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1498","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1466","attributes":{"selected":{"type":"object","name":"Selection","id":"p1467","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1468"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"AAAAAAAAWUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAWUAAAAAAAAAAAA=="},"shape":[5],"dtype":"float64","order":"little"}],["metadata_values",["APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE for HIV-1 PrEP","ATRIPLA Warnings and Side Effects","Others","The provided text appears to be a table of pharmacokinetic data for various antiviral drugs, including protease inhibitors (e.g., Atazanavir), integrase inhibitors (e.g., Simeprevir), and NS5A inhibitors (e.g., Sofosbuvir/Velpatasvir). The table shows the changes in pharmacokinetic parameters for each drug when coadministered with Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor.\\n\\n   The data includes the mean percentage change of various pharmacokinetic parameters, such as AUC (Area Under the Curve) and Cmax (Maximum Concentration), for each drug when coadministered with EFV at different doses. Some drugs show increased concentrations (e.g., Sofosbuvir/Velpatasvir), while others show decreased concentrations (e.g., Tipranavir/Ritonavir).\\n\\n   The table also includes the dose of each drug and EFV, as well as any additional information such as meal requirements or duration of administration. It is important to note that all interaction trials were conducted in healthy volunteers.\\n\\n   This data can be useful for pharmacists, physicians, and other healthcare professionals when prescribing these drugs to patients, as it helps them understand potential drug interactions and adjust dosages accordingly to ensure safe and effective treatment."]],["colors",["#006837","#a50026","#a50026","#006837","#a50026"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1499","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1500"}}},"glyph":{"type":"object","name":"HBar","id":"p1495","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1496","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1497","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1507","attributes":{"data_source":{"id":"p1466"},"view":{"type":"object","name":"CDSView","id":"p1508","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1509"}}},"glyph":{"type":"object","name":"HBar","id":"p1504","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1505","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1506","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1517","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p1511","attributes":{"selected":{"type":"object","name":"Selection","id":"p1512","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1513"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p1518","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1519"}}},"glyph":{"type":"object","name":"Line","id":"p1514","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p1515","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p1516","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1477","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p1491","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p1486","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p1487"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p1488"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1489"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1481","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1482","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1483"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1484"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1485","attributes":{"axis":{"id":"p1481"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1490","attributes":{"dimension":1,"axis":{"id":"p1486"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p1510","attributes":{"location":40.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p1520","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1521","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p1517"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"b1b796c1-4d4d-4896-b0fe-9756b8167f63","roots":{"p1469":"f315e9f0-9cfb-4c2d-ab20-2d35cbb371b1"},"root_ids":["p1469"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="f315e9f0-9cfb-4c2d-ab20-2d35cbb371b1" data-root-id="p1469" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"2ef2386e-ee33-4b8c-8607-2fc0dc12e15d":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p1400","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p1330","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p1265","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1274","attributes":{"start":0.07415413856506348,"end":12.280063152313232}},"y_range":{"type":"object","name":"Range1d","id":"p1275","attributes":{"start":-1.5933003723621368,"end":10.915313482284546}},"x_scale":{"type":"object","name":"LinearScale","id":"p1276"},"y_scale":{"type":"object","name":"LinearScale","id":"p1277"},"title":{"type":"object","name":"Title","id":"p1272","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1305","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1262","attributes":{"selected":{"type":"object","name":"Selection","id":"p1263","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1264"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[460],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[460],"dtype":"float32","order":"little"}],["topic",["ATRIPLA Drug Information","ATRIPLA Drug Information","Others","ATRIPLA Drug Information","ATRIPLA Warnings and Side Effects","Others","Others","Others","ATRIPLA Drug Information","ATRIPLA Drug Information","Antiretroviral Therapy Side Effects","ATRIPLA Drug Information","ATRIPLA Drug Information","Others","ATRIPLA Drug Information","Others","ATRIPLA Drug Information","ATRIPLA Warnings and Side Effects","Others","Antiretroviral Therapy Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Drug Information","ATRIPLA Drug Information","Others","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","ATRIPLA Warnings and Side Effects","Others","ATRIPLA Drug Information","Others","Others","Others","ATRIPLA Drug Information","ATRIPLA Drug Information","ATRIPLA Drug Information","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy Side Effects","Others","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Others","Others","Others","Others","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","Others","Others","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","Others","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","Others","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","Antiretroviral Therapy (ART) and Birth\\nDefects","ATRIPLA Drug Information","Others","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Pharmaceutical Trials","ATRIPLA Drug Information","ATRIPLA Drug Information","ATRIPLA Drug Information","ATRIPLA Drug Information","ATRIPLA Drug Information","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Others","Others","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Others","Others","Others","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","Others","Others","Others","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug).","Others","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","Others","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Resistance","Antiretroviral Resistance","Others","Antiretroviral Resistance","Antiretroviral Resistance","Antiretroviral Resistance","Antiretroviral Resistance","Antiretroviral Resistance","Antiretroviral Resistance","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Antiretroviral Therapy (ART) and Birth\\nDefects","Others","Others","Antiretroviral Therapy (ART) and Birth\\nDefects","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","ATRIPLA Warnings and Side Effects","Others","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Drug Information","ATRIPLA Drug Information","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","Others","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","ATRIPLA Warnings and Side Effects","Others","Others","Others","Others","Others","ATRIPLA Warnings and Side Effects","Others","Others","Others","Others","Others","HIV Treatment and Administration","APRETUDE Drug Information","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE HIV-1 PrEP Injection Schedule","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","Others","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","Others","Cabotegravir Pharmacokinetics and\\nInteractions","Others","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE for HIV-1 PrEP","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE HIV-1 PrEP Injection Schedule","Others","Others","Others","Others","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE for HIV-1 PrEP","APRETUDE Drug Information","Others","APRETUDE for HIV-1 PrEP","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE for HIV-1 PrEP","HIV Prevention Trials","HIV Prevention Trials","Others","Others","HIV Prevention Trials","Others","Others","Others","Others","Others","HIV Treatment Side Effects","Others","Others","Others","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","APRETUDE Drug Information","Others","Cabotegravir Pharmacokinetics and\\nInteractions","Others","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","Others","Others","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","HIV Treatment and Administration","Cabotegravir Pharmacokinetics and\\nInteractions","HIV Treatment and Administration","HIV Treatment and Administration","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Others","HIV Treatment and Administration","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","HIV Treatment and Administration","HIV Treatment and Administration","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Others","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Others","Cabotegravir Pharmacokinetics and\\nInteractions","Cabotegravir Pharmacokinetics and\\nInteractions","Pharmaceutical Trials","APRETUDE Drug Information","HIV Prevention Trials","HIV Prevention Trials","HIV Prevention Trials","HIV Prevention Trials","HIV Prevention Trials","HIV Prevention Trials","HIV Prevention Trials","Others","APRETUDE HIV-1 PrEP Injection Schedule","APRETUDE for HIV-1 PrEP","APRETUDE for HIV-1 PrEP","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","Others","APRETUDE for HIV-1 PrEP","Others","Others","Others","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE Drug Information","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE for HIV-1 PrEP","APRETUDE for HIV-1 PrEP","APRETUDE for HIV-1 PrEP","APRETUDE for HIV-1 PrEP","APRETUDE for HIV-1 PrEP","APRETUDE Drug Information","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","APRETUDE HIV-1 PrEP Injection Schedule","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","Others","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","APRETUDE Drug Information","APRETUDE Drug Information","Others","Others","Medication Administration Instructions","Medication Administration Instructions","Medication Administration Instructions","Medication Administration Instructions","Others","Medication Administration Instructions","Medication Administration Instructions","Others","Others","Others","Others","Others","Others","HIV Treatment and Administration","HIV Treatment and Administration","HIV Treatment and Administration","HIV Treatment and Administration","HIV Treatment and Administration","Others","ISENTRESS Drug Information","ISENTRESS Drug Information","HIV Treatment Side Effects","HIV Treatment Side Effects","Others","Raltegravir Pharmacokinetics","Pharmaceutical Trials","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","HIV Treatment Side Effects","Pharmaceutical Trials","Others","HIV Treatment Side Effects","HIV Treatment Side Effects","Others","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","Pharmaceutical Trials","Others","HIV Treatment Side Effects","HIV Treatment Side Effects","HIV Treatment Side Effects","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","HIV Treatment Side Effects","HIV Treatment Side Effects","HIV Treatment Side Effects","HIV Treatment Side Effects","Others","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","HIV Treatment Side Effects","HIV Treatment Side Effects","Others","Raltegravir Pharmacokinetics","Others","Others","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Others","Pharmaceutical Trials","Raltegravir Pharmacokinetics","Pharmaceutical Trials","Others","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","Others","Raltegravir Pharmacokinetics","Raltegravir Pharmacokinetics","Others","Raltegravir Pharmacokinetics","Raltegravir Pharmacokinetics","Raltegravir Pharmacokinetics","Raltegravir Pharmacokinetics","Others","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","Raltegravir Pharmacokinetics","Raltegravir Pharmacokinetics","Raltegravir Pharmacokinetics","Others","Others","The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment.","Others","Others","Others","Others","Others","Others","Others","Others","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs.","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Raltegravir Pharmacokinetics","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","Pharmaceutical Trials","ISENTRESS Drug Information","Others","HIV Treatment and Administration","ISENTRESS Drug Information","Antiretroviral Therapy Side Effects","Antiretroviral Therapy Side Effects","Others","Others","Cabotegravir Pharmacokinetics and\\nInteractions","HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE","Others","Others","ISENTRESS Drug Information","ISENTRESS Drug Information","Others","Others","Others","Others","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","ISENTRESS Drug Information","Medication Administration Instructions","Medication Administration Instructions","Medication Administration Instructions","ISENTRESS Drug Information","ISENTRESS Drug Information","Others","HIV Treatment and Administration"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459]],["content",["ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\nfumarate tablet, film coated \\n \\nGilead Sciences, Inc.\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\neffectively. See full prescribing information for ATRIPLA.\\nATRIPLA\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\nGILEAD ACCESS PROGRAM\\nInitial U.S. Approval: 2006\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...","discontinuation of ATRIPLA. Closely monitor hepatic function with both clinical and\\nlaboratory follow-up for at least several months in patients who are coinfected with\\nHIV-1 and HBV and discontinue ATRIPLA. If appropriate, initiation of anti-hepatitis B\\ntherapy may be warranted. (\\n5.1\\n)\\nRECENT MAJOR CHANGES\\nWarnings and Precautions\\n  Nervous System Symptoms (\\n5.6\\n)\\n10/2019\\n    Immune Reconstitution Syndrome (\\n5.12\\n)\\n10/2019\\nINDICATIONS AND USAGE\\nATRIPLA is a three-drug combination of efavirenz ...","agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. (\\n1\\n)\\nDOSAGE AND ADMINISTRATION\\nTesting: Consult Full Prescribing Information for important testing recommendations prior to initiation\\nand during treatment with ATRIPLA. (\\n2.1\\n)\\nRecommended dosage in adults and pediatric patients weighing at least 40 kg: \\nOne tablet once daily\\ntaken orally on an empty stomach, preferably at bedtime. (\\n2.2\\n)\\nRenal impairment: \\nNot recommended in patients with es...","2.5\\n)\\nDOSAGE FORMS AND STRENGTHS\\nTablets: 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate. (\\n3\\n)\\nCONTRAINDICATIONS\\nPreviously demonstrated hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or\\ntoxic skin eruptions) to efavirenz, a component of ATRIPLA. (\\n4\\n)\\nCoadministration with voriconazole. (\\n4\\n)\\nCoadministration with elbasvir/grazoprevir. (\\n4\\n)\\nWARNINGS AND PRECAUTIONS","WARNINGS AND PRECAUTIONS\\nRash: Discontinue if severe rash develops. (\\n5.2\\n, \\n6.1\\n)\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\noccurred in patients with no pre-existing hepatic disease. (\\n5.3\\n, \\n6.2\\n, \\n8.7\\n)\\nRisk of adverse reactions or loss of ...","in patients at higher risk of Torsade de Pointes. (\\n5.4\\n)\\nSerious psychiatric symptoms: Immediate medical evaluation is recommended. (\\n5.5\\n, \\n6.1\\n)\\nNervous system symptoms (NSS): NSS are frequent, usually begin 1\\u22122 days after initiating therapy,\\nand resolve in 2\\u22124 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset\\nof psychiatric symptoms. (\\n2.2\\n, \\n5.6\\n)\\nNew onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Prior\\nto initiati...","trimester. Avoid pregnancy while receiving ATRIPLA and for 12 weeks after discontinuation. (\\n5.8\\n, \\n8.1\\n)\\nDecreases in bone mineral density (BMD): Consider assessment of BMD in patients with a history of\\npathological fracture or other risk factors for osteoporosis or bone loss. (\\n5.9\\n)\\nConvulsions: Use caution in patients with a history of seizures. (\\n5.10\\n)\\nLactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop\\nsymptoms or laboratory findings suggestiv...","clinical trial of EFV, FTC, and TDF are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia,\\nabnormal dreams, and rash. (\\n6.1\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at\\nsafety_fc@gilead.com or the US FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.\\nDRUG INTERACTIONS\\nConsult Full Prescribing Information prior to and during treatment for important potential drug\\ninteractions. (\\n4\\n, \\n5.4\\n, \\n7\\n)\\nHIV-1 protease inhibitors: \\nCoadministration of ATRIPLA ...","7.3\\n)\\nUSE IN SPECIFIC POPULATIONS\\nPregnancy: \\nAvoid pregnancy while receiving ATRIPLA and for 12 weeks after discontinuation. (\\n5.8\\n, \\n8.3\\n)\\nLactation: Breastfeeding is not recommended. (\\n8.2\\n)\\nFemales and Males of Reproductive Potential: Pregnancy testing and contraception are recommended.\\n(\\n8.3\\n)\\nPediatrics: \\nThe incidence of rash was higher than in adults. (\\n5.2\\n, \\n6.1\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 10/2019\\nFULL PRESCRIBING INFORMATION:...","2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\n2.5 Dosage Adjustment with Rifampin\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\nHBV\\n5.2 Ra...","5.11 Lactic Acidosis/Severe Hepatomegaly with Steatosis\\n5.12 Immune Reconstitution Syndrome\\n5.13 Fat Redistribution\\n6 ADVERSE REACTIONS\\n6.1 Clinical Trials Experience\\n6.2 Postmarketing Experience\\n7 DRUG INTERACTIONS\\n7.1 Efavirenz\\n7.2 Drugs Affecting Renal Function\\n7.3 Established and Potentially Significant Interactions\\n7.4 Efavirenz Assay Interference\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\n8.2 Lactation\\n8.3 Females and Males of Reproductive Potential\\n8.4 Pediatric Use\\n8.5 Geriatric Use\\n8.6...","16 HOW SUPPLIED/STORAGE AND HANDLING\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\nreported in patients who are coinfected with HIV-1 and HBV and have\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\nClosely monitor hepatic function with both clinical and laboratory follow-\\nup f...","agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at\\nleast 40 kg.\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\nPrior to or when initiating ATRIPLA, test patients for hepatitis B virus infection \\n[see\\nWarnings and Precautions (5.1)\\n].\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\nserum creatinine, estimated creatinine clearance, urine glucose and urine protein in all\\n...","childbearing potential \\n[see \\nWarnings and Precautions (5.8)\\n, \\nUse in Specific Populations\\n(8.1\\n, \\n8.3)\\n].\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at\\nLeast 40 kg\\nSections or subsections omitted from the full prescribing information are not listed.","ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\nThe recommended dosage of ATRIPLA in \\nadults and pediatric patients weighing at least\\n40 kg\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\nimprove the tolerability of nervous system symptoms \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...","Impairment\\nATRIPLA is not recommended in patients with moderate to severe hepatic impairment\\n(Child-Pugh B or C) \\n[see \\nWarnings and Precautions (5.3)\\n and \\nUse in Specific Populations\\n(8.7)\\n]\\n.\\n2.5 Dosage Adjustment with Rifampin\\nIf ATRIPLA is co-administered with rifampin in patients weighing 50 kg or more, take one\\ntablet of ATRIPLA once daily followed by one additional 200 mg per day of efavirenz \\n[see\\nDrug Interactions (7.3)\\n and \\nClinical Pharmacology (12.3)\\n]\\n.\\n3 DOSAGE FORMS AND STRENGTH...","4 CONTRAINDICATIONS\\nATRIPLA is contraindicated in patients with previously demonstrated clinically\\nsignificant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme,\\nor toxic skin eruptions) to efavirenz, a component of ATRIPLA [see \\nWarnings and\\nPrecautions (5.2)\\n].\\nATRIPLA is contraindicated to be coadministered with voriconazole or\\nelbasvir/grazoprevir \\n[see \\nDrug Interactions (7.3)\\n and \\nClinical Pharmacology (12.3)\\n].\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Severe Acute Exacerbation ...","closely monitored, with both clinical and laboratory follow-up for at least several months\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\nliver failure.\\n5.2 Rash\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\nexperienced new-onset skin rash co...","EFV in all trials and expanded access was 0.1%. Rashes are usually mild-to-moderate\\nmaculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with\\nEFV (median time to onset of rash in adults was 11 days) and, in most subjects\\ncontinuing therapy with EFV, rash resolves within 1 month (median duration, 16 days).\\nThe discontinuation rate for rash in adult clinical trials was 1.7% (17/1,008). ATRIPLA can\\nbe reinitiated in patients interrupting therapy because of rash. AT...","patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson\\nsyndrome), alternative therapy should be considered \\n[see \\nContraindications (4)\\n]\\n.\\nExperience with EFV in subjects who discontinued other antiretroviral agents of the\\nNNRTI class is limited. Nineteen subjects who discontinued nevirapine because of rash\\nhave been treated with EFV. Nine of these subjects developed mild-to-moderate rash\\nwhile receiving therapy with EFV, and two of these subjects discontinued becaus...","days). Prophylaxis with appropriate antihistamines before initiating therapy with ATRIPLA\\nin pediatric patients should be considered.\\n5.3 Hepatotoxicity\\nPostmarketing cases of hepatitis, including fulminant hepatitis progressing to liver failure\\nrequiring transplantation or resulting in death, have been reported in patients treated\\nwith EFV, a component of ATRIPLA. Reports have included patients with underlying\\nhepatic disease, including coinfection with hepatitis B or C, and patients without pr...","[see \\nDosage and Administration (2.1)\\n].\\n Consider discontinuing ATRIPLA in patients with\\npersistent elevations of serum transaminases to greater than five times the upper limit\\nof the normal range.\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\nsigns or symptoms of hepatitis or hepatic decompensation \\n[see \\nAdverse Reactions\\n(6.1)\\n].\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\nInteractions\\nThe concomitant use of ATRIPLA and other d...","concomitant drug.\\nQTc prolongation has been observed with the use of EFV \\n[see \\nDrug Interactions (7.1)\\nand \\nClinical Pharmacology (12.2)\\n]\\n. Consider alternatives to ATRIPLA when\\ncoadministered with a drug with a known risk of Torsade de Pointes or when\\nadministered to patients at higher risk of Torsade de Pointes.\\nSee \\nTable 3\\n for steps to prevent or manage these possible and known significant drug\\ninteractions, including dosing recommendations. Consider the potential for drug\\ninteractions pr...","EFV, a component of ATRIPLA. In controlled trials of 1,008 subjects treated with\\nregimens containing EFV for a mean of 2.1 years and 635 subjects treated with control\\nregimens for a mean of 1.5 years, the frequency (regardless of causality) of specific\\nserious psychiatric events among subjects who received EFV or control regimens,\\nrespectively, were: severe depression (2.4%, 0.9%), suicidal ideation (0.7%, 0.3%),\\nnonfatal suicide attempts (0.5%, 0%), aggressive behavior (0.4%, 0.5%), paranoid\\nre...","follow-up 180 weeks, 102 weeks, and 76 weeks for subjects treated with EFV +\\nzidovudine + lamivudine, EFV + indinavir, and indinavir + zidovudine + lamivudine,\\nrespectively), treatment with EFV was associated with an increase in the occurrence of\\nthese selected psychiatric symptoms. Other factors associated with an increase in the\\noccurrence of these psychiatric symptoms were history of injection drug use,\\npsychiatric history, and receipt of psychiatric medication at trial entry; similar\\nassocia...","discontinued or interrupted treatment because of one or more of these selected\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\nhave also been reported and may be associated with increased EFV exposure. Patients\\nwith serious psychiatric adverse experiences should seek immediate medical ev...","central nervous system symptoms (any grade, regardless of causality) compared to\\n25% (156/635) of subjects receiving control regimens. These symptoms included\\ndizziness (28.1% of the 1,008 subjects), insomnia (16.3%), impaired concentration\\n(8.3%), somnolence (7.0%), abnormal dreams (6.2%), and hallucinations (1.2%). Other\\nreported symptoms were euphoria, confusion, agitation, amnesia, stupor, abnormal\\nthinking, and depersonalization. The majority of these symptoms were mild to moderate\\n(50.7%);...","severity ranged from 5% to 9% in subjects treated with regimens containing EFV and\\nfrom 3% to 5% in subjects treated with a control regimen. Patients should be informed\\nthat these common symptoms were likely to improve with continued therapy and were\\nnot predictive of subsequent onset of the less frequent psychiatric symptoms \\n[see\\nWarnings and Precautions (5.5)\\n]\\n. Dosing at bedtime may improve the tolerability of these\\nnervous system symptoms \\n[see \\nDosage and Administration (2.2)\\n]\\n.\\nAnalysis...","confusion, psychomotor slowing, psychosis, delirium), may occur months to years after\\nbeginning EFV therapy. Some events of late-onset neurotoxicity have occurred in\\npatients with CYP2B6 genetic polymorphisms which are associated with increased EFV\\nlevels despite standard dosing of EFV. Patients presenting with signs and symptoms of\\nserious neurologic adverse experiences should be evaluated promptly to assess the\\npossibility that these events may be related to EFV use, and whether discontinuatio...","concentration, and/or drowsiness should avoid potentially hazardous tasks such as\\ndriving or operating machinery.\\n5.7 New Onset or Worsening Renal Impairment\\nEmtricitabine and tenofovir are principally eliminated by the kidney; however, EFV is not.","Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\ncomponent of ATRIPLA \\n[see \\nAdverse Reactions (6.2)\\n].\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\nATRIPLA is...","[see \\nDrug\\nInteractions (7.2)\\n]\\n. Cases of acute renal failure after initiation of high-dose or multiple\\nNSAIDs have been reported in HIV-infected patients with risk factors for renal\\ndysfunction who appeared stable on TDF. Some patients required hospitalization and\\nrenal replacement therapy. Alternatives to NSAIDs should be considered, if needed, in\\npatients at risk for renal dysfunction.\\nPersistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain\\nor weakness may be ...","5.8 Embryo-Fetal Toxicity\\nEfavirenz may cause fetal harm when administered during the first trimester of\\npregnancy. Advise adults and adolescents of childbearing potential who are receiving\\nATRIPLA to avoid pregnancy while receiving ATRIPLA and for 12 weeks after\\ndiscontinuation \\n[see \\nDosage and Administration (2.1)\\n, \\nUse in Specific Populations (8.1\\n,\\n8.3)\\n]\\n.\\n5.9 Bone Loss and Mineralization Defects\\nBone Mineral Density\\nIn clinical trials in HIV-1 infected adults, TDF (a component of ATRIPLA...","Clinical trials evaluating TDF in pediatric and adolescent subjects were conducted. Under\\nnormal circumstances, BMD increases rapidly in pediatric patients. In HIV-1 infected\\nsubjects aged 2 years to less than 18 years, bone effects were similar to those\\nobserved in adult subjects and suggest increased bone turnover. Total body BMD gain\\nwas less in the TDF treated HIV-1 infected pediatric subjects as compared to the control\\ngroups. Similar trends were observed in chronic hepatitis B infected ado...","considered for adult and pediatric patients who have a history of pathologic bone\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\nconsultation should be obtained.\\nMineralization Defects\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\npain or pain in extre...","be considered in patients at risk of renal dysfunction who present with persistent or\\nworsening bone or muscle symptoms while receiving TDF-containing products \\n[see\\nWarnings and Precautions (5.7)\\n].\\n5.10 Convulsions\\nConvulsions have been observed in adult and pediatric patients receiving EFV, generally\\nin the presence of known medical history of seizures. Caution must be taken in any\\npatient with a history of seizures.\\nPatients who are receiving concomitant anticonvulsant medications primarily ...","reported with the use of nucleoside analogs, including TDF and FTC, components of\\nATRIPLA, alone or in combination with other antiretrovirals. Treatment with ATRIPLA\\nshould be suspended in any patient who develops clinical or laboratory findings\\nsuggestive of lactic acidosis or pronounced hepatotoxicity (which may include\\nhepatomegaly and steatosis even in the absence of marked transaminase elevations).\\n5.12 Immune Reconstitution Syndrome\\nImmune reconstitution syndrome has been reported in patie...","infections (such as \\nMycobacterium avium\\n infection, cytomegalovirus, \\nPneumocystis\\njirovecii\\n pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and\\ntreatment.\\nAutoimmune disorders (such as Graves&#x27; disease, polymyositis, Guillain-Barr\\u00e9 syndrome,\\nand autoimmune hepatitis) have also been reported to occur in the setting of immune\\nreconstitution; however, the time to onset is more variable, and can occur many months\\nafter initiation of treatment.\\n5.13 Fat Redistribution\\nRe...","enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\n\\"cushingoid appearance,\\" has been observed in patients receiving antiretroviral therapy,\\nincluding EFV. The mechanism and long-term consequences of these events are\\ncurrently unknown. A causal relationship has not been established.\\n6 ADVERSE REACTIONS\\nThe following adverse reactions are discussed in other sections of the labeling:\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...","[see \\nWarnings and Precautions (5.7)\\n].\\nEmbryo-Fetal Toxicity \\n[see \\nWarnings and Precautions (5.8)\\n]\\n.\\nBone Loss and Mineralization Defects \\n[see \\nWarnings and Precautions (5.9)\\n].\\nConvulsions \\n[see \\nWarnings and Precautions (5.10)\\n]\\n.\\nLactic Acidosis/Severe Hepatomegaly with Steatosis \\n[see \\nWarnings and Precautions\\n(5.11)\\n]\\n.\\nImmune Reconstitution Syndrome \\n[see \\nWarnings and Precautions (5.12)\\n].\\nFat Redistribution \\n[see \\nWarnings and Precautions (5.13)\\n].\\n6.1 Clinical Trials Experience\\nBeca...","Study 934 was an open-label active-controlled trial in which 511 antiretroviral-na\\u00efve\\nsubjects received either FTC + TDF administered in combination with EFV (N=257) or\\nzidovudine (AZT)/lamivudine (3TC) administered in combination with EFV (N=254).\\nThe most common adverse reactions (incidence greater than or equal to 10%, any\\nseverity) occurring in Study 934 include diarrhea, nausea, fatigue, headache, dizziness,\\ndepression, insomnia, abnormal dreams, and rash. Adverse reactions observed in Stud...","*\\n\\u2020\\n\\u2021\\nDizziness\\n8%\\n7%\\nUpper respiratory tract infections\\n8%\\n5%\\nSinusitis\\n8%\\n4%\\nRash Event\\n7%\\n9%\\nHeadache\\n6%\\n5%\\nInsomnia\\n5%\\n7%\\nAnxiety\\n5%\\n4%\\nNasopharyngitis\\n5%\\n3%\\nVomiting\\n2%\\n5%\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\nconsistent with those seen in Study 934 and those seen with the individ...","antiretroviral agents.\\nEfavirenz:\\n \\nThe most significant adverse reactions observed in subjects treated with EFV\\nwere nervous system symptoms \\n[see \\nWarnings and Precautions (5.6)\\n],\\n psychiatric\\nsymptoms \\n[see \\nWarnings and Precautions (5.5)\\n],\\n and rash \\n[see \\nWarnings and\\nPrecautions (5.2)\\n]\\n.\\nSelected adverse reactions of moderate-to-severe intensity observed in greater than or\\nequal to 2% of EFV-treated subjects in two controlled clinical trials included pain,\\nimpaired concentration, abnorm...","significantly higher number of subjects treated with EFV 600 mg than in control\\nsubjects.\\nSkin discoloration has been reported with higher frequency among FTC-treated subjects;\\nit was manifested by hyperpigmentation on the palms and/or soles and was generally\\nmild and asymptomatic. The mechanism and clinical significance are unknown.\\nClinical Trials in Pediatric Subjects\\nEfavirenz:\\n \\nAssessment of adverse reactions is based on three pediatric clinical trials in\\n182 HIV-1 infected pediatric subje...","Frequencies of adverse reactions are based on all treatment-emergent adverse events,\\nregardless of relationship to study drug.\\nFrom Weeks 96 to 144 of the trial, subjects received FTC/TDF administered in combination with\\nEFV in place of FTC + TDF with EFV.\\nRash event includes rash, exfoliative rash, rash generalized, rash macular, rash maculopapular,\\nrash pruritic, and rash vesicular.\\n\\u2021","exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\n[see \\nWarnings\\nand Precautions (5.2)\\n]\\n.\\nEmtricitabine:\\n \\nIn addition to the adverse reactions reported in adults, anemia and\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\nwho received treatment with FTC in the larger of ...","[see\\nWarnings and Precautions (5.9)\\n]\\n.\\nLaboratory Abnormalities\\nEfavirenz, Emtricitabine and Tenofovir DF:\\n Laboratory abnormalities observed in Study\\n934 were generally consistent with those seen in previous trials (Table 2).\\nTable 2 \\nSignificant Laboratory Abnormalities Reported in \\u22651% of Subjects in\\nEither Treatment Group in Study 934 (0\\u2013144 Weeks)\\nFTC+TDF+EFV\\nAZT/3TC+EFV\\nN=257\\nN=254\\n*\\nAny \\u2265 Grade 3 Laboratory\\nAbnormality\\n30%\\n26%\\nFasting Cholesterol (&gt;240 mg/dL)\\n22%\\n24%\\nCreatine Kinase\\n(M: &gt;...","&lt;1%\\n1%\\nNeutrophils (&lt;750/mm\\n)\\n3%\\n5%\\nFasting Triglycerides (&gt;750 mg/dL)\\n4%\\n2%\\nLaboratory abnormalities observed in Study 073 were generally consistent with those in\\nStudy 934.\\nHepatic Events:\\n \\nIn Study 934, 19 subjects treated with EFV, FTC, and TDF and 20\\n*\\nFrom Weeks 96 to 144 of the trial, subjects received FTC/TDF administered in combination with\\nEFV in place of FTC + TDF with EFV.\\n3","subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...","or establish a causal relationship to drug exposure.\\nEfavirenz:\\nCardiac Disorders\\n \\nPalpitations\\nEar and Labyrinth Disorders\\n \\nTinnitus, vertigo\\nEndocrine Disorders\\n \\nGynecomastia\\nEye Disorders\\n \\nAbnormal vision\\nGastrointestinal Disorders\\n \\nConstipation, malabsorption\\nGeneral Disorders and Administration Site Conditions\\n \\nAsthenia\\nHepatobiliary Disorders\\n \\nHepatic enzyme increase, hepatic failure, hepatitis\\nImmune System Disorders\\n \\nAllergic reactions\\nMetabolism and Nutrition Disorders\\n \\nRedistr...","disturbances, convulsions, hypoesthesia, paresthesia, neuropathy, tremor\\nPsychiatric Disorders\\n \\nAggressive reactions, agitation, delusions, emotional lability, mania, neurosis, paranoia,\\npsychosis, suicide, catatonia\\nRespiratory, Thoracic and Mediastinal Disorders","Dyspnea\\nSkin and Subcutaneous Tissue Disorders\\n \\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\nEmtricitabine\\n:\\n No postmarketing adverse reactions have been identified for inclusion in\\nthis section.\\nTenofovir DF:\\nImmune System Disorders\\n \\nAllergic reaction, including angioedema\\nMetabolism and Nutrition Disorders\\n \\nLactic acidosis, hypokalemia, hypophosphatemia\\nRespiratory, Thoracic, and Mediastinal Disorders\\n \\nDyspnea\\nGastrointestinal Disorders\\n \\nPancreatitis,...","fractures), muscular weakness, myopathy\\nRenal and Urinary Disorders\\n \\nAcute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal\\nrenal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes\\ninsipidus, renal insufficiency, increased creatinine, proteinuria, polyuria\\nGeneral Disorders and Administration Site Conditions\\n \\nAsthenia\\nThe following adverse reactions, listed under the body system headings above, may\\noccur as a consequence of proxima...","are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when\\ncoadministered with EFV.\\nDrugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be\\nexpected to increase the clearance of EFV, resulting in lowered plasma concentrations\\n[see \\nDosage and Administration (2.2)\\n]\\n.","There is limited information available on the potential for a pharmacodynamic interaction\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\nobserved with the use of EFV \\n[see \\nClinical Pharmacology (12.2)\\n].\\n Consider alternatives to\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\n7.2 Drugs Affecting Renal Function\\nFTC and tenofovir are primarily eliminated by the kidneys\\n[see \\nClinical Pharmacology\\n(12.3)\\n].\\n Coadministration of ATRI...","high-dose or multiple NSAIDs \\n[see \\nWarnings and Precautions (5.7)\\n]\\n. Drugs that decrease\\nrenal function may increase concentrations of FTC and/or tenofovir.\\n7.3 Established and Potentially Significant Interactions\\nOther important drug interaction information for ATRIPLA is summarized in Table 3. The\\ndrug interactions described are based on trials conducted with either ATRIPLA, the\\ncomponents of ATRIPLA (EFV, FTC, or TDF) as individual agents, or are potential drug\\ninteractions \\n[see \\nClinical ...","combined effect of EFV plus TDF on\\natazanavir plasma concentrations is not\\nknown. There are insufficient data to\\nsupport dosing recommendations for\\natazanavir or atazanavir/ritonavir in\\ncombination with ATRIPLA.\\nProtease inhibitor:\\n  fosamprenavir\\n  calcium\\n\\u2193 amprenavir\\nFosamprenavir (unboosted): Appropriate\\ndoses of fosamprenavir and ATRIPLA\\nwith respect to safety and efficacy have\\nnot been established.\\nFosamprenavir/ritonavir: An additional\\n100 mg/day (300 mg total) of ritonavir is\\nrecommended...","the increased indinavir metabolism due to\\nEFV.\\nProtease inhibitor:\\n  darunavir/ritonavir\\n\\u2191 tenofovir\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions. Discontinue ATRIPLA in\\npatients who develop TDF-associated\\nadverse reactions.\\n  lopinavir/ritonavir\\n\\u2193 lopinavir\\n\\u2191 tenofovir\\nDo not use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for all\\npatients when coadministered with ...","reactions\\nProtease inhibitor:\\n  ritonavir\\n\\u2191 ritonavir\\n\\u2191 efavirenz\\nWhen ritonavir 500 mg every 12 hours\\nwas coadministered with EFV 600 mg\\nonce daily, the combination was\\nassociated with a higher frequency of\\nadverse clinical experiences (e.g.,\\ndizziness, nausea, paresthesia) and\\nlaboratory abnormalities (elevated liver\\nenzymes). Monitoring of liver enzymes is\\nrecommended when ATRIPLA is used in\\ncombination with ritonavir.\\nProtease inhibitor:\\n  saquinavir\\n\\u2193 saquinavir\\nAppropriate doses of the com...","didanosine should be monitored closely\\nfor didanosine-associated adverse\\nreactions. Discontinue didanosine in\\npatients who develop didanosine-\\nassociated adverse reactions. Higher\\ndidanosine concentrations could\\npotentiate didanosine-associated adverse\\nreactions, including pancreatitis, and\\nneuropathy. Suppression of CD4+ cell\\ncounts has been observed in patients","NRTI:\\n  didanosine\\n\\u2191 didanosine\\nreceiving TDF with didanosine 400 mg\\ndaily. \\nIn patients weighing greater than 60 kg,\\nreduce the didanosine dose to 250 mg\\nwhen it is coadministered with ATRIPLA.\\nIn patients weighing less than 60 kg,\\nreduce the didanosine dose to 200 mg\\nwhen it is coadministered with ATRIPLA.\\nWhen coadministered, ATRIPLA and\\nVidex EC may be taken under fasted\\nconditions or with a light meal (less than\\n400 kcal, 20% fat).\\nNNRTI:\\n  Other NNRTIs\\n\\u2191 or \\u2193 efavirenz\\nand/or NNRTI\\nCombini...","\\u2193 boceprevir\\nPlasma trough concentrations of\\nboceprevir were decreased when\\nboceprevir was coadministered with EFV,\\nwhich may result in loss of therapeutic\\neffect. The combination should be\\navoided.\\n  elbasvir/grazoprevir\\n\\u2193 elbasvir\\n\\u2193 grazoprevir\\nCoadministration of ATRIPLA with\\nelbasvir/grazoprevir is contraindicated\\n[see \\nContraindications (4)\\n]\\n because it\\nmay lead to loss of virologic response to\\nelbasvir/grazoprevir.\\n  glecaprevir/pibrentasvir\\n\\u2193 glecaprevir\\n\\u2193 pibrentasvir\\nCoadministration o...","simeprevir\\n\\u2193 simeprevir\\n\\u2194 efavirenz\\nConcomitant administration of simeprevir\\nwith EFV is not recommended because it\\nmay result in loss of therapeutic effect of\\nsimeprevir.\\n  sofosbuvir/velpatasvir\\n  sofosbuvir/velpatasvir/\\nvoxilaprevir\\n\\u2191 tenofovir\\n\\u2193 velpatasvir\\n\\u2193 voxilaprevir\\nCoadministration of EFV-containing\\nregimens and EPCLUSA\\u2122\\n(sofosbuvir/velpatasvir) or VOSEVI\\u2122\\n(sofosbuvir/velpatasvir/voxilaprevir) is\\nnot recommended.\\nOther agents","Anticoagulant:\\n  warfarin\\n\\u2191 or \\u2193 warfarin\\nPlasma concentrations and effects\\npotentially increased or decreased by\\nEFV.\\nAnticonvulsants:\\n  carbamazepine\\n\\u2193 carbamazepine\\n\\u2193 efavirenz\\nThere are insufficient data to make a\\ndose recommendation for ATRIPLA.\\nAlternative anticonvulsant treatment\\nshould be used.\\n  phenytoin\\n  phenobarbital\\n\\u2193 anticonvulsant\\n\\u2193 efavirenz\\nPotential for reduction in anticonvulsant\\nand/or EFV plasma levels; periodic\\nmonitoring of anticonvulsant plasma\\nlevels should be conducted...","sertraline\\n\\u2193 sertraline\\nIncreases in sertraline dose should be\\nguided by clinical response.\\nAntifungals:\\n  itraconazole\\n\\u2193 itraconazole\\n\\u2193 hydroxy-\\nitraconazole\\nSince no dose recommendation for\\nitraconazole can be made, alternative\\nantifungal treatment should be\\nconsidered.\\n  ketoconazole\\n\\u2193 ketoconazole\\nDrug interaction trials with ATRIPLA and\\nketoconazole have not been conducted.\\nEfavirenz has the potential to decrease\\nplasma concentrations of ketoconazole.\\n  posaconazole\\n\\u2193 posaconazole\\nAvoid con...","Anti-infective:\\n  clarithromycin\\n\\u2193 clarithromycin\\n\\u2191 14-OH metabolite\\nConsider alternatives to macrolide\\nantibiotics because of the risk of QT\\ninterval prolongation.\\nAntimycobacterial:\\n  rifabutin\\n\\u2193 rifabutin\\nIncrease daily dose of rifabutin by 50%.\\nConsider doubling the rifabutin dose in\\nregimens where rifabutin is given 2 or 3\\ntimes a week.\\n  rifampin\\n\\u2193 efavirenz\\nIf ATRIPLA is coadministered with\\nrifampin to patients weighing 50 kg or\\nmore, an additional 200 mg/day of EFV is\\nrecommended.\\nAntima...","artemether/lumefantrine\\n  atovaquone/proquanil\\n\\u2193 dihydroartemisinin\\n\\u2193 lumefantrine\\n\\u2193 atovaquone\\n\\u2193 proguanil\\nrisk of QT interval prolongation \\n[see\\nWarnings and Precautions (5.4)\\n]\\n.\\nConcomitant administration of\\natovaquone/proguanil with ATRIPLA is\\nnot recommended.\\nCalcium channel\\nblockers:\\n  diltiazem\\n\\u2193 diltiazem\\n\\u2193 desacetyl\\ndiltiazem\\n\\u2193 N-monodes-\\nmethyl diltiazem\\nDiltiazem dose adjustments should be\\nguided by clinical response (refer to the\\nfull prescribing information for diltiazem).\\nNo dose ...","CYP3A. The potential exists for reduction\\nin plasma concentrations of the calcium\\nchannel blocker. Dose adjustments\\nshould be guided by clinical response\\n(refer to the full prescribing information\\nfor the calcium channel blocker).\\nHMG-CoA reductase\\ninhibitors:\\n  atorvastatin\\n  pravastatin\\n  simvastatin\\n\\u2193 atorvastatin\\n\\u2193 pravastatin\\n\\u2193 simvastatin\\nPlasma concentrations of atorvastatin,\\npravastatin, and simvastatin decreased\\nwith EFV. Consult the Full Prescribing\\nInformation for the HMG-CoA reductas...","concentrations, but progestin levels\\n(norelgestromin and levonorgestrel) were\\nmarkedly decreased. No effect of ethinyl\\nestradiol/norgestimate on EFV plasma\\nconcentrations was observed.\\nImplant:\\n  etonogestrel\\n\\u2193 etonogestrel\\nA reliable method of barrier\\ncontraception must be used in addition\\nto hormonal contraceptives. Decreased\\nexposure of etonogestrel may be\\nexpected. There have been\\npostmarketing reports of contraceptive\\nfailure with etonogestrel in EFV-exposed\\npatients.\\nImmunosuppressants:\\n  ...","*\\ntacrolimus, sirolimus, and\\nothers metabolized by\\nCYP3A\\nsuppressant\\nmay be required. Close monitoring of\\nimmunosuppressant concentrations for\\nat least 2 weeks (until stable\\nconcentrations are reached) is\\nrecommended when starting or stopping\\ntreatment with ATRIPLA.\\nNarcotic analgesic:\\n  methadone\\n\\u2193 methadone\\nCoadministration of EFV in HIV-1 infected\\nindividuals with a history of injection drug\\nuse resulted in signs of opiate\\nwithdrawal. Methadone dose was\\nincreased by a mean of 22% to alleviate...","positive urine cannabinoid test results have been reported with some screening assays\\nin uninfected and HIV-infected subjects receiving EFV. Confirmation of positive screening\\ntests for cannabinoids by a more specific method is recommended.\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nAntiretroviral Pregnancy Registry\\nThere is a pregnancy exposure registry that monitors pregnancy outcomes in adults\\nand adolescents exposed to ATRIPLA during pregnancy. Healthcare providers are\\nencouraged to registe...","Prospective pregnancy data from the APR are not sufficient to adequately assess this\\nrisk. Although a causal relationship has not been established between exposure to EFV\\nin the first trimester and neural tube defects, similar malformations have been observed\\nin studies conducted in monkeys at doses similar to the human dose \\n(see \\nData\\n)\\n. In\\naddition, fetal and embryonic toxicities occurred in rats at a dose 10 times less than the\\nhuman exposure at the recommended clinical human dose (RHD) of ...","for EFV, FTC, or TDF compared with the background rate for major birth defects of\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\nProgram (MACDP) \\n(see \\nData\\n)\\n.\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\nThe background risk of major birth defects and miscarriage for the indicated population\\nis unknown. The APR uses the MACDP as t...","FTC and TDF were administered separately at doses/exposures \\u226560 (FTC), \\u226514 (TDF)\\nand 2.7 (tenofovir) times those at the RHD of ATRIPLA (\\nsee \\nData\\n).\\nData\\nHuman Data\\nEfavirenz:\\n There are retrospective postmarketing reports of findings consistent with\\nneural tube defects, including meningomyelocele, all in infants of mothers exposed to\\nEFV-containing regimens in the first trimester.\\nBased on prospective reports to the APR of 1,217 exposures to EFV-containing\\nregimens during pregnancy resulting i...","defects in live births was 2.3% (95% CI: 1.5% to 3.5%) with first trimester exposure to\\nEFV-containing regimens, and 1.5% (95% CI: 0.3% to 4.5%) with the second/third\\ntrimester exposure to EFV-containing regimens. One of these prospectively reported\\ndefects with first-trimester exposure was a neural tube defect. A single case of\\nanophthalmia with first-trimester exposure to EFV has also been prospectively reported.\\nThis case also included severe oblique facial clefts and amniotic banding, which ...","increase in overall major birth defects with FTC compared with the background birth\\ndefect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of\\nbirth defects in live births was 2.4% (95% CI: 1.9% to 3.1%) with first trimester\\nexposure to FTC-containing regimens and 2.3% (95% CI: 1.5% to 3.3%) with the\\nsecond/third trimester exposure to FTC-containing regimens.\\nTenofovir DF:\\n Based on prospective reports from the APR of 5,105 exposures to TDF-\\ncontaining regimens during p...","birth defects in live births was 2.3% (95% CI: 1.8% to 2.9%) with first trimester\\nexposure to TDF-containing regimens, and 2.2% (95% CI: 1.6% to 3.1%) with the\\nsecond/third trimester exposure to TDF-containing regimens.","Animal Data\\nEfavirenz:\\n Effects of EFV on embryo-fetal development have been studied in three\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...","established for this study because only one dosage was evaluated. In rats, EFV was\\nadministered either during organogenesis (gestation Days 7 to 18) or from gestation\\nDay 7 through lactation Day 21 at 50, 100, or 200 mg/kg/day. Administration of 200\\nmg/kg/day in rats was associated with an increase in the incidence of early resorptions,\\nand doses 100 mg/kg/day and greater were associated with early neonatal mortality. The\\nAUC at the NOAEL (50 mg/kg/day) in this rat study was 0.1 times that in hu...","mg/kg/day) in rabbits was 0.4 times that in humans at the RHD.\\nEmtricitabine:\\n FTC was administered orally to pregnant mice (at 0, 250, 500, or 1,000\\nmg/kg/day), and rabbits (at 0, 100, 300, or 1,000 mg/kg/day) through organogenesis\\n(on gestation days 6 through 15, and 7 through 19, respectively). No significant\\ntoxicological effects were observed in embryo-fetal toxicity studies performed with FTC\\nin mice at exposures (AUC) approximately 60 times higher and in rabbits at\\napproximately 120 times...","(AUC) of approximately 60 times higher than human exposures at the RHD.\\nTenofovir DF:\\n TDF was administered orally to pregnant rats (at 0, 50, 150, or 450\\nmg/kg/day) and rabbits (at 0, 30, 100, or 300 mg/kg/day) through organogenesis (on\\ngestation days 7 through 17, and 6 through 18, respectively). No significant\\ntoxicological effects were observed in embryo-fetal toxicity studies performed with TDF\\nin rats at doses up to 14 times the RHD based on body surface area comparisons and in\\nrabbits at ...","tenofovir exposures of approximately 2.7 times higher than human exposures at the\\nRHD.\\n8.2 Lactation\\nRisk Summary\\nThe Centers for Disease Control and Prevention recommend that HIV-1 infected\\nmothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. \\n.","Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\nin human breast milk.\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\nbreastfeed if they are receiving ATRIPLA....","]\\n.\\nContraception\\nAdvise adults and adolescents of childbearing potential to use effective contraception\\nduring treatment with ATRIPLA and for 12 weeks after discontinuing ATRIPLA due to the\\nlong half-life of EFV, a component of ATRIPLA. Hormonal methods that contain\\nprogesterone may have decreased effectiveness Always use barrier contraception in\\ncombination with other methods of contraception \\n[see \\nDrug Interactions (7.1\\n, \\n7.3)\\n]\\n.\\n8.4 Pediatric Use\\nThe effectiveness and safety of ATRIPLA as...","infection and data from pediatric studies of the individual components of ATRIPLA (EFV,\\nFTC, and TDF).\\nATRIPLA should only be administered to pediatric patients with a body weight greater\\nthan or equal to 40 kg. Because ATRIPLA is a fixed-dose combination tablet, the dose of\\nATRIPLA cannot be adjusted for patients of lower weight \\n[see \\nWarnings and Precautions\\n(5.2\\n, \\n5.9)\\n, \\nAdverse Reactions (6.1)\\n, and \\nClinical Pharmacology (12.3)\\n].\\n8.5 Geriatric Use\\nClinical trials of EFV, FTC, or TDF did...","disease or other drug therapy.\\n8.6 Renal Impairment\\nBecause ATRIPLA is a fixed-dose combination, and cannot be dose adjusted, it is not\\nrecommended in patients with moderate or severe renal impairment (estimated\\ncreatinine clearance below 50 mL/min) \\n[see \\nDosage and Administration (2.3)\\n, \\nWarnings\\nand Precautions (5.7)\\n].","8.7 Hepatic Impairment\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\nin patients with hepatic impairment, caution should be exercised in administering\\nATRIPLA to these patients \\n[see \\nDosage and Administra...","FTC and TDF (refer to detailed information below), but is unlikely to significantly remove\\nEFV from the blood.\\nEfavirenz:\\n \\nSome patients accidentally taking 600 mg twice daily have reported increased\\nnervous system symptoms. One patient experienced involuntary muscle contractions.\\nEmtricitabine:\\n Hemodialysis treatment removes approximately 30% of the FTC dose over\\na 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400\\nmL/min and a dialysate flow rate of 600 mL...","hemodialysis session removed approximately 10% of the administered tenofovir dose.\\n11 DESCRIPTION\\nATRIPLA is a fixed-dose combination tablet containing EFV, FTC, and TDF. EFV is a non-\\nnucleoside reverse transcriptase inhibitor (NNRTI). FTC is a synthetic nucleoside analog\\nof cytidine. TDF, which is converted \\nin vivo\\n to tenofovir, is an acyclic nucleoside\\nphosphonate (nucleotide) analog of adenosine 5\\u2032-monophosphate.\\nATRIPLA tablets are for oral administration. Each tablet contains 600 mg of E...","polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.\\nEfavirenz:\\n EFV is chemically described as (\\nS\\n)-6-chloro-4-(cyclopropylethynyl)-1,4-\\ndihydro-4-(trifluoromethyl)-2\\nH\\n-3,1-benzoxazin-2-one. Its molecular formula is\\nC\\nH\\nClF\\nNO\\n and its structural formula is:\\n14\\n9\\n3\\n2","Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\nis practically insoluble in water (less than 10 \\u00b5g/mL).\\nEmtricitabine:\\n The chemical name of FTC is 5-fluoro-1-(2\\nR\\n,5\\nS\\n)-[2-(hydroxymethyl)-1,3-\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\nIt has a molecular formula of C\\nH\\nFN\\nO\\nS and a molecular weight of 247.24. It has the\\nfollo...","R\\n)-\\n2[[bis[[(isopropoxycarbonyl)oxy]- methoxy]phosphinyl]methoxy]propyl]adenine\\nfumarate (1:1). It has a molecular formula of C\\nH\\nN\\nO\\nP \\u2219 C\\nH\\nO\\n and a molecular\\nweight of 635.52. It has the following structural formula:\\nTDF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at\\n25 \\u00b0C.\\n12 CLINICAL PHARMACOLOGY\\n8\\n10\\n3\\n3\\n19\\n30\\n5\\n10\\n4\\n4\\n4","12.1 Mechanism of Action\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\n[see\\nMicrobiology (12.4)\\n].\\n12.2 Pharmacodynamics\\nCardiac Electrophysiology\\nEfavirenz:\\n \\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\n of EFV in\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...","CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days\\n[see \\nWarnings and Precautions (5.4)\\n].\\n12.3 Pharmacokinetics\\nATRIPLA:\\n \\nOne ATRIPLA tablet is bioequivalent to one Sustiva or Stocrin tablet (600 mg)\\nplus one EMTRIVA\\u2122 capsule (200 mg) plus one VIREAD\\u2122 tablet (300 mg) following\\nsingle-dose administration to fasting healthy subjects (N=45).\\nEfavirenz:\\n \\nIn HIV-1 infected subjects time-to-peak plasma concentrations were\\napproximately 3\\u20135 hours and steady-state plas...","predominantly albumin. Following administration of \\nC-labeled EFV, 14\\u201334% of the dose\\nwas recovered in the urine (mostly as metabolites) and 16\\u201361% was recovered in feces\\n(mostly as parent drug). In vitro studies suggest CYP3A and CYP2B6 are the major\\nisozymes responsible for EFV metabolism. EFV has been shown to induce CYP enzymes,\\nresulting in induction of its own metabolism. EFV has a terminal half-life of 52\\u201376 hours\\nafter single doses and 40\\u201355 hours after multiple doses.\\nEmtricitabine:\\n \\nF...","\\u00b1 3.1 \\u00b5g\\u2219hr/mL. The mean steady state plasma trough concentration at 24 hours\\npostdose was 0.09 \\u00b5g/mL. The mean absolute bioavailability of FTC was 93%. Less than\\n4% of FTC binds to human plasma proteins \\nin vitro\\n and the binding is independent of\\nconcentration over the range of 0.02\\u2013200 \\u00b5g/mL. Following administration of\\nradiolabelled FTC, approximately 86% is recovered in the urine and 13% is recovered as\\nmetabolites. The metabolites of FTC include 3\\u2032-sulfoxide diastereomers and their\\nglucuro...","Tenofovir DF:\\n \\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\ninfected subjects in the fasted state, maximum serum concentrations (C\\n) were\\nachieved in 1.0 \\u00b1 0.4 hrs (mean \\u00b1 SD) and C\\n and AUC values were 296 \\u00b1 90 ng/mL\\nand 2287 \\u00b1 685 ng\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...","normal renal function of 243 \\u00b1 33 mL/min (mean \\u00b1 SD). Following a single oral dose, the\\nterminal elimination half-life of tenofovir is approximately 17 hours.\\nEffects of Food on Oral Absorption\\nATRIPLA has not been evaluated in the presence of food. Administration of EFV tablets\\nwith a high-fat meal increased the mean AUC and C\\n of EFV by 28% and 79%,\\nrespectively, compared to administration in the fasted state. Compared to fasted\\nadministration, dosing of TDF and FTC in combination with either ...","among the racial groups studied.\\nEmtricitabine:\\n No pharmacokinetic differences due to race have been identified following\\nthe administration of FTC.\\nTenofovir DF:\\n There were insufficient numbers from racial and ethnic groups other than\\nCaucasian to adequately determine potential pharmacokinetic differences among these\\npopulations following the administration of TDF.\\nGender\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\n \\nEFV, FTC, and tenofovir pharmacokinetics are\\nsimilar in male and female subj...","weighing &gt;40 kg, receiving the 600 mg dose of EFV, C\\n was 6.57 \\u03bcg/mL, C\\n was\\n2.82 \\u03bcg/mL, and AUC\\n was 254.78 \\u03bcM\\u2219hr.\\nEmtricitabine:\\n \\nThe pharmacokinetics of FTC at steady state were determined in 27 HIV-1-\\ninfected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg/kg up to\\na maximum dose of 240 mg oral solution or a 200 mg capsule; 26 of 27 subjects in this\\nage group received the 200 mg capsule. Mean \\u00b1 SD C\\n and AUC were 2.7 \\u00b1 0.9\\n\\u03bcg/mL and 12.6 \\u00b1 5.4 \\u03bcg\\u2219hr/mL, respectively...","daily dose of 200 mg.\\nTenofovir DF:\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\ninfected pediatric subjects (12 to less than 18 years). Mean \\u00b1 SD C\\n and AUC\\n are\\n0.38 \\u00b1 0.13 \\u03bcg/mL and 3.39 \\u00b1 1.22 \\u03bcg\\u2219hr/mL, respectively. Tenofovir exposure\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\nGeriatric Patients\\nPharmacokinetics of EFV, FTC, and tenofovir have not...","impact of renal impairment on EFV elimination should be minimal.\\nEmtricitabine and Tenofovir DF:\\n \\nThe pharmacokinetics of FTC and TDF are altered in\\nsubjects with renal impairment. In subjects with creatinine clearance below 50 mL/min,\\nC\\n and AUC\\n of FTC and tenofovir were increased \\n[see \\nWarnings and Precautions\\n(5.7)\\n].\\nPatients with Hepatic Impairment\\nEfavirenz:\\n \\nA multiple-dose trial showed no significant effect on EFV pharmacokinetics in\\nsubjects with mild hepatic impairment (Child-Pugh ...","hepatic impairment; however, FTC is not significantly metabolized by liver enzymes, so\\nthe impact of liver impairment should be limited.\\nTenofovir DF:\\n \\nThe pharmacokinetics of tenofovir following a 300 mg dose of TDF have\\nbeen studied in non-HIV infected subjects with moderate to severe hepatic impairment.\\nThere were no substantial alterations in tenofovir pharmacokinetics in subjects with\\nhepatic impairment compared with unimpaired subjects.\\nAssessment of Drug Interactions\\nThe drug interaction...","drug interaction trials have not been performed with EFV and NRTIs other than\\ntenofovir, lamivudine, and zidovudine. Clinically significant interactions would not be\\nexpected based on NRTIs elimination pathways.\\nEfavirenz has been shown \\nin vivo\\n to cause hepatic enzyme induction, thus increasing\\nthe biotransformation of some drugs metabolized by CYP3A and CYP2B6. \\nIn vitro\\nstudies have shown that EFV inhibited CYP isozymes 2C9 and 2C19 with K\\n values (8.5\\u2013\\n17 \\u00b5M) in the range of observed EFV pl...","concentrations well above those achieved clinically. Coadministration of EFV with drugs\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\nlowered plasma concentrations.\\nDrug interaction trials were performed with EFV and other drugs likely to be\\ncoadministered or drugs commonly used as probes for phar...",", AUC, and C\\n are\\nsummarized in Table 4 (effect of other drugs on EFV) and Table 5 (effect of EFV on\\nother drugs) \\n[see \\nDrug Interactions (7)\\n].\\nTable 4 Drug Interactions: Changes in Pharmacokinetic Parameters for EFV in\\nthe Presence of the Coadministered Drug\\nMean % Change of EFV\\nPharmacokinetic\\nParameters\\n (90% CI)\\nCoadministered Drug\\nDose of\\nCoadministered\\nDrug (mg)\\nEFV\\nDose\\n(mg)\\nN\\nC\\nAUC\\nC\\nLopinavir/ ritonavir\\n400/100 mg\\nq12h \\u00d7 9 days\\n600 mg\\nqd \\u00d7 9\\ndays\\n11,\\n12\\n\\u2194\\n\\u2193 16\\n(\\u2193 38 to\\n\\u2191 15)\\n\\u2193 16\\n(\\u2193 4...","20)\\n\\u2191 20\\n(\\u2191 15 to\\n\\u2191 26)\\nNA\\nRifabutin\\n300 mg qd \\u00d7 14\\ndays\\n600 mg\\nqd \\u00d7 14\\ndays\\n11\\n\\u2194\\n\\u2194\\n\\u2193 12\\n(\\u2193 24 to\\n\\u2191 1)\\nRifampin\\n600 mg \\u00d7 7 days\\n600 mg\\nqd \\u00d7 7\\ndays\\n12\\n\\u2193 20\\n(\\u2193 11 to\\n\\u2193 28)\\n\\u2193 26\\n(\\u2193 15 to\\n\\u2193 36)\\n\\u2193 32\\n(\\u2193 15 to\\n\\u2193 46)\\nArtemether/lumefantrine\\nArtemether 20\\nmg/lumefantrine\\n120 mg tablets (6\\n4-tablet doses\\nover 3 days)\\n600 mg\\nqd \\u00d7 26\\ndays\\n12\\n\\u2194\\n\\u219317\\nNA\\nSimvastatin\\n40 mg qd \\u00d7 4\\ndays\\n600 mg\\nqd \\u00d7 15\\ndays\\n14\\n\\u2193 12\\n(\\u2193 28 to\\n\\u2191 8)\\n\\u2194\\n\\u2193 12\\n(\\u2193 25 to\\n\\u2191 3)\\ni\\nmax\\nmin\\n*\\nmax\\nmin\\n\\u2020\\n\\u2021\\n\\u2021\\n\\u2021","NA = not available\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\nCarbamazepine\\n200 mg qd \\u00d7 3\\ndays, 200 mg bid\\n\\u00d7 3 days, then\\n400 mg qd \\u00d7 15\\ndays\\n600 mg\\nqd \\u00d7 35\\ndays\\n14\\n\\u2193 21\\n(\\u2193 15 to\\n\\u2193 26)\\n\\u2193 36\\n(\\u2193 32 to\\n\\u2193 40)\\n\\u2193 47\\n(\\u2193 41 to\\n\\u2193 53)\\nDiltiazem\\n240 mg \\u00d7 14\\ndays\\n600 mg\\nqd \\u00d7 28\\ndays\\n12\\n\\u2191 16\\n(\\u2191 6 to \\u2191\\n26)\\n\\u2191 11\\n(\\u2191 5 to \\u2191\\n18)\\n\\u2191 13\\n(\\u2191 1 to \\u2191\\n26)\\nVoriconazole\\n400 mg po q12h\\n\\u00d7 1 day then 200\\nmg po q12h \\u00d7 8\\ndays\\n400 mg\\nqd \\u00d7 9\\ndays\\nNA\\n\\u2191 38\\n\\u2191 44\\nNA\\n300 mg po q12h\\ndays 2\\u20137\\n300 mg\\nqd \\u00d7 7\\ndays\\nNA\\n\\u2193 14\\n \\n(\\u2193 7 to \\u2193\\n21)\\n\\u2194\\nNA\\n400 mg po q12h\\ndays 2\\u20137\\n300 m...","Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for\\nCoadministered Drug in the Presence of EFV\\nMean % Change of\\nCoadministered Drug\\nPharmacokinetic\\nParameters\\n (90% CI)\\nCoadministered Drug\\nDose of\\nCoadministered\\nDrug (mg)\\nEFV Dose\\n(mg)\\nN\\nC\\nAUC\\nC\\nAtazanavir\\n400 mg qd with a\\nlight meal d 1\\u201320\\n600 mg qd\\nwith a light\\nmeal d 7\\u2013\\n20\\n27\\n\\u2193 59\\n(\\u2193 49 to\\n\\u2193 67)\\n\\u2193 74\\n(\\u2193 68 to\\n\\u2193 78)\\n\\u2193 93\\n(\\u2193 90 to\\n\\u2193 95)\\n400 mg qd d 1\\u20136,\\nthen 300 mg qd\\nd 7\\u201320 with\\nritonavir 100 mg\\nqd and a light\\nmeal\\n600 mg qd\\n2...","meal\\n7\\u201320\\n300 mg\\nqd/ritonavir 100\\nmg qd d 1\\u201310\\n(pm), then 400\\nmg qd/ritonavir\\n100 mg qd d 11\\u2013\\n24 (pm)\\n(simultaneous\\nwith EFV)\\n600 mg qd\\nwith a light\\nsnack d\\n11\\u201324 (pm)\\n14\\n\\u2191 17\\n(\\u2191 8 to \\u2191\\n27)\\n\\u2194\\n\\u2193 42\\n(\\u2193 31 to\\n\\u2193 51)\\nIndinavir\\n1000 mg q8h \\u00d7\\n10 days\\n600 mg qd\\n\\u00d7 10 days\\n20\\nAfter morning dose\\n\\u2194\\n\\u2193 33\\n \\n(\\u2193 26 to\\n\\u2193 39)\\n\\u2193 39\\n \\n(\\u2193 24 to\\n\\u2193 51)\\nAfter afternoon dose\\n\\u2194\\n\\u2193 37\\n \\n(\\u2193 26 to\\n\\u2193 46)\\n\\u2193 52\\n \\n(\\u2193 47 to\\n\\u2193 57)\\nAfter evening dose\\n\\u2193 29\\n \\n(\\u2193 11 to\\n\\u2193 43)\\n\\u2193 46\\n \\n(\\u2193 37 to\\n\\u2193 54)\\n\\u2193 57\\n \\n(\\u2193 50 to\\n\\u2193 63)\\nLopinavir/ritona...","600 mg qd\\n\\u00d7 10 days\\n11\\nAfter AM dose\\n\\u2191 24\\n(\\u2191 12 to\\n\\u2191 38)\\n\\u2191 18\\n(\\u2191 6 to \\u2191\\n33)\\n\\u2191 42\\n(\\u2191 9 to \\u2191\\n86)\\nAfter PM dose\\n\\u2194\\n\\u2194\\n\\u2191 24\\n(\\u2191 3 to \\u2191\\n50)\\nSaquinavir SGC\\n1200 mg q8h \\u00d7\\n10 days\\n600 mg qd\\n\\u00d7 10 days\\n12\\n\\u2193 50\\n(\\u2193 28 to\\n\\u2193 66)\\n\\u2193 62\\n(\\u2193 45 to\\n\\u2193 74)\\n\\u2193 56\\n(\\u2193 16 to\\n\\u2193 77)\\nMaraviroc\\n100 mg bid\\n600 mg qd\\n12\\n\\u2193 51\\n(\\u2193 37 to\\n\\u2193 62)\\n\\u2193 45\\n(\\u2193 38 to\\n\\u2193 51)\\n\\u2193 45\\n(\\u2193 28 to\\n\\u2193 57)\\nRaltegravir\\n400 mg single\\ndose\\n600 mg qd\\n9\\n\\u2193 36\\n(\\u2193 2 to \\u2193\\n59)\\n\\u2193 36\\n(\\u2193 20 to\\n\\u2193 48)\\n\\u2193 21\\n(\\u2193 51 to\\n\\u2191 28)\\nBoceprevir\\n800 mg tid \\u00d7 6\\ndays\\n600 mg qd\\n\\u00d7 16 days\\nN...","days\\n\\u00d7 16 days\\nto \\u2191 8)\\n25)\\n58)\\nSimeprevir\\n150 mg qd \\u00d7 14\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n23\\n\\u2193 51\\n(\\u2193 46 to\\n\\u2193 56)\\n\\u2193 71\\n(\\u2193 67 to\\n\\u2193 74)\\n\\u2193 91\\n(\\u2193 88 to\\n\\u2193 92)\\nLedipasvir/sofosbuvir\\n90/400 mg qd \\u00d7\\n14 days\\n600 mg qd\\n\\u00d7 14 days\\nLedipasvir\\n15\\n\\u2193 34\\n(\\u2193 25 to\\n\\u2193 41)\\n\\u2193 34\\n(\\u2193 25 to\\n\\u2193 41)\\n\\u2193 34\\n(\\u2193 24 to\\n\\u2193 43)\\nSofosbuvir\\n\\u2194\\n\\u2194\\nNA\\nGS-331007\\n\\u2194\\n\\u2194\\n\\u2194\\nSofosbuvir\\n400 mg qd single\\ndose\\n600 mg qd\\n\\u00d714 days\\n16\\n\\u2193 19\\n(\\u2193 40 to\\n\\u2191 10)\\n\\u2194\\nNA\\nGS-331007\\n\\u2193 23\\n(\\u2193 16 to\\n\\u2193 30)\\n\\u2193 16\\n(\\u2193 24 to\\n\\u2193 8)\\nNA\\nSofosbuvir/velpatasvir\\n400/100 mg qd \\u00d7\\n14 days\\n600...","(\\u2191 32 to\\n\\u2191 69)\\n\\u2191 34\\n(\\u2191 18 to\\n\\u2191 53)\\n\\u2191 26\\n(\\u2191 9 to \\u2191\\n45)\\nItraconazole\\n200 mg q12h \\u00d7\\n28 days\\n600 mg qd\\n\\u00d7 14 days\\n18\\n\\u2193 37\\n(\\u2193 20 to\\n\\u2193 51)\\n\\u2193 39\\n(\\u2193 21 to\\n\\u2193 53)\\n\\u2193 44\\n(\\u2193 27 to\\n\\u2193 58)\\nHydroxy-itraconazole\\n\\u2193 35\\n(\\u2193 12 to\\n\\u2193 52)\\n\\u2193 37\\n(\\u2193 14 to\\n\\u2193 55)\\n\\u2193 43\\n(\\u2193 18 to\\n\\u2193 60)\\nPosaconazole\\n400 mg (oral\\nsuspension) bid\\n\\u00d7 10 and 20\\ndays\\n400 mg qd\\n\\u00d7 10 and\\n20 days\\n11\\n\\u2193 45\\n(\\u2193 34 to\\n\\u2193 53)\\n\\u2193 50\\n(\\u2193 40 to\\n\\u2193 57)\\nNA\\nRifabutin\\n300 mg qd \\u00d7 14\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n9\\n\\u2193 32\\n(\\u2193 15 to\\n\\u2193 46)\\n\\u2193 38\\n(\\u2193 28 to\\n\\u2193 47)\\n\\u2193 45\\n(\\u2193 31 to\\n\\u2193 56)\\nArt...","120 mg tablets (6\\n4-tablet doses\\nover 3 days)\\nArtemether\\n\\u2193 21\\u2193 38\\n\\u2193 51\\nNA\\ndihydroartemisinin\\n\\u2194\\n\\u2193 46\\nNA\\nlumefantrine\\n\\u219321\\nNA\\nAtorvastatin\\n10 mg qd \\u00d7 4\\ndays\\n600 mg qd\\n\\u00d7 15 days\\n14\\n\\u2193 14\\n(\\u2193 1 to \\u2193\\n26)\\n\\u2193 43\\n(\\u2193 34 to\\n\\u2193 50)\\n\\u2193 69\\n(\\u2193 49 to\\n\\u2193 81)\\nTotal active (including\\nmetabolites)\\n\\u2193 15\\n(\\u2193 2 to \\u2193\\n26)\\n\\u2193 32\\n(\\u2193 21 to\\n\\u2193 41)\\n\\u2193 48\\n(\\u2193 23 to\\n\\u2193 64)\\nPravastatin\\n40 mg qd \\u00d7 4\\ndays\\n600 mg qd\\n\\u00d7 15 days\\n13\\n\\u2193 32\\n(\\u2193 59 to\\n\\u2191 12)\\n\\u2193 44\\n(\\u2193 26 to\\n\\u2193 57)\\n\\u2193 19\\n(\\u2193 0 to \\u2193\\n35)\\nSimvastatin\\n40 mg qd \\u00d7 4\\ndays\\n600 mg qd\\n\\u00d7 15 days\\n14\\n\\u2193 7...","Epoxide metabolite\\n\\u2194\\n\\u2194\\n\\u2193 13\\n(\\u2193 30 to\\n\\u2191 7)\\nDiltiazem\\n240 mg \\u00d7 21\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n13\\n\\u2193 60\\n(\\u2193 50 to\\n\\u2193 68)\\n\\u2193 69\\n(\\u2193 55 to\\n\\u2193 79)\\n\\u2193 63\\n(\\u2193 44 to\\n\\u2193 75)\\nDesacetyl diltiazem\\n\\u2193 64\\n(\\u2193 57 to\\n\\u2193 69)\\n\\u2193 75\\n(\\u2193 59 to\\n\\u2193 84)\\n\\u2193 62\\n(\\u2193 44 to\\n\\u2193 75)\\nN-monodesmethyl\\ndiltiazem\\n\\u2193 28\\n(\\u2193 7 to \\u2193\\n44)\\n\\u2193 37\\n(\\u2193 17 to\\n\\u2193 52)\\n\\u2193 37\\n(\\u2193 17 to\\n\\u2193 52)\\nEthinyl\\nestradiol/norgestimate\\n0.035 mg/0.25\\nmg \\u00d7 14 days\\n600 mg qd\\n\\u00d7 14 days\\nEthinyl estradiol\\n21\\n\\u2194\\n\\u2194\\n\\u2194\\nNorelgestromin\\n21\\n\\u2193 46\\n(\\u219339 to\\n\\u2193 52)\\n\\u2193 64\\n(\\u2193 62 to\\n\\u2193 67)\\n\\u2193 82\\n(\\u2193 79 to\\n\\u2193 85)\\nL...","NA = not available\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\n#\\n\\u00de\\n\\u00df\\n\\u00e0\\n\\u00e8\\n\\u00f0\\n\\u00f8\\n\\u00fd\\n\\u00a3\\nMethadone\\nmaintenance 35\\u2013\\n100 mg daily\\n\\u00d7 14\\u201321\\ndays\\n11\\n(\\u2193 25 to\\n\\u2193 59)\\n(\\u2193 33 to\\n\\u2193 66)\\nNA\\nBupropion\\n150 mg single\\ndose (sustained-\\nrelease)\\n600 mg qd\\n\\u00d7 14 days\\n13\\n\\u2193 34\\n(\\u219321 to\\n\\u219347)\\n\\u2193 55\\n(\\u219348 to\\n\\u219362)\\nNA\\nHydroxybupropion\\n\\u2191 50\\n(\\u2191 20 to\\n\\u2191 80)\\n\\u2194\\nNA\\nSertraline\\n50 mg qd \\u00d7 14\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n13\\n\\u2193 29\\n(\\u2193 15 to\\n\\u2193 40)\\n\\u2193 39\\n(\\u2193 27 to\\n\\u2193 50)\\n\\u2193 46\\n(\\u2193 31 to\\n\\u2193 58)\\nVoriconazole\\n400 mg po q12h\\n\\u00d7 1 day then 200\\nmg po q12h \\u00d7 8\\ndays\\n400 mg qd\\n\\u00d7 9 days\\nNA\\n\\u2193 61\\n\\u2193 77\\nN...","were unaffected when FTC and TDF were administered together versus each agent\\ndosed alone.\\nIn vitro\\n and clinical pharmacokinetic drug-drug interaction studies have shown that the\\npotential for CYP mediated interactions involving FTC and tenofovir with other medicinal\\nproducts is low.\\nTDF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)\\ntransporters. When TDF is coadministered with an inhibitor of these transporters, an\\nincrease in absorption may be observed.\\nN...","Parallel-group design; N for EFV + lopinavir/ritonavir, N for lopinavir/ritonavir alone.\\nValues are for lopinavir. The pharmacokinetics of ritonavir 100 mg q12h are unaffected by\\nconcurrent EFV.\\n95% CI\\nSoft Gelatin Capsule\\nStudy conducted with ATRIPLA coadministered with HARVONI.\\nThe predominant circulating nucleoside metabolite of sofosbuvir.\\nStudy conducted with ATRIPLA coadministered with SOVALDI\\u2122 (sofosbuvir).\\nStudy conducted with ATRIPLA coadministered with EPCLUSA.\\nNot available because of...","no clinically significant drug interactions have been observed between TDF and abacavir,\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\nconducted in healthy volunteers.\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\ntenofovir pharmacokinetics we...","of\\ncoadministered drugs are shown in Table 7.\\nTable 6 Drug Interactions: Changes in Pharmacokinetic Parameters for\\nTenofovir in the Presence of the Coadministered Drug\\nCoadministered\\nDrug\\nDose of\\nCoadministered\\nDrug (mg)\\nN\\nMean % Change of Tenofovir\\nPharmacokinetic Parameters\\n \\n(90% CI)\\nC\\nAUC\\nC\\n*\\nAtazanavir\\n400 once daily \\u00d7\\n14 days\\n33\\n\\u2191 14\\n(\\u2191 8 to \\u2191 20)\\n\\u2191 24\\n(\\u2191 21 to \\u2191\\n28)\\n\\u2191 22\\n(\\u2191 15 to \\u2191\\n30)\\nAtazanavir/ritonavir\\n300/100 once\\ndaily\\n12\\n\\u2191 34\\n(\\u2191 20 to \\u2191\\n51)\\n\\u2191 37\\n(\\u2191 30 to \\u2191\\n45)\\n\\u2191 29\\n(\\u2191 21 to \\u2191\\n36)\\nD...","24\\n\\u2194\\n\\u2191 32\\n(\\u2191 25 to \\u2191\\n38)\\n\\u2191 51\\n(\\u2191 37 to \\u2191\\n66)\\nSofosbuvir\\n400 once daily\\n16\\n\\u2191 25\\n(\\u2191 8 to \\u2191 45)\\n\\u2194\\n\\u2194\\nSofosbuvir/velpatasvir\\n400/100 once\\ndaily\\n15\\n\\u2191 77\\n(\\u2191 53 to \\u2191\\n104)\\n\\u2191 81\\n(\\u2191 68 to \\u2191\\n94)\\n\\u2191 121\\n(\\u2191 100 to \\u2191\\n143)\\nTipranavir/ritonavir\\n500/100 twice\\ndaily\\n22\\n\\u2193 23\\n(\\u2193 32 to \\u2193\\n13)\\n\\u2193 2\\n(\\u2193 9 to \\u2191 5)\\n\\u2191 7\\n(\\u2193 2 to \\u2191 17)\\n750/200 twice\\ndaily (23 doses)\\n20\\n\\u2193 38\\n(\\u2193 46 to \\u2193\\n29)\\n\\u2191 2\\n(\\u2193 6 to \\u2191 10)\\n\\u2191 14\\n(\\u2191 1 to \\u2191 27)\\nmax\\nmin\\nmax\\nmin\\n*\\n,\\n\\u2020\\n\\u2021\\nmax\\nmin\\nAll interaction trials conducted in healthy volunteers.\\nSubjects receive...","*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\n#\\n\\u00de\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\nCoadministered Drug in the Presence of TDF\\nCoadministered\\nDrug\\nDose of\\nCoadministered\\nDrug (mg)\\nN\\nMean % Change of Coadministered\\nDrug Pharmacokinetic Parameters\\n \\n(90% CI)\\nC\\nAUC\\nC\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\n#\\n\\u00de\\n\\u00df\\n\\u00e0\\n\\u00e8\\nAtazanavir\\n400 once daily \\u00d7\\n14 days\\n34\\n\\u2193 21\\n(\\u2193 27 to \\u2193 14)\\n\\u2193 25\\n(\\u2193 30 to \\u2193 19)\\n\\u2193 40\\n(\\u2193 48 to \\u2193 32)\\nAtazanavir/ritonavir\\n300/100 once daily\\n\\u00d7 42 days\\n10\\n\\u2193 28\\n(\\u2193 50 to \\u2191 5)\\n\\u2193 25\\n \\n(\\u2193 42 to \\u2193 3)\\n\\u2193 23\\n \\n(\\u2193 46 to \\u2191 10)\\nDa...","400/100 twice daily\\n\\u00d7 14 days\\n24\\n\\u2194\\n\\u2194\\n\\u2194\\nTipranavir\\nTipranavir/ritonavir\\n500/100 twice daily\\n22\\n\\u2193 17\\n(\\u2193 26 to \\u2193 6)\\n\\u2193 18\\n(\\u2193 25 to \\u2193 9)\\n\\u2193 21\\n(\\u2193 30 to \\u2193 10)\\nTipranavir/ritonavir\\n750/200 twice daily\\n(23 doses)\\n20\\n\\u2193 11\\n(\\u2193 16 to \\u2193 4)\\n\\u2193 9\\n(\\u2193 15 to \\u2193 3)\\n\\u2193 12\\n(\\u2193 22 to 0)\\n12.4 Microbiology\\nMechanism of Action\\nSubjects received TDF 300 mg once daily.\\nIncrease = \\u2191; Decrease = \\u2193; No Effect = \\u2194\\nReyataz Prescribing Information.\\nPrezista Prescribing Information.\\nSubjects received didanosine buffered tablets.\\nApti...","AUC and C\\n values of atazanavir that were 2.3- and 4-fold higher than the respective values\\nobserved for atazanavir 400 mg when given alone.\\nmin\\nPrezista Prescribing Information.\\nVidex EC Prescribing Information. \\nSubjects received didanosine enteric-coated capsules.\\n373 kcal, 8.2 g fat.\\nCompared with didanosine (enteric-coated) 400 mg administered alone under fasting conditions.\\nAptivus Prescribing Information.\\n\\u00a7\\n\\u00b6\\n\\u00b6\\n#\\n\\u00de\\n\\u00df\\n\\u00e0\\n\\u00e0\\n\\u00e8","Efavirenz:\\n \\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\u03b1, \\u03b2, \\u03b3, and \\u03b4 are\\nnot inhibited by EFV.\\nEmtricitabine:\\n \\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\nthe activity of the HIV-1 RT by competing wi...","Tenofovir DF:\\n \\nTDF is an acyclic nucleoside phosphonate diester analog of adenosine\\nmonophosphate. TDF requires initial diester hydrolysis for conversion to tenofovir and\\nsubsequent phosphorylations by cellular enzymes to form tenofovir diphosphate.\\nTenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural\\nsubstrate deoxyadenosine 5\\u2032-triphosphate and, after incorporation into DNA, by DNA\\nchain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA\\npo...","Efavirenz:\\n \\nThe concentration of EFV inhibiting replication of wild-type laboratory adapted\\nstrains and clinical isolates in cell culture by 90\\u201395% (EC\\n) ranged from 1.7\\u201325 nM in\\nlymphoblastoid cell lines, peripheral blood mononuclear cells, and macrophage/monocyte\\ncultures. Efavirenz demonstrated additive antiviral activity against HIV-1 in cell culture\\nwhen combined with non-nucleoside reverse transcriptase inhibitors (NNRTIs)\\n(delavirdine and nevirapine), nucleoside reverse transcriptase inh...","activity in cell culture with atazanavir. Efavirenz demonstrated antiviral activity against\\nclade B and most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, and N), but had\\nreduced antiviral activity against group O viruses. Efavirenz is not active against HIV-2.\\nEmtricitabine:\\n \\nThe antiviral activity in cell culture of FTC against laboratory and clinical\\nisolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and\\nperipheral blood mononuclear cells. The 50...","saquinavir), additive to synergistic effects were observed. Emtricitabine displayed\\nantiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC\\n values\\nranged from 0.007\\u20130.075 \\u00b5M) and showed strain specific activity against HIV-2 (EC\\nvalues ranged from 0.007\\u20131.5 \\u00b5M).\\nTenofovir DF:\\n \\nThe antiviral activity in cell culture of tenofovir against laboratory and\\nclinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary\\nmonocyte/macrophage cells and periphera...","tenofovir were in the range of 0.04\\u20138.5 \\u00b5M. In drug combination studies of tenofovir\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\n(EC\\n values ranged from 0.5\\u20132.2 \\u00b5M) and showed strain-specific ...","In addition, a K70E substitution in HIV-1 reverse transcriptase has been selected by\\ntenofovir and results in reduced susceptibility to tenofovir.\\nIn a clinical trial of treatment-na\\u00efve subjects \\n[Study 934,\\n see \\nClinical Studies (14)\\n]\\nresistance analysis was performed on HIV-1 isolates from all confirmed virologic failure\\nsubjects with greater than 400 copies/mL of HIV-1 RNA at Week 144 or early\\ndiscontinuations. Genotypic resistance to EFV, predominantly the K103N substitution,\\nwas the most ...","analyzed subject isolates in the FTC + TDF group and in 10/29 analyzed subject isolates\\nin the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects\\ndeveloped a detectable K65R substitution in their HIV-1 as analyzed through standard\\ngenotypic analysis.\\nIn a clinical trial of treatment-na\\u00efve subjects, isolates from 8/47 (17%) analyzed subjects\\nreceiving TDF developed the K65R substitution through 144 weeks of therapy; 7 of\\nthese occurred in the first 48 weeks of treatment and ...","resulting in the K65R amino acid substitution.\\nEfavirenz:\\n \\nClinical isolates with reduced susceptibility in cell culture to EFV have been\\nobtained. The most frequently observed amino acid substitution in clinical trials with EFV\\nis K103N (54%). One or more RT substitutions at amino acid positions 98, 100, 101,\\n103, 106, 108, 188, 190, 225, 227, and 230 were observed in subjects failing treatment\\nwith EFV in combination with other antiretrovirals. Other resistance substitutions\\nobserved to emerg...","V179D, double substitutions L100I/V108I, and triple substitutions L100I/V179D/Y181C in\\nRT.\\nEmtricitabine:\\n \\nEmtricitabine-resistant isolates of HIV-1 have been selected in cell culture\\nand in clinical trials. Genotypic analysis of these isolates showed that the reduced\\n50\\n50\\n50\\n90","susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\n(M184V/I).\\nTenofovir DF:\\n \\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\nfold reduction in susceptibility to tenofovir.\\nCross Resistance\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\n Cross resistance has been ...","Therefore, cross resistance among these drugs may occur in patients whose virus\\nharbors either or both of these amino acid substitutions.\\nEfavirenz:\\n \\nClinical isolates previously characterized as EFV resistant were also\\nphenotypically resistant in cell culture to delavirdine and nevirapine compared to\\nbaseline. Delavirdine- and/or nevirapine-resistant clinical viral isolates with NNRTI\\nresistance-associated substitutions (A98G, L100I, K101E/P, K103N/S, V106A, Y181X,\\nY188X, G190X, P225H, F227L, ...","zidovudine, and NNRTIs (delavirdine, EFV, and nevirapine). HIV-1 isolates containing the\\nK65R substitution, selected \\nin vivo\\n by abacavir, didanosine, and tenofovir, demonstrated\\nreduced susceptibility to inhibition by FTC. Viruses harboring substitutions conferring\\nreduced susceptibility to stavudine and zidovudine (M41L, D67N, K70R, L210W,\\nT215Y/F, and K219Q/E) or didanosine (L74V) remained sensitive to FTC.\\nTenofovir DF:\\n \\nCross resistance has been observed among NRTIs. The K65R substitution...","drugs may occur in patients whose virus harbors the K65R substitution. The K70E\\nsubstitution selected clinically by TDF results in reduced susceptibility to abacavir,\\ndidanosine, FTC, and lamivudine. HIV-1 isolates from subjects (N=20) whose HIV-1\\nexpressed a mean of 3 zidovudine-associated RT amino acid substitutions (M41L, D67N,\\nK70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility\\nto tenofovir. Subjects whose virus expressed an L74V substitution without zidovudi...","Efavirenz:\\n \\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\nwere increased above background in females. No increases in tumor incidence above\\nbackground were seen in males. In studies in which rats were administered EFV at\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\n...","or clastogenic activity in a battery of \\nin vitro\\n and \\nin vivo\\n studies. These included bacterial\\nmutation assays in \\nS. typhimurium\\n and \\nE. coli\\n, mammalian mutation assays in Chinese\\nhamster ovary cells, chromosome aberration assays in human peripheral blood\\nlymphocytes or Chinese hamster ovary cells, and an \\nin vivo\\n mouse bone marrow\\nmicronucleus assay. Given the lack of genotoxic activity of EFV, the relevance to\\nhumans of neoplasms in EFV-treated mice is not known.\\nEfavirenz did not impa...","humans given therapeutic doses of EFV.\\nEmtricitabine:\\n \\nIn long-term carcinogenicity studies of FTC, no drug-related increases in\\ntumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human\\nsystemic exposure at the therapeutic dose of 200 mg/day) or in rats at doses up to 600\\nmg/day (31 times the human systemic exposure at the therapeutic dose).\\nEmtricitabine was not genotoxic in the reverse mutation bacterial test (Ames test), or\\nthe mouse lymphoma or mouse micronucleus ...","daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of\\napproximately 60-fold higher than human exposures at the recommended 200 mg daily\\ndose.\\nTenofovir DF:\\n \\nLong-term oral carcinogenicity studies of TDF in mice and rats were\\ncarried out at exposures up to approximately 16 times (mice) and 5 times (rats) those\\nobserved in humans at the therapeutic dose for HIV-1 infection. At the high dose in\\nfemale mice, liver adenomas were increased at exposures 16 times that i...","was negative when administered to male mice.\\nThere were no effects on fertility, mating performance, or early embryonic development\\nwhen TDF was administered to male rats at a dose equivalent to 10 times the human\\ndose based on body surface area comparisons for 28 days prior to mating and to\\nfemale rats for 15 days prior to mating through Day 7 of gestation. There was, however,","an alteration of the estrous cycle in female rats.\\n13.2 Animal Toxicology and/or Pharmacology\\nEfavirenz:\\n \\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\nrecommended dose.\\nTenofovir DF:\\n \\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\nin humans caused bone toxicity. In monkeys...","unknown.\\nEvidence of renal toxicity was noted in 4 animal species administered tenofovir and TDF.\\nIncreases in serum creatinine, BUN, glycosuria, proteinuria, phosphaturia and/or\\ncalciuria and decreases in serum phosphate were observed to varying degrees in these\\nanimals. These toxicities were noted at exposures (based on AUCs) 2- to 20-times\\nhigher than those observed in humans. The relationship of the renal abnormalities,\\nparticularly the phosphaturia, to the bone toxicity is not known.\\n14 CLI...","virologic failure who switched from their current regimen to ATRIPLA.\\nIn antiretroviral treatment-experienced patients, the use of ATRIPLA tablets may be\\nconsidered for patients with HIV-1 strains that are expected to be susceptible to the\\ncomponents of ATRIPLA as assessed by treatment history or by genotypic or\\nphenotypic testing \\n[see \\nMicrobiology (12.4)\\n].\\nStudy 934:\\n \\nData through 144 weeks are reported for Study 934, a randomized, open-\\nlabel, active-controlled multicenter trial comparing ...","TDF with EFV. Subjects had a mean age of 38 years (range 18\\u201380); 86% were male, 59%\\nwere Caucasian, and 23% were Black. The mean baseline CD4\\n cell count was 245\\ncells/mm\\n (range 2\\u20131191), and median baseline plasma HIV-1 RNA was 5.01 log\\ncopies/mL (range 3.56\\u20136.54). Subjects were stratified by baseline CD4\\n cell count (&lt; or\\n\\u2265200 cells/mm\\n), and 41% had CD4\\n cell counts &lt;200 cells/mm\\n. Fifty-one percent\\n(51%) of subjects had baseline viral loads &gt;100,000 copies/mL. Treatment outcomes\\nthrough 48 a...","Outcomes\\nAt Week 48\\nAt Week 144\\nFTC+TDF+EFV\\n(N=244)\\nAZT/3TC+EFV\\n(N=243)\\nFTC+TDF+\\nEFV\\n(N=227)\\nAZT/3TC+EFV\\n(N=229)\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\nResponder\\n84%\\n73%\\n71%\\n58%\\nVirologic failure\\n2%\\n4%\\n3%\\n6%\\n  Rebound\\n1%\\n3%\\n2%\\n5%\\n  Never suppressed\\n0%\\n0%\\n0%\\n0%\\n  Change in antiretroviral\\nregimen\\n1%\\n1%\\n1%\\n1%\\nDeath\\n&lt;1%\\n1%\\n1%\\n1%\\nDiscontinued due to\\nadverse event\\n4%\\n9%\\n5%\\n12%\\nDiscontinued for other\\nreasons\\n10%\\n14%\\n20%\\n22%\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\nzidovudine/lamivudine group, respectiv...","other reasons in the zidovudine/lamivudine group in this open-label trial. In addition, 80%\\nand 70% of subjects in the FTC + TDF group and the zidovudine/lamivudine group,\\nrespectively, achieved and maintained HIV-1 RNA &lt;50 copies/mL through Week 48 (64%\\nand 56% through Week 144). The mean increase from baseline in CD4\\n cell count was\\n190 cells/mm\\n in the FTC + TDF group and 158 cells/mm\\n in the zidovudine/lamivudine\\ngroup at Week 48 (312 and 271 cells/mm\\n at Week 144).\\nThrough 48 weeks, 7 subje...","stable virologic suppression on combination antiretroviral therapy consisting of at least\\ntwo NRTIs administered in combination with a protease inhibitor (with or without\\nritonavir) or a NNRTI.\\nTo be enrolled, subjects were to have HIV-1 RNA &lt;200 copies/mL for at least 12 weeks\\non their current regimen prior to trial entry with no known HIV-1 substitutions\\nconferring resistance to the components of ATRIPLA and no history of virologic failure.\\nThe trial compared the efficacy of switching to ATRIP...","consent to continue trial after Week 48 or Week 96 were excluded from analysis.\\nSubjects achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Weeks 48 and\\n144.\\nIncludes confirmed viral rebound and failure to achieve confirmed HIV-1 RNA &lt;400 copies/mL\\nthrough Weeks 48 and 144.\\nIncludes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other\\nreasons.\\n\\u2020\\n\\u2021\\n\\u00a7\\n+\\n3\\n3\\n3","22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\nand 3% were of other races. At baseline, median CD4\\n cell count was 516 cells/mm\\n,\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\nregimen at trial enrollment.\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...","sides. Each bottle contains 30 tablets and silica gel desiccant, and is closed with a child-\\nresistant closure.\\nStore below 30 \\u00b0C (86 \\u00b0F).\\nKeep container tightly closed.\\nDispense only in original container.\\n17 PATIENT COUNSELING INFORMATION\\nAdvise the patient to read the approved patient labeling (Patient Information).\\nSevere Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV\\nInform patients that severe acute exacerbations of hepatitis B have been reported in\\npatients wh...","close medical follow-up for several months after stopping ATRIPLA to monitor for\\nexacerbations of hepatitis \\n[see \\nWarnings and Precautions (5.1)\\n].\\nRash\\nInform patients that a common side effect is rash, and that rashes usually go away\\nwithout any change in treatment. However, since rash may be serious, advise patients\\nto contact their physician promptly if rash occurs \\n[see \\nWarnings and Precautions (5.2)\\n].\\nHepatotoxicity\\nInform patients to watch for early warning signs of liver inflammation ...","[see \\nWarnings and Precautions\\n(5.3)\\n and \\nAdverse Reactions (6.1)\\n]\\n.\\nDrug Interactions\\nAdvise patients that ATRIPLA may interact with many drugs; therefore, advise patients\\nto report to their healthcare provider the use of any other medication, including other\\ndrugs for treatment of hepatitis C virus \\n[see \\nWarnings and Precautions (5.4)\\n and \\nDrug\\n+\\n3\\n+","Interactions (7)\\n]\\n.\\nPsychiatric Symptoms\\nInform patients that serious psychiatric symptoms including severe depression,\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\n[see \\nWarnings and Precautions (5.5)\\n]\\n.\\nAdvise patients to seek immediate medical evaluation if they experience severe\\npsychiatric adverse experiences.\\nAdvise patients to inform their physician of any history o...","Dosing at bedtime may improve the tolerability of these symptoms, which are likely to\\nimprove with continued therapy.\\nAlert patients to the potential for additive effects when ATRIPLA is used\\nconcomitantly with alcohol or psychoactive drugs.\\nInstruct patients that if they experience NSS to avoid potentially hazardous tasks\\nsuch as driving or operating machinery \\n[see \\nWarnings and Precautions (5.6)\\n and\\nDosage and Administration (2.2)\\n].\\nInform patients that there is a risk of developing late-on...","syndrome, has been reported. Advise patients to avoid using ATRIPLA with concurrent\\nor recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs) \\n[see \\nWarnings\\nand Precautions (5.7)\\n].\\nEmbryo-Fetal Toxicity\\nApprise patients of the potential harm to the fetus if ATRIPLA is used during the first\\ntrimester of pregnancy, or if the patient becomes pregnant while taking this drug.\\nInstruct adults and adolescents of childbearing potential receiving ATRIPLA to avoid\\npregnancy and to notify...","half-life of EFV, recommend use of adequate contraceptive measures for 12 weeks after\\ndiscontinuation of ATRIPLA \\n[see \\nUse in Specific Populations (8.1\\n, \\n8.3)\\n]\\n.\\nBone Loss and Mineralization Defects\\nInform patients that decreases in bone mineral density have been observed with the use\\nof TDF, a component of ATRIPLA. Advise patients that bone mineral density monitoring\\nmay be performed in patients who have a history of pathologic bone fracture or other\\nrisk factors for osteoporosis or bone los...","Convulsions\\nInform patients that convulsions have been reported with the use of EFV, a component\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\nmetabolized by the liver may require periodic monitoring of plasma levels \\n[see \\nWarnings\\nand Precautions (5.10)\\n and \\nDrug Interactions (7.3)\\n]\\n.\\nLactic Acidosis and Severe Hepatomegaly\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\nfatal cases, have been reported. Treatmen...","symptoms of inflammation from previous infections may occur soon after anti-HIV\\ntreatment is started. It is believed that these symptoms are due to an improvement in\\nthe body&#x27;s immune response, enabling the body to fight infections that may have been\\npresent with no obvious symptoms. Advise patients to inform their healthcare provider\\nimmediately of any symptoms of infection \\n[see \\nWarnings and Precautions (5.12)\\n]\\n.\\nFat Redistribution\\nInform patients that redistribution or accumulation of body ...","take ATRIPLA on a regular dosing schedule to avoid missing doses. Advise patients that\\ndosing at bedtime may improve the tolerability of nervous system symptoms \\n[see\\nDosage and Administration (2.1)\\n].\\nPregnancy Registry\\nAdvise patients that there is a pregnancy exposure registry that monitors pregnancy\\noutcomes in patients exposed to ATRIPLA during pregnancy \\n[see \\nUse in Specific\\nPopulations (8.1)\\n]\\n.\\nLactation\\nInstruct patients not to breastfeed because HIV-1 can be passed to the baby in the\\n...","Patient Information\\n \\nATRIPLA\\u2122 (uh TRIP luh)\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\nWhat is the most important information I should know about ATRIPLA?\\nATRIPLA can cause serious side effects, including:\\nWorsening of hepatitis B virus (HBV) infection.\\n Your healthcare provider will\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\nA\\n\\"flare-up\\" is when yo...","health often and do blood tests regularly for several months to check your HBV\\ninfection, or give you a medication to treat hepatitis B. Tell your healthcare\\nprovider about any new or unusual symptoms you may have after you stop\\ntaking ATRIPLA.\\nFor more information about side effects see the section, \\n\\"\\nWhat are the possible\\nside effects of ATRIPLA?\\n\\"\\nWhat is ATRIPLA?\\n \\nATRIPLA is a prescription medicine that contains efavirenz, emtricitabine, and tenofovir\\ndisoproxil fumarate combined in 1 tabl...","who weigh less than 88 lbs (40 kg).\\nWho should not take ATRIPLA?\\nDo not take ATRIPLA if you:\\nare allergic to efavirenz\\ntake the medicine called voriconazole, elbasvir or grazoprevir\\nAsk your healthcare provider if you are not sure if you take any of these medicines.\\nBefore taking ATRIPLA\\n, tell your healthcare provider about all of your medical\\nconditions, including if you:\\nhave liver problems, including hepatitis B or C virus infection\\nhave heart problems\\nhave or have had mental problems\\nhave a...","test before you start treatment with ATRIPLA. \\nYou should not become pregnant\\nduring treatment with ATRIPLA and for 12 weeks after stopping\\ntreatment.\\n Tell your healthcare provider if you become pregnant or think you may","be pregnant during treatment with ATRIPLA.\\nFemales who are able to become pregnant should use 2 effective\\nforms of birth control (contraception) during treatment with ATRIPLA\\nand for 12 weeks after stopping treatment.\\nA barrier form of birth control should always be used along with\\nanother type of birth control\\n. Barrier forms of birth control may include\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\nBirth control methods that contain the hormone progesterone such ...","ATRIPLA during pregnancy. The purpose of this registry is to collect information\\nabout the health of you and your baby. Talk to your healthcare provider about\\nhow you can take part in this registry.\\nare breastfeeding or plan to breastfeed. ATRIPLA can pass into your breast milk. Do\\nnot breastfeed because of the risk of passing HIV-1 to your baby.\\nTell your healthcare provider about all the medicines you take\\n, including\\nprescription and over-the-counter medicines, vitamins and herbal supplements...","healthcare provider can tell you if it is safe to take ATRIPLA with other medicines.\\nHow should I take ATRIPLA?\\nTake ATRIPLA exactly as your healthcare provider tells you to.\\nIf you take ATRIPLA with other medicines used to treat HIV-1, your healthcare\\nprovider will tell you what medicines to take and how to take them.\\nTake ATRIPLA 1 time each day on an empty stomach. You should take ATRIPLA at\\nthe same time each day.\\nTaking ATRIPLA at bedtime may make some side effects less bothersome.\\nDo not m...","with ATRIPLA.\\nIf you take too much ATRIPLA, call your healthcare provider or got to the nearest\\nhospital emergency room right away.\\nWhat should I avoid while taking ATRIPLA?\\nATRIPLA can cause dizziness, impaired concentration and drowsiness. If you have\\nthese symptoms, do not drive a car, use heavy machinery, or do anything that\\nrequires you to be alert.\\nWhat are the possible side effects of ATRIPLA?\\nATRIPLA may cause serious side effects, including:","See \\"\\nWhat is the most important information I should know about\\nATRIPLA?\\n\\"\\nRash.\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\naway without any change in your treatment. Tell your healthcare provider right away\\nif you develop a rash during treatment with ATRIPLA.\\nSevere liver problems. I\\nn rare cases, severe liver problems can happen that can\\nlead to death. \\nTell your healthcare provider right away if you get these\\nsymptoms:\\n skin or the white part of your eyes ...","manic reactions have happened in people who take ATRIPLA. These mental health\\nproblems may happen more often in people who have a history of mental problems\\nor drug use, or who take medicines to treat mental problems. Tell your healthcare\\nprovider right away if you develop serious mental problems during treatment with\\nATRIPLA.\\nNervous system problems.\\n Nervous system problems usually begin during the\\nfirst or second day of treatment with ATRIPLA and usually go away after 2 to 4\\nweeks of treatmen...","ATRIPLA. Symptoms of nervous system problems may include:\\ndizziness\\nproblems concentrating\\nabnormal dreams\\nunusually happy mood\\nagitation\\nthought problems\\nslow thoughts and physical\\nmovement\\nproblems sleeping\\nexcessive sleepiness or difficulty\\nawakening\\nseeing or hearing things that are not real\\n(hallucinations)\\nconfusion\\nmemory problems\\nlack of coordination or difficulty with\\nbalance\\nIf you have dizziness, trouble concentrating or sleepiness, do not drive a car, use\\nmachinery, or do anything th...","ATRIPLA if you develop new or worse kidney problems during treatment with\\nATRIPLA.\\nBone problems\\n can happen in some people who take ATRIPLA. Bone problems\\ninclude bone pain or softening or thinning of bones, which may lead to fractures.\\nYour healthcare provider may need to do tests to check your bones.\\nSeizures.\\n Your healthcare provider may do blood tests during treatment with\\nATRIPLA if you take certain medicines used to prevent seizures.\\nToo much lactic acid in your blood (lactic acidosis).\\n...","provider right away if you develop any of these symptoms:\\nweakness or being more tired than\\nusual\\nbeing short of breath or fast\\nbreathing\\ncold or blue hands and feet\\nfast or abnormal heartbeat\\nunusual muscle pain\\nstomach pain with nausea and vomiting\\nfeel dizzy or lightheaded\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\n Your\\nimmune system may get stronger and begin to fight infections that have been hidden...","fat in the upper back and neck (\\"buffalo hump\\"), in the breasts, and around the\\ntrunk. Loss of fat from the legs, arms, and face may also happen. The cause and\\nlong-term health effects of these body fat changes are not known.\\nThe most common side effects of ATRIPLA include:\\ndiarrhea\\ntiredness\\ndizziness\\nproblems sleeping\\nrash\\nnausea\\nheadache\\ndepression\\nabnormal dreams\\nThese are not all the possible side effects of ATRIPLA. \\nCall your doctor for medical advice about side effects. You may report si...","Medicines are sometimes prescribed for purposes other than those listed in a Patient\\nInformation leaflet. Do not use ATRIPLA for a condition for which it was not prescribed.\\nDo not give ATRIPLA to other people, even if they have the same symptoms that you\\nhave. It may harm them. You can ask your healthcare provider or pharmacist for\\ninformation about ATRIPLA that is written for health professionals.\\nWhat are the ingredients of ATRIPLA?\\nActive Ingredients:\\n efavirenz, emtricitabine, and tenofovir...","Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404\\nATRIPLA, EMTRIVA, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc., or\\nits related companies. All other trademarks referenced herein are the property of their","respective owners.\\n\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\n21937-GS-020A\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\n61958-1601-3\\n30 tablets\\nATRIPLA\\u2122\\n(efavirenz 600 mg/emtricitabine 200 mg/\\ntenofovir disoproxil fumarate 300 mg)\\ntablets\\nGILEAD ACCESS PROGRAM\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\nALERT: Find out about medicines that\\nshould NOT be taken with ATRIPLA\\nRx only\\nPOM\\nATRIPLA ACCESS  \\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...","Gilead Sciences, Inc.\\nIngredient Name\\nBasis of Strength\\nStrength\\nEFAVIRENZ\\n (UNII: JE6H2O27P8) \\n(EFAVIRENZ - UNII:JE6H2O27P8)\\nEFAVIRENZ\\n600 mg\\nEMTRICITABINE\\n (UNII: G70B4ETF4S) \\n(EMTRICITABINE - UNII:G70B4ETF4S)\\nEMTRICITABINE\\n200 mg\\nTENOFOVIR DISOPROXIL FUMARATE\\n (UNII: OTT9J7900I) \\n(TENOFOVIR\\nANHYDROUS - UNII:W4HFE001U5)\\nTENOFOVIR DISOPROXIL\\nFUMARATE\\n300 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\n (UNII: RF...","TITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nProduct Characteristics\\nColor\\nWHITE\\nScore\\nno score\\nShape\\nOVAL\\nSize\\n20mm\\nFlavor\\nImprint Code\\n123\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:61958-\\n1601-1\\n30 \\nin 1 BOTTLE, PLASTIC; Type 0: Not a\\nCombination Product\\n07/20/2006\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nEXPORT ONLY\\n07/20/2006\\nLabeler - \\nGilead Sciences, Inc. ...","APRETUDE- cabotegravir \\n \\nViiV Healthcare Company\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use APRETUDE safely and\\neffectively. See full prescribing information for APRETUDE.\\nAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use\\nInitial U.S. Approval: 2021\\nWARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-\\nEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION\\nSee full pres...","resistant HIV-1 variants have been identified with use of APRETUDE for HIV-1 PrEP by\\nindividuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP\\nunless negative infection status is confirmed. Individuals who acquire HIV-1 while\\nreceiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen.\\n(\\n2.2\\n, \\n4\\n, \\n5.1\\n)\\nRECENT MAJOR CHANGES\\nWarnings and Precautions, Hypersensitivity Reactions (\\n5.4\\n)\\n4/2025\\nINDICATIONS AND USAGE\\nAPRETUDE is an HIV-1 integrase s...","oral lead-in with oral cabotegravir) for HIV-1 PrEP. (\\n1\\n)\\nDOSAGE AND ADMINISTRATION\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nDOSAGE FORMS AND STRENGTHS\\nInjection: Single-dose vial of 600 mg/3 mL (200 mg/mL) of cabotegravir extended-release injectable\\nsuspension. (\\n3\\n)\\nCONTRAINDICATIONS\\n\\u2022\\n\\u2022\\n\\u2022\\nWARNINGS AND PRECAUTIONS\\n\\u2022\\n\\u2022\\nHIV-1 Screening: Screen all individuals for HIV-1 infection immediately prior to initiating APRETUDE for\\nHIV-1 PrEP and prior to each injection while taking APRETUDE. (\\n2.2\\n)\\nPrior to initiating APRETUDE, an or...","continue with the injections every 2 months thereafter. (\\n2.5\\n)\\nUnknown or positive HIV-1 status. (\\n4\\n)\\nPrevious hypersensitivity reaction to cabotegravir. (\\n4\\n)\\nCoadministration with drugs where significant decreases in cabotegravir plasma concentrations may\\noccur. (\\n4\\n)\\nComprehensive management to reduce the risk of HIV-1 acquisition. (\\n5.1\\n)\\nPotential risk of developing resistance to APRETUDE if an individual acquires HIV-1 either before or\\nwhile taking APRETUDE or following discontinuation o...","\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nADVERSE REACTIONS\\nThe most common adverse reactions (all grades) observed in at least 1% of participants receiving\\nAPRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea,\\ndizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back\\npain, and upper respiratory tract infection. (\\n6.1\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or\\nFDA at 1-800-FDA-1088 or \\nwww.fda.go...","1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dosage and Administration Overview\\n2.2 HIV-1 Screening for Individuals Receiving APRETUDE for HIV-1 Pre-Exposure\\nProphylaxis\\n2.3 Adherence to APRETUDE\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\n2.5 Gluteal Intramuscular Injection Dosing with APRETUDE\\n2.6 Recommended Dosing Schedule for Missed Injections\\n2.7 Administration Instructions\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Co...","5.2\\n)\\nResidual concentrations of cabotegravir may remain in the systemic circulation of individuals up to 12\\nmonths or longer. (\\n5.3\\n)\\nSerious or severe hypersensitivity reactions have been reported with cabotegravir and include\\nStevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Discontinue APRETUDE\\nimmediately if signs or symptoms of hypersensitivity reactions develop. (\\n5.4\\n)\\nHepatotoxicity has been reported in individuals receiving cabotegravir. Clinical and laboratory\\nmonitorin...","4\\n, \\n5.7\\n, \\n7\\n)\\nDrugs that induce uridine diphosphate glucuronosyltransferase (UGT)1A1 may significantly decrease\\nplasma concentrations of cabotegravir. (\\n4\\n, \\n7.2\\n, \\n7.3\\n)\\nLactation: Assess the benefit-risk of using APRETUDE to the infant while breastfeeding due to the\\npotential for adverse reactions and residual concentrations in the systemic circulation for up to\\n12 months or longer after discontinuation. (\\n8.2\\n)\\nPediatrics: Not recommended in individuals weighing &lt;35 kg. (\\n8.4\\n)","5.4 Hypersensitivity Reactions\\n5.5 Hepatotoxicity\\n5.6 Depressive Disorders\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions\\n6 ADVERSE REACTIONS\\n6.1 Clinical Trials Experience\\n6.2 Postmarketing Experience\\n7 DRUG INTERACTIONS\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\n7.2 Potential for Other Drugs to Affect APRETUDE\\n7.3 Established and Other Potentially Significant Drug Interactions\\n7.4 Drugs without Clinically Significant Interactions with C...","13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n14 CLINICAL STUDIES\\n14.1 Clinical Trials in Adults for HIV-1 Pre-Exposure Prophylaxis\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\nSections or subsections omitted from the full prescribing information are not listed.","WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR\\nHIV-1 PRE\\u2011EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1\\nINFECTION\\nIndividuals must be tested for HIV-1 infection prior to initiating\\nAPRETUDE or oral cabotegravir, and with each subsequent injection of\\nAPRETUDE, using a test approved or cleared by the FDA for the\\ndiagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1\\nvariants have been identified with use of APRETUDE by individuals with\\nundiagnosed HIV-1 infection. Do not ...",")]\\n.\\n1 INDICATIONS AND USAGE\\nAPRETUDE is indicated for pre\\u2011exposure prophylaxis (PrEP) to reduce the risk of\\nsexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who\\nare at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to\\ninitiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1\\nPrEP \\n[see Dosage and Administration (\\n2.2\\n, \\n2.4\\n), Contraindications (\\n4\\n), Warnings and\\nPrecautions (\\n5.1\\n)]\\n.\\n2 DOSAGE AND A...","or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. If an\\nantigen/antibody-specific test is used and provides negative results, then such negative\\nresults should be confirmed using an RNA-specific assay, even if the results of the RNA-\\nassay are available after APRETUDE or oral cabotegravir administration \\n[see\\nContraindications (\\n4\\n), Warnings and Precautions (\\n5.1\\n)]\\n.\\n2.3 Adherence to APRETUDE\\nAPRETUDE contains cabotegravir extended-release injectable suspension in a\\n...","Prior to starting APRETUDE, healthcare providers should carefully select individuals who\\nagree to the required injection dosing and testing schedule and counsel individuals about\\nthe importance of adherence to scheduled dosing visits to help reduce the risk of\\nacquiring HIV-1 infection and development of resistance \\n[see Dosage and Administration\\n(\\n2.1\\n), Warnings and Precautions (\\n5.1\\n, \\n5.3\\n), Microbiology (\\n12.4\\n)]\\n.\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\nThe heal...","[see Dosage and Administration (\\n2.5\\n)]\\n.\\nNo safety and efficacy data are available for use of APRETUDE without an oral lead-in\\n[see Warnings and Precautions (\\n5.3\\n), Adverse Reactions (\\n6.1\\n)].\\n However, in HIV-1\\ntreatment clinical trials, data show that an oral lead-in is not needed to ensure adequate\\nplasma cabotegravir exposure upon initiation of injections and that the safety and\\nefficacy results of CABENUVA (cabotegravir extended-release injectable suspension;\\nrilpivirine extended-release ...","APRETUDE in individuals is a single 600\\u2011mg (3-mL) intramuscular injection of APRETUDE\\ngiven 1 month apart for 2 consecutive months (\\nTable 1\\n and \\nTable 2\\n). Individuals may be\\ngiven the second APRETUDE initiation injection up to 7 days before or after the date the\\nindividual is scheduled to receive the injections.\\nContinuation Injections\\nAfter the 2 initiation injection doses given consecutively 1 month apart, the\\nrecommended continuation injection dose of APRETUDE is a single 600-mg (3-mL)\\nint...","Should be administered on the last day of oral lead-in or within 3 days thereafter.\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\nis scheduled to receive the injections.\\nOral Lead-In \\n(at Least 28 Days)\\n(Month Prior \\nto Starting Injections)\\nIntramuscular (Gluteal)\\n \\nInitiation Injection \\n(Month 1 and Month 2)\\nIntramuscular (Gluteal)\\nContinuation Injection \\n(Month 4 and \\nEvery 2 Months\\nOnwards)\\nOral cabotegravir 30 mg by\\nmouth once daily for 28 days\\nAPRET...","Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-\\nExposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\nis scheduled to receive the injections.\\nIntramuscular (Gluteal) \\nInitiation Injection \\n(Month 1 and Month 2)\\nIntramuscular (Gluteal) \\nContinuation Injection \\n(Month 4 and Every 2 Months\\nOnwards)\\nAPRETUDE\\nAPRETUDE\\n600-mg (3 mL)\\n600-mg (3 mL)\\n2.6 Recommended Dosing Schedule ...","[see Dosage and\\nAdministration (\\n2.2\\n), Warnings and Precautions (\\n5.1\\n, \\n5.2\\n)]\\n. Refer to \\nTable 3\\n for dosing\\nrecommendations after missed injections.\\nPlanned Missed Injections\\nIf an individual plans to miss a scheduled every-2-month continuation injection visit by\\nmore than 7 days, take daily oral cabotegravir for up to 2 months to replace 1 missed\\nscheduled every-2-month injection. The recommended oral daily dose is one 30-mg\\ntablet of oral cabotegravir. The first dose of oral cabotegravir ...","recommended.\\nUnplanned Missed Injections\\nIf a scheduled injection visit is missed or delayed by more than 7 days and oral dosing\\nhas not been taken in the interim, clinically reassess the individual to determine if\\nresumption of injection dosing remains appropriate \\n[see Warnings and Precautions\\n(\\n5.1\\n)]\\n. If the injection dosing schedule will be continued, see \\nTable 3\\n for dosing\\nrecommendations.\\nTable 3. Injection Dosing Recommendations after Missed Injections\\nTime since Last Injection\\nRecomm...","Greater than 2 months\\nRestart with 600-mg (3-mL) gluteal intramuscular\\ninjection of APRETUDE, followed by a second 600-mg\\n(3-mL) initiation injection dose 1 month later. Then\\ncontinue to follow the every-2-month injection dosing\\nschedule thereafter.\\nIf third or subsequent\\ninjection is missed and time\\nsince prior injection is:\\nLess than or equal to 3 months\\nAdminister 600-mg (3-mL) intramuscular injection of\\nAPRETUDE as soon as possible, then continue with\\nthe every-2-month injection dosing sched...","Refer to the Instructions for Use for complete administration instructions with\\nillustrations. Carefully follow these instructions and ensure that the vial adaptor is used\\ncorrectly when preparing the suspension for injection to avoid leakage.\\nAPRETUDE is a suspension for gluteal intramuscular injection that does not need further\\ndilution or reconstitution.\\nThe ventrogluteal site is recommended for injection. A dorsogluteal approach (upper\\nouter quadrant) is acceptable, if preferred by the healt...","with higher BMI (e.g., &gt;30 kg/m\\n) to ensure that the injection is administered\\nintramuscularly as opposed to subcutaneously.\\nIf the pack has been stored in the refrigerator, the vial should be brought to room\\ntemperature prior to administration (not to exceed 30\\u00b0C [86\\u00b0F]).\\nParenteral drug products should be inspected visually for particulate matter and\\ndiscoloration prior to administration whenever solution and container permit. The\\nAPRETUDE vial has a brown tint to the glass that may limit visu...","administered as soon as possible, but may remain in the syringe for up to 2 hours. The\\nfilled syringe should not be placed in the refrigerator. If the medicine remains in the\\nsyringe for more than 2 hours, the filled syringe and needle must be discarded \\n[see How\\nSupplied/Storage and Handling (\\n16\\n)].\\n2","3 DOSAGE FORMS AND STRENGTHS\\nInjection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir\\nextended\\u2011release injectable suspension.\\n4 CONTRAINDICATIONS\\nAPRETUDE is contraindicated in individuals:\\n\\u2022\\n\\u2022\\n\\u2022\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection\\nUse APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a\\ncomprehensive prevention strategy including adherence to the administration schedule\\nand safer sex practices,...","Risk for HIV-1 acquisition includes behavioral, biological, or epidemiologic factors\\nincluding, but not limited to, condomless sex, past or current STIs, self-identified HIV\\nrisk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high\\nprevalence area or network.\\nCounsel individuals on the use of other prevention measures (e.g., consistent and\\ncorrect condom use; knowledge of partner(s)\\u2019 HIV-1 status, including viral suppression\\nstatus; regular testing for STIs that ...","individuals with undiagnosed HIV\\u20111 infection who are taking only APRETUDE, because\\nAPRETUDE alone does not constitute a complete regimen for HIV-1 treatment \\n[see\\nMicrobiology (\\n12.4\\n)]\\n; therefore, care should be taken to minimize the risk of initiating or\\ncontinuing APRETUDE before confirming the individual is HIV-1 negative.\\n\\u2022\\nwith unknown or positive HIV-1 status \\n[see Warnings and Precautions (\\n5.1\\n, \\n5.2\\n)]\\n.\\nwith previous hypersensitivity reaction to cabotegravir \\n[see Warnings and\\nPrecau...","[see Drug Interactions (\\n7.2\\n, \\n7.3\\n), Clinical Pharmacology (\\n12.3\\n)]\\n:\\no\\no\\nAnticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin\\nAntimycobacterials: Rifampin, rifapentine\\nPrior to initiating APRETUDE for HIV-1 PrEP, ask seronegative individuals about\\nrecent (in past month) potential exposure events (e.g., condomless sex or condom\\nbreaking during sex with a partner of unknown HIV-1 status or unknown viremic","\\u2022\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each\\ninjection and upon diagnosis of any other STIs \\n[see Dosage and Administration (\\n2.2\\n,\\n2.5\\n)]\\n.\\n\\u2022\\nCounsel individuals without HIV-1 to strictly adhere to the recommended dosing and\\ntesting schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the\\npotential development of resistance \\n[see Dosage and Administration (\\n2.3\\n, \\n2.5\\n),\\nMicrobiology (\\n12.4\\n)]\\n. Some individuals, such as adolescents,...","HIV-1 either before or while taking APRETUDE or following discontinuation of APRETUDE\\n[see Warnings and Precautions (\\n5.1\\n, \\n5.3\\n)]\\n.\\nTo minimize this risk, it is essential to clinically reassess individuals for risk of HIV-1\\nacquisition and to test before each injection to confirm HIV-1 negative status. Individuals\\nwho are confirmed to have HIV-1 infection must transition to a complete HIV-1\\ntreatment regimen.\\nAlternative forms of PrEP should be considered following discontinuation of APRETUDE\\n...","individuals for prolonged periods (up to 12 months or longer). It is important to carefully\\nselect individuals who agree to the required every-2-month injection dosing schedule\\nbecause non-adherence to every\\u20112-monthly injections or missed doses could lead to\\nHIV-1 acquisition and development of resistance.\\nHealthcare providers should take the prolonged-release characteristics of cabotegravir\\ninto consideration when APRETUDE is prescribed \\n[see Dosage and Administration (\\n2.3\\n),\\nWarnings and Prec...","consistent with acute HIV-1 infection (e.g., fever, fatigue, myalgia, skin rash).\\nIf recent (&lt;1 month) exposures to HIV-1 are suspected or clinical symptoms\\nconsistent with acute HIV-1 infection are present, use a test approved or cleared\\nby the FDA as an aid in the diagnosis of acute or primary HIV-1 infection.\\nIf an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent with\\nacute HIV-1 infection develop following an exposure event, additional HIV testing to\\ndetermine HIV sta...","include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\n[see Adverse\\nReactions (\\n6.2\\n)]\\n. Administration of cabotegravir oral lead-in dosing was used in clinical\\nstudies to help identify participants who may be at risk of a hypersensitivity reaction.\\nRemain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected\\n[see Dosage and Administration (\\n2.4\\n), Contraindications (\\n4\\n), Adverse Reactions (\\n6\\n)]\\n.\\nDiscontinue APRETUDE immediately if signs or symptoms o...","difficulty breathing). Clinical status, including liver transaminases, should be monitored\\nand appropriate therapy initiated. For information regarding the long-acting properties of\\nAPRETUDE \\n[see Warnings and Precautions (\\n5.3\\n)]\\n.\\n5.5 Hepatotoxicity\\nHepatotoxicity has been reported in a limited number of individuals receiving\\ncabotegravir with or without known pre-existing hepatic disease or identifiable risk\\nfactors \\n[see Adverse Reactions (\\n6.1\\n)]\\n.\\nClinical and laboratory monitoring should ...","persistent depressive disorder, suicidal ideation, suicide attempt) have been reported\\nwith APRETUDE \\n[see Adverse Reactions (\\n6.1\\n)]\\n. Promptly evaluate individuals with\\ndepressive symptoms to assess whether the symptoms are related to APRETUDE and\\nto determine whether the risks of continued therapy outweigh the benefits.\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug\\nInteractions\\nThe concomitant use of APRETUDE and other drugs may result in reduced drug\\nconcentration of APRETUD...","interactions prior to and during use of, and after discontinuation of APRETUDE; review\\nconcomitant medications during use of APRETUDE \\n[see Drug Interactions (\\n7.3\\n, \\n7.4\\n)]\\n.\\n6 ADVERSE REACTIONS\\nThe following adverse reactions are described below and in other sections of the\\nlabeling:\\n\\u2022\\n\\u2022\\n\\u2022\\nHypersensitivity reactions \\n[see Warnings and Precautions (\\n5.4\\n)]\\nHepatotoxicity \\n[see Warnings and Precautions (\\n5.5\\n)]\\nDepressive disorders \\n[see Warnings and Precautions (\\n5.6\\n)]","6.1 Clinical Trials Experience\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction\\nrates observed in the clinical trials of a drug cannot be directly compared with rates in\\nthe clinical trials of another drug and may not reflect rates observed in practice.\\nClinical Trials Experience in Adults\\nThe safety assessment of APRETUDE is based on the analysis of data from 2\\ninternational, multicenter, double-blind trials, HPTN 083 and HPTN 084 \\n[see Clinical\\nStudies (\\n...","2 days (range: 1 day to 156 weeks and 1 day), with a total exposure on cabotegravir of\\n3,231 person\\u2011years. The median time on blinded study product in HPTN 084 was 64\\nweeks and 1 day (range: 1 day to 153 weeks and 1 day), with a total exposure on\\ncabotegravir of 2,009 person\\u2011years.\\nThe most common adverse reactions regardless of severity reported in at least 1% of\\nparticipants in HPTN 083 or HPTN 084 are presented in \\nTable 4\\n.\\nIn HPTN 083, 6% of participants in the group receiving APRETUDE intr...","aminotransferase with APRETUDE and TRUVADA.\\nIn HPTN 084, 1% of participants receiving APRETUDE and 1% of participants receiving\\nTRUVADA discontinued due to adverse events. The most commonly reported adverse\\nevent (all causality) leading to discontinuation was increased alanine aminotransferase\\n(&lt;1%) with APRETUDE and TRUVADA. The side-by-side tabulation is to simplify\\npresentation; direct comparison across trials should not be made due to differing trials.\\nTable 4. Adverse Drug Reactions\\n (All G...","Adverse reactions defined as \\u201ctreatment-related\\u201d as assessed by the investigator, with\\nexception of injection site reactions, where all injection site reactions were reported\\nregardless of causality.\\n Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA\\n(n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).\\n Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.\\n Fatigue includes fatigue, malaise.\\n Sleep disorders includes insomnia, abnorm...","&lt;1%\\n&lt;1%\\n2%\\n4%\\nSomnolence\\n&lt;1%\\n&lt;1%\\n2%\\n2%\\nBack pain\\n&lt;1%\\n&lt;1%\\n1%\\n&lt;1%\\nUpper\\nrespiratory tract\\ninfection\\n0\\n&lt;1%\\n4%\\n4%\\nInjection-Associated Adverse Reactions: Local Injection Site Reactions (ISRs) with\\nAPRETUDE:\\n The most frequent adverse reactions associated with the intramuscular\\nadministration of APRETUDE in HPTN 083 were ISRs. After 20,286 injections, 8,900 ISRs\\nwere reported. Of the 2,117 participants who received at least one injection of\\nAPRETUDE, 1,740 (82%) participants experienced at least one ...","participants, and severe (Grade 3) in 3% of participants. The median duration of overall\\nISR events was 4 days. The proportion of participants reporting ISRs at each visit and\\nthe severity of the ISRs decreased over time. The most commonly reported ISRs (all\\ncausality and grades) in at least 1% of participants who received APRETUDE and\\nexperienced at least one ISR from HPTN 083 are presented in \\nTable 5\\n.\\nThe most frequent adverse reactions associated with the intramuscular administration\\nof APR...","experienced at least one ISR, the maximum severity of reactions was mild (Grade 1) in\\n66% of participants, moderate (Grade 2) in 34% of participants, and severe (Grade 3) in\\nless than 1% of participants. The median duration of overall ISR events was 8 days. The\\nproportion of participants reporting ISRs at each visit and the severity of the ISRs\\ngenerally decreased over time. The most commonly reported ISRs (all causality and\\na\\nb\\nc\\nd\\ne\\nf\\ng\\nf\\ng","grades) in at least 1% of participants who received APRETUDE and experienced at least\\none ISR from HPTN 084 are presented in \\nTable 5\\n.\\nTable 5. Injection Site Reactions (All Grades) Reported in at Least 1% of\\nParticipants Who Experienced at Least One Injection Site Reaction (All\\nCausality) with APRETUDE in Either HPTN 083 or HPTN 084\\n Placebo injectable suspension: intralipid 20% fat emulsion.\\nInjection Site\\nReactions\\nHPTN 083\\nHPTN 084\\nAPRETUDE\\n(n = 1,740)\\nTRUVADA\\n(n = 724)\\nAPRETUDE\\n(n = 578)\\nT...","&lt;1%\\n0\\n1%\\n0\\n          Other Injection-Associated Adverse Reactions: \\nIn the HPTN 083 clinical trial, an\\nincreased incidence of pyrexia (including pyrexia, feeling hot, chills, influenza-like illness)\\n(4%) was reported by participants receiving APRETUDE compared with participants\\nreceiving TRUVADA (&lt;1%). There were no differences reported in the incidence of\\npyrexia between groups in HPTN 084.\\nVasovagal or pre-syncopal reactions considered treatment related were reported in\\n&lt;1% of participants aft...","Hepatobiliary Disorders:\\n Hepatotoxicity.\\n          Investigations: \\nWeight increase (see below).\\n          Psychiatric Disorders: Depression; suicidal ideation, and suicide attempt (these\\nevents were observed primarily in participants with a pre\\u2011existing history of depression or\\nother psychiatric illness).\\nWeight Increase: \\nAt the Week 41 and Week 97 timepoints in HPTN 083, participants who\\nreceived APRETUDE gained a median of 1.2 kg (Interquartile Range [IQR]; -1.0, 3.5;\\nn = 1,623) and 2.1 kg ...","At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE\\ngained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in\\nweight from baseline, respectively. Those who received TRUVADA gained a median of\\n1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from\\nbaseline, respectively.\\nLaboratory Abnormalities: \\nGrade 3 or 4 post-baseline maximum toxicity laboratory\\nabnormalities for HPTN 083 or HPTN 084 are summarized in \\nTa...","(n = 2,285)\\nAPRETUDE\\nEvery 2\\nMonths\\n(n = 1,614)\\nTRUVADA\\nOnce Daily\\n(n = 1,610)\\nALT (\\u22655.0 x ULN)\\n2%\\n2%\\n&lt;1%\\n1%\\nAST (\\u22655.0 x\\nULN)\\n3%\\n3%\\n&lt;1%\\n&lt;1%\\nCreatine\\nphosphokinase\\n(\\u226510.0 x ULN)\\n15%\\n14%\\n2%\\n2%\\nLipase (\\u22653.0 x\\nULN)\\n3%\\n3%\\n&lt;1%\\n&lt;1%\\nCreatinine (&gt;1.8\\nx ULN) or\\nincrease to \\u22651.5\\nx baseline)\\n3%\\n3%\\n5%\\n4%\\n          Serum Lipids: \\nChanges from baseline to Month 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol, triglycerides, and total cholesterol to HDL ratio in HPTN 083\\nand HPTN 084 are presented in ...","Nearly 60% of participants with baseline data available had Week 57 data available in\\nboth arms of both trials. Within each trial, baseline values were comparable among\\nparticipants receiving APRETUDE and TRUVADA.\\nHDL cholesterol\\nratio\\nClinical Trials Experience in Adolescents\\nIn adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to\\nthe safety data reported in adults receiving APRETUDE for HIV-1 PrEP \\n[see Use in\\nSpecific Populations (\\n8.4\\n)].\\n6.2 Postmarketing Experi...","Immune System Disorders\\nHypersensitivity reactions (including angioedema and urticaria) \\n[see Warnings and\\nPrecautions (\\n5.4\\n)]\\n.\\nSkin and Subcutaneous Tissue Disorders\\nStevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\n[see Warnings and\\nPrecautions (\\n5.4\\n)]\\n.\\n7 DRUG INTERACTIONS\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\nResidual concentrations of cabotegravir may remain in the systemic circulation of\\nindividuals for prolonged periods (up to 12 months ...","Cabotegravir is primarily metabolized by UGT1A1 with some contribution from UGT1A9.\\nDrugs that are strong inducers of UGT1A1 or 1A9 are expected to decrease\\ncabotegravir plasma concentrations; therefore, coadministration of APRETUDE with\\nthese drugs is contraindicated \\n[see Contraindications (\\n4\\n)]\\n.\\n7.3 Established and Other Potentially Significant Drug Interactions\\nInformation regarding potential drug interactions with cabotegravir is provided in \\nTable\\n8\\n. These recommendations are based on e...","inclusive.\\nTable 8. Drug Interactions with APRETUDE\\n\\u2191 = Increase, \\u2193 = Decrease, \\u2194 = No change.\\nConcomitant Drug\\nClass:\\nDrug Name\\nEffect on\\nConcentration\\nClinical Comment\\nAnticonvulsants:\\nCarbamazepine\\nOxcarbazepine\\nPhenobarbital\\nPhenytoin\\n\\u2193Cabotegravir\\nCoadministration is contraindicated with\\nAPRETUDE due to potential for significant\\ndecreases in plasma concentration of\\nAPRETUDE.\\nAntimycobacterials:\\nRifampin\\nRifapentine\\n\\u2193Cabotegravir\\nAntimycobacterial:\\nRifabutin\\n\\u2193Cabotegravir\\nWhen rifabutin is s...","the second initiation injection or later, the\\nrecommended dosing schedule of\\nAPRETUDE is 600\\u2011mg (3 mL) monthly\\nwhile on rifabutin.\\nAfter stopping rifabutin, the\\nrecommended dosing schedule of\\nAPRETUDE is 600-mg (3 mL) every 2\\nmonths.\\n7.4 Drugs without Clinically Significant Interactions with Cabotegravir\\nBased on drug interaction study results, the following drugs can be coadministered with\\ncabotegravir (non-antiretrovirals) or given after discontinuation of cabotegravir\\n(antiretrovirals and non...","Pregnancy Exposure Registry\\nThere is a pregnancy exposure registry that monitors pregnancy outcomes in individuals\\nexposed to APRETUDE during pregnancy. Healthcare providers are encouraged to\\nregister individuals by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-","4263.\\nRisk Summary\\nThere are insufficient human data on the use of APRETUDE during pregnancy to\\nadequately assess a drug-associated risk of birth defects and miscarriage. Discuss the\\nbenefit-risk of using APRETUDE with individuals of childbearing potential or during\\npregnancy.\\nCabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be\\nused during pregnancy only if the expected benefit justifies the potential risk to the\\nfetus.\\nThe APR has been established to monitor for ...","miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to\\n20%. The APR uses the MACDP as the U.S. reference population for birth defects in the\\ngeneral population. The MACDP evaluates mothers and infants from a limited geographic\\narea and does not include outcomes for births that occurred at &lt;20 weeks\\u2019 gestation.\\nIn animal reproduction studies with oral cabotegravir, a delay in the onset of parturition\\nand increased stillbirths and neonatal deaths were observed in...","during organogenesis \\n(see Data)\\n.\\nClinical Considerations\\nCabotegravir is detected in systemic circulation for up to 12 months or longer after\\ndiscontinuing injections of APRETUDE; therefore, consideration should be given to the\\npotential for fetal exposure during pregnancy \\n[see Warnings and Precautions (\\n5.3\\n)]\\n.\\nData\\nAnimal Data:\\n Cabotegravir was administered orally to pregnant rats at 0, 0.5, 5, or\\n1,000 mg/kg/day from 15 days before cohabitation, during cohabitation, and from\\nGestation Da...","humans at the RHD), and no drug-related fetal malformations were observed at any\\ndose.\\nCabotegravir was administered orally to pregnant rabbits at 0, 30, 500, or\\n2,000 mg/kg/day from Gestation Days 7 to 19. No drug-related fetal toxicities were\\nobserved at 2,000 mg/kg/day (approximately 0.7 times the exposure in humans at the\\nRHD).\\nIn a rat pre- and postnatal development study, cabotegravir was administered orally to\\npregnant rats at 0, 0.5, 5, or 1,000 mg/kg/day from Gestation Day 6 to Lactatio...","exposure in humans at the RHD); there were no alterations to growth and development\\nof surviving offspring. In a cross-fostering study, similar incidences of stillbirths and\\nearly postnatal deaths were observed when rat pups born to cabotegravir-treated\\nmothers were nursed from birth by control mothers. There was no effect on neonatal\\nsurvival of control pups nursed from birth by cabotegravir-treated mothers. A lower\\ndose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with\\n...","present in animal milk \\n(see Data)\\n. When a drug is present in animal milk, it is likely that\\nthe drug will be present in human milk. It is not known if cabotegravir affects human milk\\nproduction, or has effects on the breastfed infant. If cabotegravir is present in human\\nmilk, residual exposures may remain for 12 months or longer after the last injections\\nhave been administered \\n[see Warnings and Precautions (\\n5.3\\n)]\\n.\\nCabotegravir concentrations may be detectable in systemic circulation for up...","Breastfeeding is not recommended if acute HIV-1 infection is suspected to avoid the risk\\nof postnatal transmission of HIV-1 infection.\\nData\\nAnimal lactation studies with cabotegravir have not been conducted. However,\\ncabotegravir was detected in the plasma of nursing pups on Lactation Day 10 in the rat\\npre- and postnatal development study.\\n8.4 Pediatric Use\\nThe safety and effectiveness of APRETUDE for HIV-1 PrEP in adolescents weighing at\\nleast 35 kg who are at risk for HIV-1 acquisition is supp...","[see Dosage\\nand Administration (\\n2.5\\n), Adverse Reactions (\\n6.1\\n), Clinical Pharmacology (\\n12.3\\n), Clinical\\nStudies (\\n14.1\\n)]\\n.\\nAPRETUDE for HIV-1 PrEP was evaluated in 2 open-label multicenter clinical trials, HPTN\\n083-01 and HPTN 084-01, in adolescent individuals 12 to less than 18 years of age\\nweighing at least 35 kg who are at risk for HIV-1 acquisition. Sixty-four adolescents were\\nenrolled. Of these, 62 adolescent participants received one or more injections. In\\nadolescents receiving APRETU...","APRETUDE. Adolescents may benefit from more frequent visits and counseling to\\nsupport adherence to the dosing and testing schedule \\n[see Dosage and Administration\\n(\\n2.2\\n), Warnings and Precautions (\\n5.1\\n)].\\nThe safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants\\nyounger than 12 years of age or weighing &lt;35 kg have not been established.\\n8.5 Geriatric Use\\nNo dose adjustment is required in elderly individuals. There are limited data available on\\nthe use of APRETUDE in indiv...","12.3\\n)]\\n.\\n8.6 Renal Impairment\\nBased on studies with oral cabotegravir, no dosage adjustment of APRETUDE is\\nnecessary for individuals with mild (creatinine clearance \\u226560 to &lt;90 mL/min), moderate\\n(creatinine clearance \\u226530 to &lt;60 mL/min) or severe renal impairment (creatinine\\nclearance \\u226515 to &lt;30 mL/min) \\n[see Clinical Pharmacology (\\n12.3\\n)]\\n. In individuals with\\nend-stage renal disease not on dialysis, effects on the pharmacokinetics of cabotegravir\\nare unknown. As cabotegravir is &gt;99% protein bo...","cabotegravir is unknown \\n[see Clinical Pharmacology (\\n12.3\\n)]\\n.\\n10 OVERDOSAGE\\nThere is no known specific treatment for overdose with APRETUDE. If overdose occurs,\\nmonitor the individual and apply standard supportive treatment as required as well as\\nobservation of the clinical status of the individual. As APRETUDE is highly bound to\\nplasma proteins, it is unlikely that it will be significantly removed by dialysis. Consider the\\nprolonged exposure to APRETUDE following an injection when assessing t...","Cabotegravir extended-release injectable suspension is a white to light pink free-flowing\\nsuspension for intramuscular injection in a sterile single-dose vial. Each vial contains\\n3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol\\n(35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL),\\nand Water for Injection.\\nThe vial stoppers are not made with natural rubber latex.\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nCabotegravir is an HIV...","12 hours resulted in a geometric mean C\\n approximately 2.8- and 5.6-fold above the\\ngeometric mean steady-state C\\n associated with the recommended 30-mg dose of\\noral cabotegravir and the recommended 600-mg dose given every 2 months of\\ncabotegravir extended-release injectable suspension, respectively.\\n12.3 Pharmacokinetics\\nAbsorption, Distribution, and Elimination\\nThe pharmacokinetic properties of cabotegravir are provided in \\nTable 9\\n. The multiple-\\ndose pharmacokinetic parameters are provided in...","CSF = Cerebrospinal fluid.\\n When taken orally with a high-fat meal versus fasted, the AUC\\n (geometric mean\\nratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).\\n The clinical relevance of CSF-to-plasma concentration ratios is unknown.\\nConcentrations were measured at steady-state 1 week after intramuscular\\nadministration of cabotegravir extended-release injectable suspensions given monthly or\\nevery 2 months.\\n Elimination half-life driven by slow absorption rate from the intramuscular injection s...","Excretion\\n    Major route of elimination\\nMetabolism\\n    % of dose excreted as total \\nC (unchanged drug) in\\nurine\\n27 (0)\\n    % of dose excreted as total \\nC (unchanged drug) in\\nfeces\\n59 (47)\\nTable 10. Pharmacokinetic Parameters following Once-Daily Oral Cabotegravir\\nand following Initiation and Every-2-Month Continuation Intramuscular\\nInjections of APRETUDE\\nIM = Intramuscular.\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\ncabotegravir population pharmacokinetic...","Initial injection C\\n values primarily reflect oral dosing because the initial injection was\\nadministered on the same day as the last oral dose; however, AUC\\n and the C\\nvalues reflect the initial injection. When administered without oral lead-in to recipients\\nDosing Phase\\nDosage\\nRegimen\\nGeometric Mean (5\\n, 95\\n Percentile)\\nAUC\\n \\n(mcg\\u2022h/mL)\\nC\\n \\n(mcg/mL)\\nC\\n \\n(mcg/mL)\\nOral lead-in\\n30 mg\\n145\\n8.0\\n4.6\\nonce daily\\n(93.5, 224)\\n(5.3, 11.9)\\n(2.8, 7.5)\\nInitial injection\\n600 mg IM\\n1,591\\n8.0\\n1.5\\ninitial dose\\n(7...","with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile)\\nC\\n (1-week post\\u2011initial injection) was 1.89 mcg/mL (0.438, 5.69) and C\\n was\\n1.43 mcg/mL (0.403, 3.90).\\n Pharmacokinetic parameter values represent steady state.\\nSpecific Populations\\nNo clinically significant differences in the pharmacokinetics of cabotegravir were\\nobserved based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are\\nno data available for the use of cabotegravir in participants wit...","stage renal disease not on dialysis. As cabotegravir is &gt;99% protein bound, dialysis is\\nnot expected to alter exposures of cabotegravir \\n[see Use in Specific Populations (\\n8.6\\n)]\\n.\\nHepatic Impairment:\\n No clinically significant differences in the pharmacokinetics of\\ncabotegravir are expected in mild to moderate (Child-Pugh A or B) hepatic impairment.\\nThe effect of severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of\\ncabotegravir has not been studied \\n[see Use in Specific Populatio...","adjustment is necessary based on gender.\\nGeriatrics:\\n No dose adjustment is required in elderly individuals. There are limited data\\navailable on the use of cabotegravir in individuals aged 65 years and older. In general,\\ncaution should be exercised in administration of cabotegravir in elderly individuals,\\nreflecting greater frequency of decreased hepatic, renal, or cardiac function and of\\nconcomitant disease or other drug therapy \\n[see Use in Specific Populations (\\n8.5\\n)]\\n.\\nPediatrics:\\n Populati...","needed for adolescents weighing \\u226535 kg (\\nTable 11\\n).\\nTable 11. Pharmacokinetic Parameters following Once-Daily Oral Cabotegravir\\nand following Initiation and Every-2-Month Continuation Intramuscular\\nInjections of APRETUDE in Adolescent Participants Aged 12 to Younger than\\n18 Years (\\u226535 kg)\\nDosing Phase\\nDosage\\nRegimen\\nGeometric Mean (5\\n, 95\\n Percentile)\\nAUC\\n(mcg\\u2022h/mL)\\nC\\n(mcg/mL)\\nC\\n(mcg/mL)\\nOral lead-in\\n30 mg\\n203\\n10.7\\n6.43\\nonce daily\\n(136, 320)\\n(7.36, 16.6)\\n(4.15, 10.5)\\nInitial injection\\n600 mg IM...","IM = intramuscular.\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\npopulation pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing\\n35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. \\n tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection,\\nand 2 months for every 2 months for intramuscular injections of extended-release\\ninjectable suspension.\\n Oral lead-in pharmacokinetic para...","Pharmacokinetic parameter values represent steady state.\\nEvery-2-month\\ninjection\\n600 mg IM\\n5,184\\n5.10\\n2.54\\nevery 2\\nmonths\\n(3,511; 7,677)\\n(3.06, 8.24)\\n(1.25, 4.19)\\nDrug Interaction Studies\\nCabotegravir is not a clinically relevant inhibitor of the following enzymes and\\ntransporters: cytochrome P450 (CYP)1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4;\\nUGT1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B15, and 2B17; P-glycoprotein (P\\u2011gp); breast\\ncancer resistance protein (BCRP); bile salt export pump (BSEP); org...","= 0.81 microM) and OAT3\\n(IC\\n = 0.41 microM). Based on physiologically based pharmacokinetic (PBPK) modeling,\\ncabotegravir may increase the AUC of OAT1/3 substrates up to approximately 80%.\\nIn vitro, cabotegravir did not induce CYP1A2, CYP2B6, or CYP3A4.\\nSimulations using PBPK modeling show that no clinically significant interaction is\\nexpected during coadministration of cabotegravir with drugs that inhibit UGT1A1.\\nIn vitro, cabotegravir was not a substrate of OATP1B1, OATP1B3, OATP2B1, or OCT1.\\n...","12\\n and \\n13\\n.\\nTable 12. Effect of Coadministered Drugs on the Pharmacokinetics of\\nCabotegravir\\nCoadministered\\nGeometric Mean Ratio (90% CI) of\\nCabotegravir Pharmacokinetic\\nParameters with/without Coadministered\\nDrugs\\na\\nb\\nc\\nd\\nmax\\n(0-tau)\\ntau\\ne\\ne\\n50\\n50","n = Maximum number of participants with data, CI = Confidence Interval.\\nCoadministered\\nDrug(s)\\nand Dose(s)\\nDose of\\nCabotegravir\\nn\\nNo Effect = 1.00\\nC\\nAUC\\nC\\n or C\\nEtravirine\\n30 mg\\n12\\n1.04\\n1.01\\n1.00\\n    200 mg twice\\ndaily\\nonce daily\\n(0.99, 1.09)\\n(0.96, 1.06)\\n(0.94, 1.06)\\nRifabutin\\n30 mg\\n12\\n0.83\\n0.77\\n0.74\\n    300 mg once\\ndaily\\nonce daily\\n(0.76, 0.90)\\n(0.74, 0.83)\\n(0.70, 0.78)\\nRifampin\\n30-mg\\n15\\n0.94\\n0.41\\n0.50\\n    600 mg once\\ndaily\\nsingle dose\\n(0.87, 1.02)\\n(0.36, 0.46)\\n(0.44, 0.57)\\nRilpivirine\\n30 mg\\n1...","Cabotegravir\\nn\\nGeometric Mean Ratio (90% CI) of\\nPharmacokinetic Parameters of\\nCoadministered Drug with/without\\nCabotegravir\\nNo Effect = 1.00\\nC\\nAUC\\nC\\n or\\nC\\nEthinyl estradiol\\n30 mg\\n19\\n0.92\\n1.02\\n1.00\\n    0.03 mg once\\ndaily\\nonce daily\\n(0.83, 1.03)\\n(0.97, 1.08)\\n(0.92,\\n1.10)\\nLevonorgestrel\\n30 mg\\n19\\n1.05\\n1.12\\n1.07\\n    0.15 mg once\\ndaily\\nonce daily\\n(0.96, 1.15)\\n(1.07, 1.18)\\n(1.01,\\n1.15)\\nMidazolam\\n30 mg\\n12\\n1.09\\n1.10\\nNA\\n    3 mg\\nonce daily\\n(0.94, 1.26)\\n(0.95, 1.26)\\nRilpivirine\\n30 mg\\n11\\n0.96\\n0.99\\n0.92\\n    ...","12.4 Microbiology\\nMechanism of Action\\nCabotegravir inhibits HIV integrase by binding to the integrase active site and blocking\\nthe strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is\\nessential for the HIV replication cycle. The mean 50% inhibitory concentration (IC\\n)\\nvalue of cabotegravir in a strand transfer assay using purified recombinant HIV-1\\nintegrase was 3.0 nM.\\nAntiviral Activity in Cell Culture\\nCabotegravir exhibited antiviral activity against laboratory s...","M subtypes A, B, C, D, E, F, and G and 3 in group O) with a median EC\\n value of 0.19\\nnM (range: 0.02 to 1.06 nM, n = 24). The median EC\\n value against subtype B clinical\\nisolates was 0.05 nM (range: 0.02 to 0.50 nM, n = 3). Against clinical HIV-2 isolates, the\\nmedian EC\\n value was 0.12 nM (range: 0.10 to 0.14 nM, n = 3).\\nIn cell culture, cabotegravir was not antagonistic in combination with the non-nucleoside\\nreverse transcriptase inhibitor (NNRTI) rilpivirine, or the nucleoside reverse transcri...","that emerged and conferred decreased susceptibility to cabotegravir included Q146L\\n(fold change: 1.3 to 4.6), S153Y (fold change: 2.8 to 8.4), and I162M (fold change: 2.8).\\nThe integrase substitution T124A also emerged alone (fold change: 1.1 to 7.4 in\\ncabotegravir susceptibility), in combination with S153Y (fold change: 3.6 to 6.6 in\\ncabotegravir susceptibility) or I162M (2.8-fold change in cabotegravir susceptibility). Cell\\nculture passage of virus harboring integrase substitutions Q148H, Q148...","V72I+E138K+Q148K conferred the greatest reductions of 53- to 260\\u2011fold change and\\n410\\u2011fold change, respectively.\\nClinical Trials: \\nThere were 12 incident infections and 4 prevalent infections among\\nparticipants in the APRETUDE arm of HPTN 083. Genotypic data were generated for\\nviruses from 13 of these 16 participants (4 participants with prevalent infections and 9\\nparticipants with incident infections) and phenotypic data were generated for 3 of these\\nviruses. INSTI resistance-associated substitu...","susceptible to cabotegravir), and L74I+E138E/K+G140G/S+Q148R+E157Q.\\nThere were 3 incident infections and 1 prevalent infection among participants in the\\nAPRETUDE arm of HPTN 084. All 3 incident infections occurred during periods with\\n50\\n50\\n50\\n50\\n50","cabotegravir exposures below the target concentration. No variants expressing INSTI\\nresistance-associated substitutions were detected.\\nCross-Resistance\\nCross-resistance has been observed among INSTIs. Cabotegravir had reduced\\nsusceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the\\nfollowing integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M,\\nE92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R,\\nY143H+N155H, and Q148R+N155H (range: 5...","isolates with genotypic evidence of cabotegravir resistance had cross-resistance to\\nelvitegravir and raltegravir but retained phenotypic susceptibility to dolutegravir and\\nwhen tested bictegravir.\\nViruses harboring E138A+Q148R or G140A+Q148R with reduced susceptibility to\\ncabotegravir were isolated from participants using APRETUDE in HPTN 083. These\\nviruses remained susceptible to bictegravir and dolutegravir but had cross-resistance to\\nelvitegravir and raltegravir.\\n13 NONCLINICAL TOXICOLOGY\\n13....","those in humans at the RHD. In rats, no drug-related increases in tumor incidence were\\nobserved at cabotegravir exposures up to approximately 26 times higher than those in\\nhumans at the RHD.\\nMutagenesis\\nCabotegravir was not genotoxic in the bacterial reverse mutation assay, mouse\\nlymphoma assay, or in the in vivo rodent micronucleus assay.\\nImpairment of Fertility\\nIn rats, no effects on fertility were observed at cabotegravir exposures (AUC) &gt;20 times\\n(male) and 28 times (female) the exposure in ...","in men and transgender women without HIV-1 who have sex with men and have\\nevidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women\\nwithout HIV-1 at risk of acquiring HIV-1.\\nParticipants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral\\ncabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE\\n600\\u2011mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months\\nthereafter and a daily placebo tablet. Participants ra...","have sex with men were randomized 1:1 and received either APRETUDE (n = 2,281) or\\nTRUVADA (n = 2,285) as blinded study medication up to Week 153.\\nAt baseline, the median age of participants was 26 years, 12% were transgender\\nwomen, 72% were non-White, and 67% were younger than 30 years.\\nThe primary endpoint was the rate of incident HIV-1 infections among participants\\nrandomized to daily oral cabotegravir and intramuscular injections of APRETUDE every 2\\nmonths compared with daily oral TRUVADA (co...","yielding a 69% reduction in the risk of HIV-1 incident infection relative to TRUVADA\\n(\\nTable 14\\n).\\nTable 14. HIV-1 Infection Results During Randomized Phase in HPTN 083:\\nExtended Retrospective Virologic Testing with Readjudicated Endpoints\\n mITT from Supplemental Virology Report.\\n Following the primary analysis, extended retrospective virologic testing was performed\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 13 HIV-1\\nincident infections in participants receiving...","Results from all subgroup analyses were consistent with the overall protective effect. A\\nlower rate of incident HIV\\u20111 infections was observed for participants randomized to\\nAPRETUDE compared with participants randomized to TRUVADA (\\nTable 15\\n).\\nTable 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended\\nRetrospective Virologic Testing with Readjudicated Endpoints\\nSubgroup\\nAPRETUDE\\nIncidence per\\n100 Person-\\nYears\\nAPRETUDE\\nPerson-Years\\nTRUVADA\\nIncidence\\nper 100\\nPerson-\\nYears\\nTRUVADA\\nP...","mITT from Supplemental Virology Report. \\n Cisgender men who have sex with men.\\n Transgender women who have sex with men.\\nTGW\\n0.54\\n371\\n1.80\\n389\\n0.34\\n(0.08,\\n1.56)\\nRace (US)\\nBlack\\n0.58\\n691\\n2.28\\n703\\n0.26\\n(0.09,\\n0.76)\\nNon-Black\\n0.00\\n836\\n0.50\\n801\\n0.11\\n(0.00,\\n2.80)\\nRegion\\nUS\\n0.26\\n1,528\\n1.33\\n1,504\\n0.21\\n(0.07,\\n0.60)\\nLatin\\nAmerica\\n0.49\\n1,020\\n1.09\\n1,011\\n0.47\\n(0.17,\\n1.35)\\nAsia\\n0.35\\n570\\n1.03\\n581\\n0.39\\n(0.08,\\n1.82)\\nAfrica\\n1.08\\n93\\n2.07\\n97\\n0.63\\n(0.06,\\n6.50)\\nTrial 201739 (HPTN 084 [NCT03164564])\\nIn HPTN 084, a su...","The primary endpoint was the rate of incident HIV-1 infections among participants\\nrandomized to oral cabotegravir and injections of APRETUDE compared with oral\\nTRUVADA (corrected for early stopping). The primary analysis demonstrated the\\nsuperiority of APRETUDE compared with TRUVADA with an 88% reduction in the risk of\\nacquiring incident HIV-1 infection, hazard ratio (95% CI) 0.12 (0.05, 0.31); further\\ntesting revealed 1 of the infections on APRETUDE to be prevalent then yielding a 90%\\nreduction...","mITT from Supplemental Virology Report.\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\n0.31).\\n(N = 1,613)\\n(N = 1,610)\\nP\\n Value\\nPerson-years\\n1,960\\n1,946\\nHIV-1 incident infections\\n(incidence rate per 10...","randomized to APRETUDE compared with participants randomized to TRUVADA (\\nTable\\n17\\n).\\nTable 17. Incident of HIV-1 Infections by Subgroup in HPTN 084: Extended\\nRetrospective Virologic Testing with Readjudicated Endpoints\\na\\nb \\nb\\na","mITT from Supplemental Virology Report.\\nSubgroup\\nAPRETUDE\\nIncidence\\nper 100\\nPerson-\\nYears\\nAPRETUDE\\nPerson-\\nYears\\nTRUVADA\\nIncidence\\nper 100\\nPerson-\\nYears\\nTRUVADA\\nPerson-\\nYears\\nHazard\\nRatio\\n(95% CI)\\nAge\\n&lt;25 years\\n0.23\\n868\\n2.34\\n853\\n0.12\\n(0.03, 0.46)\\n\\u226525 years\\n0.09\\n1,093\\n1.46\\n1,093\\n0.09\\n(0.02, 0.49)\\nBody Mass Index\\n&lt;30\\n0.22\\n1,385\\n1.88\\n1,435\\n0.12\\n(0.04, 0.38)\\n\\u226530\\n0.00\\n575\\n1.76\\n511\\n0.04\\n(0.00, 0.93)\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nHow Supplied\\nAPRETUDE is supplied in a kit containing one 600-mg/3...","Store APRETUDE at 2\\u00b0C to 25\\u00b0C (36\\u00b0F to 77\\u00b0F) in the original carton until ready to use.\\nExposure up to 30\\u00b0C permitted. Do not freeze. Do not mix with any other product or\\ndiluent.\\nIf the pack has been stored in the refrigerator, the vial should be brought to room\\ntemperature prior to administration (not to exceed 30\\u00b0C [86\\u00b0F]).\\nOnce the suspension has been drawn into the syringe, the injection should be\\nadministered as soon as possible, but may remain in the syringe for up to 2 hours. The\\nfilled ...","Important Information for Individuals without HIV-1 Taking APRETUDE for HIV-1\\nPre\\n\\u2011\\nExposure Prophylaxis\\nAdvise individuals without HIV-1 about the following \\n[see Warnings and Precautions\\n(\\n5.1\\n)]\\n:\\na","\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nPotential Risk of Resistance with APRETUDE\\nAdvise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1\\nis acquired either before or while taking APRETUDE or following discontinuation of\\nAPRETUDE \\n[see Warnings and Precautions (\\n5.2\\n)]\\n.\\nTo minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1\\nacquisition and tested frequently to confirm HIV-1 negative status. Advise individuals\\nwho are confirmed to have with HIV...","initiated within 2 months of the final injection of APRETUDE \\n[see Warnings and\\nPrecautions (\\n5.2\\n)]\\n.\\nLong-Acting Properties of APRETUDE\\nAdvise individuals that APRETUDE is an extended-release injectable that may be\\nsystemically present for 12 months or longer and consideration should be taken\\nregarding the prolonged release characteristics when APRETUDE is discontinued \\n[see\\nWarnings and Precautions (\\n5.3\\n), Drug Interactions (\\n7\\n)]\\n.\\nAdherence to APRETUDE\\nCounsel individuals about the importa...","[see Clinical\\nStudies (\\n14.1\\n)]\\n. The time from initiation of APRETUDE for HIV-1 PrEP to maximal\\nprotection against HIV-1 infection is unknown.\\nCounsel individuals on the use of other prevention measures (e.g., knowledge of\\npartner HIV-1 status, testing for STIs condom use). Inform individuals about and\\nsupport their efforts in reducing sexual risk behavior.\\nAPRETUDE should be used to reduce the risk of acquiring HIV-1 only in individuals\\nconfirmed to be HIV-1 negative \\n[see Contraindications (\\n...","confirming the individual is HIV-1 negative.\\nIf recent (&lt;1 month) exposures to HIV-1 are suspected or clinical symptoms\\nconsistent with acute HIV-1 infection are present, use a test approved or cleared\\nby the FDA as an aid in the diagnosis of acute or primary HIV-1 infection.\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to\\neach injection of APRETUDE, and upon diagnosis of any other STIs.\\nIf an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent ...","Counsel individuals about the importance of continued medication adherence and\\nscheduled visits to help reduce the risk of acquiring HIV-1 infection and development of\\nresistance \\n[see Dosage and Administration (\\n2.3\\n), Warnings and Precautions (\\n5.1\\n)]\\n.\\nHypersensitivity Reactions\\nAdvise individuals to immediately contact their healthcare provider if they develop a rash.\\nInstruct individuals to immediately stop taking APRETUDE and seek medical attention if\\nthey develop a rash associated with an...","lips, tongue, or mouth; difficulty breathing; and/or signs and symptoms of liver problems\\n(e.g., yellowing of the skin or whites of the eyes; dark or tea\\u2011colored urine; pale-colored\\nstools or bowel movements; nausea; vomiting; loss of appetite; or pain, aching, or\\nsensitivity on the right side below the ribs). Advise individuals that if hypersensitivity\\noccurs, they will be closely monitored, laboratory tests will be ordered, and appropriate\\ntherapy will be initiated \\n[see Warnings and Precautio...","if hepatoxicity is confirmed \\n[see Warnings and Precautions (\\n5.5\\n)]\\n.\\nDepressive Disorders\\nInform individuals that depressive disorders (including depression, depressed mood,\\nmajor depression, persistent depressive disorder, suicidal ideation, suicide attempt) have\\nbeen reported with APRETUDE \\n[see Adverse Reactions (\\n6.1\\n)]\\n. Advise individuals to seek\\nprompt medical evaluation if they experience depressive symptoms \\n[see Warnings and\\nPrecautions (\\n5.6\\n)]\\n.\\nDrug Interactions\\nInform individuals...","[see\\nContraindications (\\n4\\n), Warnings and Precautions (\\n5.7\\n), Drug Interactions (\\n7.2\\n, \\n7.3\\n)]\\n.\\nMissed Dose\\nInform individuals that APRETUDE can remain in the body for up to 12 months or longer\\nafter receiving their last injection. Advise individuals that they should contact their\\nhealthcare provider if they miss or plan to miss a scheduled monthly injection visit and\\nthat oral dosing may be used to replace up to 2 consecutive monthly injections. Advise\\nindividuals that if they discontinue u...","reproductive potential should be informed of the long duration of exposure of\\nAPRETUDE and that there is very limited clinical experience in human pregnancy\\n [see","Warnings and Precautions (\\n5.3\\n), Use in Specific Populations (\\n8.1\\n)]\\n.\\nLactation\\nInform individuals that due to the potential for adverse reactions and residual\\nconcentrations in the systemic circulation for up to 12 months or longer after\\ndiscontinuing injections of APRETUDE, it is recommended that mothers breastfeed only\\nif the expected benefit justifies the potential risk to the infant. The benefits and risks of\\nAPRETUDE while breastfeeding should be evaluated, including the risk of HIV-1\\na...","APRETUDE, CABENUVA, and VOCABRIA are trademarks owned by or licensed to the ViiV\\nHealthcare group of companies.\\nThe other brand listed is a trademark owned by or licensed to its respective owner and\\nis not a trademark owned by or licensed to the ViiV Healthcare group of companies. The\\nmaker of this brand is not affiliated with and does not endorse the ViiV Healthcare group\\nof companies or its products.\\nManufactured for:\\nViiV Healthcare\\nDurham, NC 27701\\n\\u00a92025 ViiV Healthcare group of companies or...","risk of getting human immunodeficiency virus-1 (HIV-1) infection, also called\\npre-exposure prophylaxis or \\u201cPrEP\\u201d:\\nBefore receiving APRETUDE to reduce your risk of getting HIV-1:\\n\\u2022\\n\\u2022\\n\\u2022\\n \\n \\n \\n \\nYou must be HIV-1 negative to start APRETUDE. You must get tested to\\nmake sure that you do not already have HIV-1 infection.\\nDo not receive APRETUDE for HIV-1 PrEP unless you are confirmed to be\\nHIV-1 negative.\\nSome HIV-1 tests can miss HIV-1 infection in a person who has recently become\\ninfected. If you ha...","While you are receiving APRETUDE for HIV-1 PrEP:\\n\\u2022\\n\\u2022\\nIf you have HIV-1 and receive only APRETUDE, over time your HIV-1 may\\nbecome harder to treat.\\nWhat is APRETUDE?\\nAPRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting\\nHIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).\\nHIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).\\nIt is not known if APRETUDE is safe and effective in children younger than 12 years o...","the risk of getting sexually transmitted infections.\\nYou must stay HIV-1 negative to keep receiving APRETUDE for HIV-1\\nPrEP.\\no\\no\\no\\no\\no\\no\\no\\no\\nKnow your HIV-1 status and the HIV-1 status of your partners.\\nAsk your partners with HIV-1 if they are taking anti-HIV-1 medicines and have\\nan undetectable viral load. An undetectable viral load is when the amount of\\nvirus in the blood is too low to be measured in a lab test. To maintain an\\nundetectable viral load, your partners must keep taking HIV-1 medic...","HIV-1\\u2013infected, the HIV-1 infection may become harder to treat.\\nGet tested for other sexually transmitted infections such as syphilis,\\nchlamydia, and gonorrhea. These infections make it easier for HIV-1 to infect\\nyou.\\nIf you think you were exposed to HIV-1, tell your healthcare provider right\\naway. They may want to do more tests to be sure you are still HIV-1 negative.\\nGet information and support to help reduce sexual risk behaviors.\\nDo not miss any injections of APRETUDE. Missing injections inc...","do not know your HIV-1 infection status.\\n You may already be HIV-1 positive.\\nYou need to take other medicines to treat HIV-1. APRETUDE can only help reduce\\nyour risk of getting HIV-1 infection \\nbefore\\n you are infected.\\nhave ever had an allergic reaction to cabotegravir","\\u2022\\n\\u2022\\n \\n \\n \\n \\n \\n \\nBefore receiving APRETUDE, tell your healthcare provider about all your\\nmedical conditions, including if you:\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nTell your healthcare provider about all the medicines you take,\\n including\\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\\nSome medicines may interact with APRETUDE. Keep a list of your medicines and show it\\nto your healthcare provider and pharmacist when you get a new medicine.\\nYou can ask your healthcare provider or pharmacist fo...","\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nhave ever had an allergic reaction to cabotegravir\\nare taking any of the following medicines:\\n\\u25cb   carbamazepine\\n\\u25cb   oxcarbazepine\\n\\u25cb   phenobarbital\\n\\u25cb   phenytoin\\n\\u25cb   rifampin\\n\\u25cb   rifapentine\\nhave ever had a skin rash or an allergic reaction to medicines that contain\\ncabotegravir.\\nhave or have had liver problems.\\nhave ever had mental health problems.\\nare pregnant or plan to become pregnant. It is not known if APRETUDE will harm\\nyour unborn baby. APRETUDE can remain in your body for up to ...","about the health of you and your baby. Talk to your healthcare provider about how\\nyou can take part in this registry.\\nare breastfeeding or plan to breastfeed. APRETUDE may pass into your breast milk.\\nTalk with your healthcare provider about the best way to feed your baby while or\\nafter receiving APRETUDE.\\nAPRETUDE will be given to you as an injection by your healthcare provider.\\nAPRETUDE is initially given as an injection into the muscle of your buttock 1 time\\nevery month for the first 2 months,...","tolerate cabotegravir.\\nAPRETUDE is a long-acting medicine and may stay in your body for 12 months or\\nlonger after your last injection.\\nStay under the care of a healthcare provider while receiving APRETUDE. It is\\nimportant that you receive APRETUDE as scheduled.\\nIf you miss or plan to miss a scheduled injection of APRETUDE by more than 7\\ndays, call your healthcare provider right away to discuss your PrEP options.\\nIf you stop receiving APRETUDE, talk to your healthcare provider about other\\noptions...","What are the possible side effects of APRETUDE?\\nAPRETUDE may cause serious side effects including:\\n\\u2022\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n\\u2022\\n \\n \\n \\n \\n \\n \\n \\n\\u2022\\nThe most common side effects of APRETUDE include:\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nAllergic reactions.\\n Call your healthcare provider right away if you develop a rash\\nwith APRETUDE. \\nStop receiving APRETUDE and get medical help right away\\nif you develop a rash with any of the following signs or symptoms:\\n\\u25cb   fever\\n\\u25cb   generally ill feeling\\n\\u25cb   tiredness\\n\\u25cb   mu...","to check your liver function. \\nCall your healthcare provider right away if you develop any of the\\nfollowing signs or symptoms of liver problems:\\n\\u25cb   your skin or the white part of\\nyour eyes turns yellow (jaundice)\\n\\u25cb   dark or \\u201ctea-colored\\u201d urine\\n\\u25cb   light-colored stools (bowel\\nmovements)\\n\\u25cb   nausea or vomiting\\n\\u25cb   loss of appetite\\n\\u25cb   pain, aching, or tenderness on the\\nright side of your stomach area\\n\\u25cb   itching\\nDepression or mood changes. Call your healthcare provider or get\\nmedical help right ...","discoloration\\ndiarrhea\\nheadache\\nfever\\ntiredness\\nsleep problems\\nnausea\\ndizziness\\npassing gas\\nstomach pain\\nvomiting\\nmuscle pain\\nrash\\nloss of appetite\\ndrowsiness\\nback pain\\nupper respiratory infection","These are not all the possible side effects of APRETUDE.\\nCall your doctor for medical advice about side effects. You may report side effects to\\nFDA at 1-800-FDA-1088.\\nGeneral information about the safe and effective use of APRETUDE.\\nMedicines are sometimes prescribed for purposes other than those listed in a Patient\\nInformation leaflet. You can ask your pharmacist or healthcare provider for information\\nabout APRETUDE that is written for health professionals.\\nWhat are the ingredients in APRETUDE?...","APR:5PIL\\nFor more information, go to \\nwww.apretude.com\\n or call 1-877-844-8872.\\n \\nThis Patient Information has been approved by the U.S. Food and Drug\\nAdministration.               Revised: 4/2025","Overview:\\nA complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.\\nAPRETUDE is a suspension that does not need further dilution or reconstitution.\\nCarefully follow these instructions when preparing the suspension for injection to avoid\\nleakage.\\nAPRETUDE is for gluteal intramuscular use only.\\nNote:\\n The ventrogluteal site is recommended.\\n Storage information\\nStore at 2\\u00b0C to 25\\u00b0C (36\\u00b0F to 77\\u00b0F). Exposure up to 30\\u00b0C (86\\u00b0F) permitted.\\nDo not \\nfreeze.\\nPrior to administration:\\n...","\\u2022\\nYour pack contains:\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\nConsider the individual\\u2019s build and use medical judgment to select an appropriate\\ninjection needle length.\\nYou will also need:\\n\\u2022\\n\\u2022\\n\\u2022\\n\\u2022\\ntemperature prior to administration (not to exceed 30\\u00b0C [86\\u00b0F]).\\nOnce APRETUDE has been drawn into the syringe, the medicine can remain in the\\nsyringe for up to 2 hours before injection. The filled syringe should not be placed in\\nthe refrigerator. If the medicine remains in the syringe for more than 2 hours, the\\nfilled syringe and ne...","Preparation:\\n1. Inspect the vial.\\nFigure A\\n\\u2022\\n\\u2022\\n \\n \\n\\u2022\\n2. Shake the vial vigorously.\\nFigure B\\n\\u2022\\n3. Inspect suspension.\\nFigure C\\n\\u2022\\n\\u2022\\n\\u2022\\n4. Remove the vial cap.\\nCheck that the\\nexpiration date has\\nnot passed. \\nSee\\nFigure A.\\nInspect the vial\\nimmediately. If you\\ncan see foreign\\nmatter, do not use\\nthe product.\\nNote:\\n The vial has a\\nbrown tint to the\\nglass.\\nDo not\\n use if the\\nexpiration date has\\npassed.\\nIf the pack has been\\nstored in the\\nrefrigerator, allow the\\nmedication to come to\\nroom temperature.\\nHold...","Figure D\\n\\u2022\\n\\u2022\\n \\n5. Peel open the vial adapter.\\nFigure E\\n\\u2022\\n \\n \\n6. Place vial on flat surface and attach the vial adapter.\\nFigure F\\n\\u2022\\n\\u2022\\n\\u2022\\n7. Lift off the packaging.\\nRemove the cap from\\nthe vial. \\nSee Figure\\nD.\\nWipe the rubber\\nstopper with an\\nalcohol wipe.\\nDo not\\n allow\\nanything to touch the\\nrubber stopper after\\nwiping it.\\nPeel off the paper\\nbacking from the vial\\nadapter packaging.\\nSee Figure E.\\nNote:\\n Do not remove\\nthe adapter from its\\npackaging for the\\nnext step. The\\nadapter \\nwill not\\n fall\\nout wh...","Figure G\\n\\u2022\\n8. Prepare the syringe.\\nFigure H\\n\\u2022\\n\\u2022\\n9. Attach the syringe.\\nFigure I\\n\\u2022\\n\\u2022\\n10. Press the plunger.\\nLift off the vial\\nadapter packaging, as\\nshown.\\n See Figure\\nG.\\nRemove the syringe\\nfrom its packaging.\\nDraw 1 mL of air into\\nthe syringe. This will\\nmake it easier to draw\\nup the medicine later.\\nSee Figure H.\\nHold the vial adapter\\nand vial firmly, as\\nshown.\\nScrew the syringe\\nfirmly onto the vial\\nadapter. \\nSee Figure\\nI.","Figure J\\n\\u2022\\n11. Slowly draw up the dose.\\nFigure K\\n\\u2022\\n \\n12. Unscrew the syringe.\\nFigure L\\n\\u2022\\n\\u2022\\n \\n13. Attach the needle.\\nPress the plunger all\\nthe way down to push\\nthe air into the vial.\\nSee Figure J.\\nInvert the syringe and\\nvial and slowly\\nwithdraw as much of\\nthe medicine as\\npossible into the\\nsyringe. There may be\\nmore medicine than\\nthe dose amount.\\nSee Figure K.\\nNote:\\n Keep the\\nsyringe upright to\\navoid leakage.\\nHold the syringe\\nplunger firmly in place\\nas shown to prevent\\nleakage. It is normal\\nto fee...","Figure M\\n\\u2022\\n\\u2022\\n\\u2022\\nInjection:\\n14. Prepare the injection site.\\nFigure N\\n \\n \\n\\u2022\\n\\u2022\\n \\n15. Remove the cap.\\nPeel open the needle\\npackaging part way to\\nexpose the needle\\nbase.\\nKeeping the syringe\\nupright, firmly twist\\nthe syringe onto the\\nneedle.\\nRemove the needle\\npackaging from the\\nneedle. \\nSee Figure\\nM.\\nAPRETUDE must be\\nadministered to a\\ngluteal site. \\nSee\\nFigure N\\n.\\nSelect from the\\nfollowing areas for the\\ninjection:\\nVentrogluteal, as\\nshown\\n(recommended)\\nDorsogluteal, not\\nshown (upper outer\\nquadrant)\\nNote...","Figure O\\n\\u2022\\n\\u2022\\n16. Remove extra liquid from the syringe.\\nFigure P\\n\\u2022\\n \\n17. Stretch the skin.\\n \\n\\u2022\\n\\u2022\\nFold the needle guard\\naway from the needle.\\nSee Figure O.\\nPull off the injection\\nneedle cap.\\nHold the syringe with\\nthe needle pointing\\nup. Press the plunger\\nto the 3 mL dosing\\nmark to remove extra\\nliquid and any air\\nbubbles. \\nSee Figure\\nP.\\nNote:\\n Clean the\\ninjection site with an\\nalcohol wipe. Allow the\\nskin to air dry before\\ncontinuing.\\nUse the z-track\\ninjection technique to\\nminimize medicine\\nleakage ...","Figure Q\\n18. Insert the needle.\\nFigure R\\n\\u2022\\n19. Inject the dose of medicine.\\nFigure S\\n\\u2022\\n\\u2022\\n\\u2022\\n20. Assess the injection site.\\nInsert the needle to\\nits full depth, or deep\\nenough to reach the\\nmuscle. \\nSee Figure\\nR.\\nStill holding the skin\\nstretched \\u2013 slowly\\npress the plunger all\\nthe way down. \\nSee\\nFigure S.\\nEnsure the syringe is\\nempty.\\nWithdraw the needle\\nand release the\\nstretched skin\\nimmediately.","Figure T\\n\\u2022\\n\\u2022\\n \\n21. Make the needle safe.\\nFigure U\\n\\u2022\\nFigure V\\n\\u2022\\n\\u2022\\nAfter injection:\\n22. Dispose safely.\\nApply pressure to the\\ninjection site using a\\ngauze pad. \\nSee\\nFigure T.\\nA small bandage may\\nbe used if bleeding\\noccurs.\\nDo not\\n massage the\\narea.\\nFold the needle guard\\nover the needle. \\nSee\\nFigure U.\\nGently apply pressure\\nusing a hard surface\\nto lock the needle\\nguard in place.\\nThe needle guard will\\nmake a click when it\\nlocks. \\nSee Figure V.","Figure W\\n\\u2022\\nQuestions and Answers\\n1.\\n \\n2.\\n3.\\n4.\\nManufactured for:\\nViiV Healthcare\\nDurham, NC 27701\\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.\\n\\u00a92024 ViiV Healthcare group of companies or its licensor.\\nAPR:5IFU\\n \\nDispose of used\\nneedle, syringe, vial,\\nand vial adapter\\naccording to local\\nhealth and safety\\nlaws. \\nSee Figure W.\\nIf the pack has been stored in the refrigerator, is it safe to warm the\\nvial up to room temperature more quickly?\\n \\nThe vial should be broug...","it up. However, APRETUDE can remain in the syringe for up to 2 hours before\\ninjection.\\nIf the medicine remains in the syringe for more than 2 hours, the filled syringe and\\nneedle must be discarded.\\nWhy do I need to inject air into the vial?\\n \\nInjecting 1 mL of air into the vial makes it easier to draw up the medicine into the\\nsyringe. Without the air, some liquid may flow back into the vial unintentionally,\\nleaving less medicine than intended in the syringe.\\nWhy is the ventrogluteal administrati...","Principal Display Panel\\nNDC 49702-264-23\\nApretude\\n(cabotegravir extended-release injectable suspension)\\n600 mg/3 mL\\n(200 mg/mL)\\nRx Only\\nFor gluteal intramuscular use only.\\nHealthcare Professional Administration Only.\\nContents:\\n1 Single-dose vial\\n1 Vial adapter\\n1 Syringe\\n1 Injection needle (23 gauge, 1 \\u00bd inch)\\nPrescribing Information\\nPatient Information\\nInstructions for Use\\nEnsure vial adapter is used correctly.\\nViiV Healthcare\\n600 mg/ 3 mL Kit\\nMade in Singapore and Belgium\\nRev. 2/24\\n\\u00a92024 ViiV H...","Principal Display Panel\\nNDC 49702-280-63\\nApretude\\n(cabotegravir extended-release injectable suspension)\\n600 mg/3 mL\\n(200 mg/mL)\\nRx Only\\nSample-Not for Sale\\nFor gluteal intramuscular use only.","Healthcare Professional Administration Only.\\nContents:\\n1 Single-dose vial\\n1 Vial adapter\\n1 Syringe\\n1 Injection needle (23 gauge, 1 \\u00bd inch)\\nPrescribing Information\\nPatient Information\\nInstructions for Use\\nEnsure vial adapter is used correctly.\\nViiV Healthcare\\n600 mg/ 3 mL Kit\\nMade in Singapore and Belgium\\nRev. 5/24\\n\\u00a92024 ViiV Healthcare group of companies or its licensor.\\n62000000094179","APRETUDE  \\ncabotegravir kit\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:49702-264\\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:49702-264-\\n23\\n1 \\nin 1 CARTON; Type 1: Convenience Kit of Co-\\nPackage\\n12/20/2021","Quantity of Parts\\nPart #\\nPackage Quantity\\nTotal Product Quantity\\nPart 1\\n1 VIAL\\n3 mL\\nPart 1 of 1\\nCABOTEGRAVIR  \\ncabotegravir injection, suspension, extended release\\nProduct Information\\nItem Code (Source)\\nNDC:49702-238\\nRoute of Administration\\nINTRAMUSCULAR\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCABOTEGRAVIR\\n (UNII: HMH0132Z1Q) \\n(CABOTEGRAVIR - UNII:HMH0132Z1Q)\\nCABOTEGRAVIR\\n200 mg  in 1 mL\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMANNITOL\\n (UNII: 3OWL53L36A)...","Date\\n1\\nNDC:49702-238-\\n03\\n3 mL in 1 VIAL; Type 0: Not a Combination\\nProduct\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate","NDA\\nNDA215499\\n12/20/2021\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nNDA\\nNDA215499\\n12/20/2021\\nAPRETUDE  \\ncabotegravir kit\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:49702-280\\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:49702-280-\\n63\\n1 \\nin 1 CARTON; Type 1: Convenience Kit of Co-\\nPackage\\n03/31/2024\\nQuantity of Parts\\nPart #\\nPackage Quantity\\n...","ViiV Healthcare Company\\nMANNITOL\\n (UNII: 3OWL53L36A)\\n \\nPOLYETHYLENE GLYCOL 3350\\n (UNII: G2M7P15E5P)\\n \\nPOLYSORBATE 20\\n (UNII: 7T1F30V5YH)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nProduct Characteristics\\nColor\\nWHITE (white to light pink)\\nScore\\n    \\nShape\\nSize\\nFlavor\\nImprint Code\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:49702-238-\\n61\\n3 mL in 1 VIAL; Type 0: Not a Combination\\nProduct\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Mono...","ISENTRESS- raltegravir tablet, film coated \\n \\nNuCare Pharmaceuticals,Inc.\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use ISENTRESS safely and\\neffectively. See full prescribing information for ISENTRESS. \\nISENTRESS \\n (raltegravir) film-coated tablets, for oral use \\nISENTRESS \\n (raltegravir) chewable tablets, for oral use \\nISENTRESS \\n (raltegravir) for oral suspension \\nInitial U.S. Approval: 2007\\nINDICATIONS AND USAGE\\nISENTRESS is...","response ( \\n14\\n).\\nDOSAGE AND ADMINISTRATION\\nISENTRESS can be administered with or without food ( \\n2.1\\n).\\nDo not substitute ISENTRESS chewable tablets or ISENTRESS for oral suspension for the ISENTRESS 400\\nmg film-coated tablet.\\nSee specific dosing guidance for chewable tablets and the formulation for oral suspension ( \\n2.1\\n).\\nAdults\\n400 mg film-coated tablet orally, twice daily ( \\n2.2\\n).\\nDuring coadministration with rifampin in adults, 800 mg twice daily ( \\n2.1\\n).\\nChildren and Adolescents\\nIf at ...","between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used,\\nas specified in Table 2 ( \\n2.3\\n).\\nDOSAGE FORMS AND STRENGTHS\\nFilm-Coated Tablets: 400 mg ( \\n3\\n).\\nChewable Tablets: 100 mg scored and 25 mg ( \\n3\\n).\\nFor Oral Suspension: Single-use packet of 100 mg ( \\n3\\n).\\nCONTRAINDICATIONS\\nNone ( \\n4\\n).\\nWARNINGS AND PRECAUTIONS\\nSevere, potentially life-threatening and fatal skin reactions have been reported. This includes cases of\\nStevens-Johnson syndrome, hypersen...","5.1\\n).\\nMonitor for Immune Reconstitution Syndrome ( \\n5.2\\n).\\nInform patients with phenylketonuria that the 100 mg and 25 mg chewable tablets contain\\nphenylalanine ( \\n5.3\\n).\\nADVERSE REACTIONS\\nThe most common adverse reactions of moderate to severe intensity (\\u22652%) are insomnia, headache,\\n\\u00ae\\n\\u00ae\\n\\u00ae","The most common adverse reactions of moderate to severe intensity (\\u22652%) are insomnia, headache,\\ndizziness, nausea and fatigue ( \\n6.1\\n).\\nCreatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and\\nrhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or\\nrhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions\\nand patients with a history of rhabdomyolysis, myopathy or increased serum cre...","Coadministration of ISENTRESS and other drugs may alter the plasma concentration of raltegravir. The\\npotential for drug-drug interactions must be considered prior to and during therapy ( \\n7\\n).\\nCoadministration of ISENTRESS with drugs that are strong inducers of UGT1A1, such as rifampin, may\\nresult in reduced plasma concentrations of raltegravir ( \\n2.1\\n, \\n7.2\\n).\\nUSE IN SPECIFIC POPULATIONS\\nPregnancy:\\nISENTRESS should be used during pregnancy only if the potential benefit justifies the potential r...","2 DOSAGE AND ADMINISTRATION\\n2.1 General Dosing Recommendations\\n2.2 Adults\\n2.3 Pediatrics\\n2.4 Method of Administration\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Severe Skin and Hypersensitivity Reactions\\n5.2 Immune Reconstitution Syndrome\\n5.3 Phenylketonurics\\n6 ADVERSE REACTIONS\\n6.1 Clinical Trials Experience\\n6.2 Postmarketing Experience\\n7 DRUG INTERACTIONS\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\n7.2 Effect of Other Agents on the Pha...","8.5 Geriatric Use\\n8.6 Use in Patients with Hepatic Impairment\\n8.7 Use in Patients with Renal Impairment\\n10 OVERDOSAGE\\n11 DESCRIPTION\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\n12.2 Pharmacodynamics\\n12.3 Pharmacokinetics\\n12.4 Microbiology\\n13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n14 CLINICAL STUDIES\\n14.1 \\nTreatment-Na\\u00efve Adult Subjects\\n14.2 Treatment-Experienced Adult Subjects\\n14.3 Pediatric Subjects\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n17 PATIENT ...","of treatment response \\n[see \\nClinical Studies (14)\\n] \\n.\\n2 DOSAGE AND ADMINISTRATION\\n2.1 General Dosing Recommendations\\nISENTRESS Film-Coated Tablets, Chewable Tablets and For Oral Suspension can be\\nadministered with or without food \\n[see \\nClinical Pharmacology (12.3)\\n] \\n.\\nBecause the formulations are not bioequivalent, do not substitute ISENTRESS\\nchewable tablets or ISENTRESS for oral suspension for the ISENTRESS 400 mg film-\\ncoated tablet. See specific dosing guidance for chewable tablets and t...","years of age \\n[see \\nDrug Interactions (7.2)\\n] \\n.\\nMaximum dose of chewable tablets is 300 mg twice daily.\\nMaximum dose of oral suspension is 100 mg twice daily.\\nSections or subsections omitted from the full prescribing information are not listed.","Each single-use packet for oral suspension contains 100 mg of raltegravir which is\\nsuspended in 5 mL of water giving a final concentration of 20 mg/mL.\\n2.2 Adults\\nFor the treatment of adult patients with HIV-1 infection, the dosage of ISENTRESS is one\\n400 mg film-coated tablet administered orally, twice daily.\\n2.3 Pediatrics\\nIf at least 25 kg:\\n One 400 mg film-coated tablet orally, twice daily.\\nIf unable to swallow a tablet, consider the chewable tablet, as specified in Table 1.\\nTable 1: Alterna...","2 \\u00d7 100 mg twice\\ndaily\\nAt least 40\\n300 mg twice daily\\n3 \\u00d7 100 mg twice\\ndaily\\nIf at least 4 weeks of age and weighing at least 3 kg to less than 25 kg:\\nWeight based dosing, as specified in Table 2.\\nFor patients weighing between 11 and 20 kg, either the chewable tablet or oral\\nsuspension can be used, as specified in Table 2. Patients can remain on the oral\\nsuspension as long as their weight is below 20 kg. Refer to Table 2 for appropriate\\ndosing \\n[see \\nClinical Studies (14.3)\\n] \\n.\\nTable 2: Recomme...","2 mL (40 mg) twice\\ndaily\\n8 to less than 11\\n3 mL (60 mg) twice\\ndaily\\n*\\nThe weight-based dosing recommendation for the chewable tablet is\\nbased on approximately 6 mg/kg/dose twice daily \\n[see \\nClinical\\nPharmacology (12.3)] \\n.\\nThe 100 mg chewable tablet can be divided into equal halves.\\n\\u2020\\n*","*\\n\\u2020\\n\\u2021\\n11 to less than 14 \\n4 mL (80 mg) twice\\ndaily\\n3 \\u00d7 25 mg twice daily\\n14 to less than 20 \\n5 mL (100 mg) twice\\ndaily\\n1 \\u00d7 100 mg twice\\ndaily\\n20 to less than 25\\n1.5 \\u00d7 100 mg \\n twice\\ndaily\\n2.4 Method of Administration\\nISENTRESS Film-Coated Tablets\\nFilm-Coated Tablets must be swallowed whole\\nISENTRESS Chewable Tablets\\nChewable Tablets may be chewed or swallowed whole\\nISENTRESS For Oral Suspension\\nEach single-use ISENTRESS packet for oral suspension contains 100 mg of raltegravir\\nwhich is to be sus...","mixing\\nDiscard any remaining suspension\\nFor more details on preparation and administration of the suspension, see\\nInstructions for Use\\n.\\n3 DOSAGE FORMS AND STRENGTHS\\nFilm-coated Tablets \\n400 mg pink, oval-shaped, film-coated tablets with \\"227\\" on one side.\\nChewable Tablets \\n100 mg pale orange, oval-shaped, orange-banana flavored, chewable tablets scored\\non both sides and imprinted on one face with the Merck logo and \\"477\\" on opposite\\nsides of the score. \\n25 mg pale yellow, round, orange-banana f...","4 CONTRAINDICATIONS\\nThe weight-based dosing recommendation for the chewable tablet and\\noral suspension is based on approximately 6 mg/kg/dose twice daily\\n[see \\nClinical Pharmacology (12.3)] \\n.\\nFor weight between 11 and 20 kg either formulation can be used. \\nNote:\\nThe chewable tablets are available as 25 mg and 100 mg tablets.\\nThe 100 mg chewable tablet can be divided into equal halves.\\n\\u2020\\n\\u2020\\n\\u2021","None\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Severe Skin and Hypersensitivity Reactions\\nSevere, potentially life-threatening, and fatal skin reactions have been reported. These\\ninclude cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.\\nHypersensitivity reactions have also been reported and were characterized by rash,\\nconstitutional findings, and sometimes, organ dysfunction, including hepatic failure.\\nDiscontinue ISENTRESS and other suspect agents immediately if signs or symptoms of\\nsevere...","angioedema). Clinical status including liver aminotransferases should be monitored and\\nappropriate therapy initiated. Delay in stopping ISENTRESS treatment or other suspect\\nagents after the onset of severe rash may result in a life-threatening reaction.\\n5.2 Immune Reconstitution Syndrome\\nImmune reconstitution syndrome has been reported in patients treated with\\ncombination antiretroviral therapy, including ISENTRESS. During the initial phase of\\ncombination antiretroviral treatment, patients whose...","Autoimmune disorders (such as Graves&#x27; disease, polymyositis, and Guillain-Barr\\u00e9\\nsyndrome) have also been reported to occur in the setting of immune reconstitution;\\nhowever, the time to onset is more variable, and can occur many months after initiation\\nof treatment.\\n5.3 Phenylketonurics\\nISENTRESS Chewable Tablets contain phenylalanine, a component of aspartame. Each\\n25 mg ISENTRESS Chewable Tablet contains approximately 0.05 mg phenylalanine. Each\\n100 mg ISENTRESS Chewable Tablet contains approxi...","clinical trials of another drug and may not reflect the rates observed in practice.\\n6.1 Clinical Trials Experience\\nTreatment-Na\\u00efve Adults\\nThe following safety assessment of ISENTRESS in treatment-na\\u00efve subjects is based on\\nthe randomized double-blind active controlled study of treatment-na\\u00efve subjects,","STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed\\ndose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600\\nmg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-\\nblind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily\\n+ emtricitabine (+) tenofovir was 1104 patient-years and 1036 patient-years for\\nsubjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenof...","to be causally related to ISENTRESS + emtricitabine (+) tenofovir or efavirenz +\\nemtricitabine (+) tenofovir. Clinical ADRs of moderate to severe intensity occurring in\\n\\u22652% of treatment-na\\u00efve subjects treated with ISENTRESS are presented in Table 3.\\nTable 3: Adverse Drug Reactions \\n of Moderate to Severe\\nIntensity \\n Occurring in \\u22652% of Treatment-Na\\u00efve Adult\\nSubjects Receiving ISENTRESS (240 Week Analysis)\\nSystem Organ\\nClass, Preferred\\nTerm\\nRandomized Study Protocol 021\\nISENTRESS 400 mg \\nTwice Da...","Nervous System Disorders\\n Headache\\n4%\\n5%\\n Dizziness\\n2%\\n6%\\nPsychiatric Disorders\\n Insomnia\\n4%\\n4%\\nLaboratory Abnormalities\\nThe percentages of adult subjects treated with ISENTRESS 400 mg twice daily or\\nefavirenz in Protocol 021 with selected Grades 2 to 4 laboratory abnormalities that\\nrepresent a worsening Grade from baseline are presented in Table 4.\\nTable 4: Selected Grade 2 to 4 Laboratory Abnormalities\\nReported in Treatment-Na\\u00efve Subjects (240 Week\\n*\\n\\u2020\\nIncludes adverse experiences considered b...","Analysis)\\nRandomized Study Protocol\\n021\\nLaboratory\\nParameter\\nPreferred\\nTerm (Unit)\\nLimit\\nISENTRESS\\n400 mg \\nTwice Daily +\\nEmtricitabine\\n(+) Tenofovir \\n(N = 281)\\nEfavirenz 600\\nmg \\nAt Bedtime +\\nEmtricitabine\\n(+) Tenofovir \\n(N = 282)\\nHematology\\nAbsolute neutrophil count (10 \\n/\\u00b5L)\\n  Grade 2\\n0.75 - 0.999\\n3%\\n5%\\n  Grade 3\\n0.50 - 0.749\\n3%\\n1%\\n  Grade 4\\n&lt;0.50\\n1%\\n1%\\nHemoglobin (gm/dL)\\n  Grade 2\\n7.5 - 8.4\\n1%\\n1%\\n  Grade 3\\n6.5 - 7.4\\n1%\\n1%\\n  Grade 4\\n&lt;6.5\\n&lt;1%\\n0%\\nPlatelet count (10 \\n/\\u00b5L)\\n  Grade 2\\n50 - 99.999\\n1%\\n...","&lt;1%\\n0%\\nSerum aspartate aminotransferase\\n  Grade 2\\n2.6 - 5.0 \\u00d7 ULN\\n8%\\n10%\\n  Grade 3\\n5.1 - 10.0 \\u00d7\\nULN\\n5%\\n3%\\n  Grade 4\\n&gt;10.0 \\u00d7 ULN\\n1%\\n&lt;1%\\nSerum alanine aminotransferase\\n  Grade 2\\n2.6 - 5.0 \\u00d7 ULN\\n11%\\n12%\\n  Grade 3\\n5.1 - 10.0 \\u00d7\\nULN\\n2%\\n2%\\n  Grade 4\\n&gt;10.0 \\u00d7 ULN\\n2%\\n1%\\nSerum alkaline phosphatase\\n  Grade 2\\n2.6 - 5.0 \\u00d7 ULN\\n1%\\n3%\\n  Grade 3\\n5.1 - 10.0 \\u00d7\\nULN\\n0%\\n1%\\n  Grade 4\\n&gt;10.0 \\u00d7 ULN\\n&lt;1%\\n&lt;1%\\n3\\n3","ULN = Upper limit of normal range\\nLipids, Change from Baseline\\nChanges from baseline in fasting lipids are shown in Table 5.\\nTable 5: Lipid Values, Mean Change from Baseline, Protocol 021\\nLaboratory\\nParameter\\nPreferred\\nTerm\\nISENTRESS 400 mg \\nTwice Daily + Emtricitabine\\n(+) Tenofovir \\nN = 207\\nEfavirenz 600 mg \\nAt Bedtime + Emtricitabine\\n(+) Tenofovir \\nN = 187\\nChange\\nfrom\\nBaseline\\nat \\nWeek\\n240\\nChange\\nfrom\\nBaseline\\nat \\nWeek\\n240\\nBaseline \\nMean\\nWeek\\n240 \\nMean\\nMean\\nChange\\nBaseline \\nMean\\nWeek\\n240 \\nMean...","lipid values prior to the change in therapy were used in the analysis. If the\\nmissing data was due to other reasons, subjects were censored thereafter for\\nthe analysis. At baseline, serum lipid-reducing agents were used in 5% of\\nsubjects in the group receiving ISENTRESS and 3% in the efavirenz group.\\nThrough Week 240, serum lipid-reducing agents were used in 9% of subjects in\\nthe group receiving ISENTRESS and 15% in the efavirenz group.\\n*\\nLDL-Cholesterol\\n96\\n106\\n10\\n93\\n118\\n25\\nHDL-\\nCholesterol \\n38\\n...","BENCHMRK 1 and BENCHMRK 2 (Protocols 018 and 019) in antiretroviral treatment-\\nexperienced HIV-1 infected adult subjects. A total of 462 subjects received the\\nrecommended dose of ISENTRESS 400 mg twice daily in combination with optimized\\nbackground therapy (OBT) compared to 237 subjects taking placebo in combination with\\nFasting (non-random) laboratory tests at Week 240.\\n*\\n*\\n*\\n*","OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving\\nISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to\\nISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of\\ndiscontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5%\\nin subjects receiving placebo.\\nClinical ADRs were considered by investigators to be causally related to ISENTRESS +\\nOBT or placebo + OBT. Clinical ADRs of moderate to s...","Compared to Placebo (96 Week Analysis)\\nSystem Organ\\nClass, Adverse\\nReactions\\nRandomized Studies Protocol 018 and\\n019\\nISENTRESS 400 mg\\nTwice Daily + OBT \\n(n = 462)\\nPlacebo + OBT \\n(n = 237)\\nNervous System Disorders\\nn=total number of subjects per treatment group.\\n*\\n\\u2020\\nHeadache\\n2%\\n&lt;1%\\nLaboratory Abnormalities\\nThe percentages of adult subjects treated with ISENTRESS 400 mg twice daily or placebo\\nin Protocols 018 and 019 with selected Grade 2 to 4 laboratory abnormalities\\nrepresenting a worsening Grade...","OBT \\n(N = 237)\\nHematology\\nAbsolute neutrophil count (10 \\n/\\u00b5L)\\n  Grade 2\\n0.75 - 0.999\\n4%\\n5%\\n  Grade 3\\n0.50 - 0.749\\n3%\\n3%\\n*\\n\\u2020\\nIncludes adverse reactions at least possibly, probably, or definitely\\nrelated to the drug.\\nIntensities are defined as follows: Moderate (discomfort enough to\\ncause interference with usual activity); Severe (incapacitating with\\ninability to work or do usual activity).\\n3","Grade 4\\n&lt;0.50\\n1%\\n&lt;1%\\nHemoglobin (gm/dL)\\n  Grade 2\\n7.5 - 8.4\\n1%\\n3%\\n  Grade 3\\n6.5 - 7.4\\n1%\\n1%\\n  Grade 4\\n&lt;6.5\\n&lt;1%\\n0%\\nPlatelet count (10 \\n/\\u00b5L)\\n  Grade 2\\n50 - 99.999\\n3%\\n5%\\n  Grade 3\\n25 - 49.999\\n1%\\n&lt;1%\\n  Grade 4\\n&lt;25\\n1%\\n&lt;1%\\nBlood chemistry\\nFasting (non-random) serum glucose test (mg/dL)\\n  Grade 2\\n126 - 250\\n10%\\n7%\\n  Grade 3\\n251 - 500\\n3%\\n1%\\n  Grade 4\\n&gt;500\\n0%\\n0%\\nTotal serum bilirubin\\n  Grade 2\\n1.6 - 2.5 \\u00d7 ULN\\n6%\\n3%\\n  Grade 3\\n2.6 - 5.0 \\u00d7 ULN\\n3%\\n3%\\n  Grade 4\\n&gt;5.0 \\u00d7 ULN\\n1%\\n0%\\nSerum aspartate aminotransferase...","ULN\\n&lt;1%\\n1%\\n  Grade 4\\n&gt;10.0 \\u00d7 ULN\\n1%\\n&lt;1%\\nSerum pancreatic amylase test\\n  Grade 2\\n1.6 - 2.0 \\u00d7 ULN\\n2%\\n1%\\n  Grade 3\\n2.1 - 5.0 \\u00d7 ULN\\n4%\\n3%\\n  Grade 4\\n&gt;5.0 \\u00d7 ULN\\n&lt;1%\\n&lt;1%\\nSerum lipase test\\n  Grade 2\\n1.6 - 3.0 \\u00d7 ULN\\n5%\\n4%\\n  Grade 3\\n3.1 - 5.0 \\u00d7 ULN\\n2%\\n1%\\n  Grade 4\\n&gt;5.0 \\u00d7 ULN\\n0%\\n0%\\nSerum creatine kinase\\n  Grade 2\\n6.0 - 9.9 \\u00d7 ULN\\n2%\\n2%\\n  Grade 3\\n10.0 - 19.9 \\u00d7\\nULN\\n4%\\n3%\\n  Grade 4\\n\\u226520.0 \\u00d7 ULN\\n3%\\n1%\\n3","ULN = Upper limit of normal range\\nLess Common Adverse Reactions Observed in Treatment-Na\\u00efve and Treatment-\\nExperienced Studies\\nThe following ADRs occurred in &lt;2% of treatment-na\\u00efve or treatment-experienced\\nsubjects receiving ISENTRESS in a combination regimen. These events have been\\nincluded because of their seriousness, increased frequency on ISENTRESS compared\\nwith efavirenz or placebo, or investigator&#x27;s assessment of potential causal relationship.\\nGastrointestinal Disorders: \\nabdominal pain, ...","psychiatric illness), including suicidal ideation and behaviors\\nRenal and Urinary Disorders:\\n nephrolithiasis, renal failure\\nSelected Adverse Events - Adults\\nCancers were reported in treatment-experienced subjects who initiated ISENTRESS or\\nplacebo, both with OBT, and in treatment-na\\u00efve subjects who initiated ISENTRESS or\\nefavirenz, both with emtricitabine (+) tenofovir; several were recurrent. The types and\\nrates of specific cancers were those expected in a highly immunodeficient population\\n(ma...","with ISENTRESS (see \\nTable 7\\n). Myopathy and rhabdomyolysis have been reported. Use\\nwith caution in patients at increased risk of myopathy or rhabdomyolysis, such as\\npatients receiving concomitant medications known to cause these conditions and\\npatients with a history of rhabdomyolysis, myopathy or increased serum creatine\\nkinase.\\nRash occurred more commonly in treatment-experienced subjects receiving regimens\\ncontaining ISENTRESS + darunavir/ritonavir compared to subjects receiving ISENTRESS\\nwi...","Patients with Co-existing Conditions - Adults\\nPatients Co-infected with Hepatitis B and/or Hepatitis C Virus\\nIn the randomized, double-blind, placebo-controlled trials, treatment-experienced\\nsubjects (N = 114/699 or 16%) and treatment-na\\u00efve subjects (N = 34/563 or 6%) with\\nchronic (but not acute) active hepatitis B and/or hepatitis C virus co-infection were\\npermitted to enroll provided that baseline liver function tests did not exceed 5 times the\\n3","upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with\\nhepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without\\nhepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT\\nabnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-\\ninfection for all treatment groups. At 96 weeks, in treatment-experienced subjects,\\nGrade 2 or higher laboratory abnormalities that represent a wors...","Grade 2 or higher laboratory abnormalities that represent a worsening Grade from\\nbaseline of AST, ALT or total bilirubin occurred in 22%, 44% and 17%, respectively, of\\nco-infected subjects treated with ISENTRESS as compared to 13%, 13% and 5% of all\\nother subjects treated with ISENTRESS.\\nPediatrics\\n2 to 18 Years of Age\\nISENTRESS has been studied in 126 antiretroviral treatment-experienced HIV-1 infected\\nchildren and adolescents 2 to 18 years of age, in combination with other antiretroviral\\nagent...","One patient experienced drug related clinical adverse reactions of Grade 3 psychomotor\\nhyperactivity, abnormal behavior and insomnia; one patient experienced a Grade 2\\nserious drug related allergic rash.\\nOne patient experienced drug related laboratory abnormalities, Grade 4 AST and Grade 3\\nALT, which were considered serious.\\n4 Weeks to less than 2 Years of Age\\nISENTRESS has also been studied in 26 HIV-1 infected infants and toddlers 4 weeks to\\nless than 2 years of age, in combination with other ...","treatment discontinuation.\\n6.2 Postmarketing Experience\\nThe following adverse reactions have been identified during postapproval use of\\nISENTRESS. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\\ncausal relationship to drug exposure.\\nBlood and Lymphatic System Disorders:\\n thrombocytopenia\\nGastrointestinal Disorders:\\n diarrhea\\nHepatobiliary Disorders:\\n hepatic failure (with and witho...","patients with underlying liver disease and/or concomitant medications\\nMusculoskeletal and Connective Tissue Disorders:\\n rhabdomyolysis\\nNervous System Disorders: \\ncerebellar ataxia\\nPsychiatric Disorders: \\nanxiety, paranoia\\n7 DRUG INTERACTIONS\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\nRaltegravir does not inhibit (IC \\n&gt;100 \\u00b5M) CYP1A2, CYP2B6, CYP2C8, CYP2C9,\\nCYP2C19, CYP2D6 or CYP3A \\nin vitro\\n. Moreover, \\nin vitro\\n, raltegravir did not induce\\nCYP1A2, CYP2B6 or CYP3A4. A mid...","&gt;50 \\u00b5M) of UGT1A1 or UGT2B7, and raltegravir does not inhibit P-glycoprotein-\\nmediated transport. Based on these data, ISENTRESS is not expected to affect the\\npharmacokinetics of drugs that are substrates of these enzymes or P-glycoprotein\\n(e.g., protease inhibitors, NNRTIs, opioid analgesics, statins, azole antifungals, proton\\npump inhibitors and anti-erectile dysfunction agents).\\n7.2 Effect of Other Agents on the Pharmacokinetics of Raltegravir\\nRaltegravir is not a substrate of cytochrome P450...","that induce UGT1A1, such as rifampin, may reduce plasma levels of raltegravir.\\nThe impact of other inducers of drug metabolizing enzymes, such as phenytoin and\\nphenobarbital, on UGT1A1 is unknown.\\nSelected drug interactions are presented in Table 8 \\n[see \\nClinical Pharmacology (12.3)\\n] \\n.\\nTable 8: Selected Drug Interactions in Adults\\nConcomitant\\nDrug Class: \\nDrug Name\\nEffect on\\nConcentration\\nof Raltegravir\\nClinical Comment\\nMetal-Containing Antacids\\naluminum and/or\\nmagnesium-\\ncontaining\\nantacids\\n...","rifampin\\n\\u2193\\ndaily during coadministration\\nwith rifampin. There are no\\ndata to guide co-\\nadministration of ISENTRESS\\nwith rifampin in patients below\\n18 years of age \\n[see \\nDosage\\nand Administration (2.1)\\n].\\n7.3 Drugs without Clinically Significant Interactions with ISENTRESS\\nIn drug interaction studies, raltegravir did not have a clinically meaningful effect on the\\npharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine,\\ntenofovir, etravirine, darunavir/ritonavir, or boce...","8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nPregnancy Category C\\nISENTRESS should be used during pregnancy only if the potential benefit justifies the\\npotential risk to the fetus. There are no adequate and well-controlled studies in pregnant\\nwomen. In addition, there have been no pharmacokinetic studies conducted in pregnant\\npatients.\\nDevelopmental toxicity studies were performed in rabbits (at oral doses up to 1000\\nmg/kg/day) and rats (at oral doses up to 600 mg/kg/day). The reproductive toxici...","treatment-related effects on embryonic/fetal survival or fetal weights were observed. In\\naddition, no treatment-related external, visceral, or skeletal changes were observed in\\nrabbits. However, treatment-related increases over controls in the incidence of\\nsupernumerary ribs were seen in rats at 600 mg/kg/day (exposures 3-fold the exposure\\nat the recommended human dose).\\nPlacenta transfer of drug was demonstrated in both rats and rabbits. At a maternal\\ndose of 600 mg/kg/day in rats, mean drug co...","dose of 1000 mg/kg/day in rabbits.\\nAntiretroviral Pregnancy Registry\\nTo monitor maternal-fetal outcomes of pregnant patients exposed to ISENTRESS, an\\nAntiretroviral Pregnancy Registry has been established. Physicians are encouraged to\\nregister patients by calling 1-800-258-4263.","8.3 Nursing Mothers\\nBreastfeeding is not recommended while taking ISENTRESS. In addition, it is\\nrecommended that HIV-1-infected mothers not breastfeed their infants to avoid risking\\npostnatal transmission of HIV-1.\\nIt is not known whether raltegravir is secreted in human milk. However, raltegravir is\\nsecreted in the milk of lactating rats. Mean drug concentrations in milk were\\napproximately 3-fold greater than those in maternal plasma at a maternal dose of 600\\nmg/kg/day in rats. There were no ef...","[see \\nClinical Pharmacology\\n(12.3)\\n and \\nClinical Studies (14.3)\\n] \\n. The safety profile was comparable to that observed in\\nadults \\n[see \\nAdverse Reactions (6.1)\\n] \\n. See \\nDosage and Administration (2.3) \\nfor dosing\\nrecommendations for children 4 weeks of age and older. The safety and dosing\\ninformation for ISENTRESS have not been established in infants less than 4 weeks of\\nage.\\n8.5 Geriatric Use\\nClinical studies of ISENTRESS did not include sufficient numbers of subjects aged 65 and\\nover to det...","cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac\\nfunction, and of concomitant disease or other drug therapy.\\n8.6 Use in Patients with Hepatic Impairment\\nNo clinically important pharmacokinetic differences between subjects with moderate\\nhepatic impairment and healthy subjects were observed. No dosage adjustment is\\nnecessary for patients with mild to moderate hepatic impairment. The effect of severe\\nhepatic impairment on the pharmacokinetics of raltegravir has not...","].\\n10 OVERDOSAGE\\nNo specific information is available on the treatment of overdosage with ISENTRESS.\\nDoses as high as 1600-mg single dose and 800-mg twice-daily multiple doses were\\nstudied in healthy volunteers without evidence of toxicity. Occasional doses of up to\\n1800 mg per day were taken in the clinical studies of HIV-1 infected subjects without","evidence of toxicity.\\nIn the event of an overdose, it is reasonable to employ the standard supportive\\nmeasures, e.g., remove unabsorbed material from the gastrointestinal tract, employ\\nclinical monitoring (including obtaining an electrocardiogram), and institute supportive\\ntherapy if required. The extent to which ISENTRESS may be dialyzable is unknown.\\n11 DESCRIPTION\\nISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase\\nstrand transfer inhibitor. The chemical name fo...","Raltegravir potassium is a white to off-white powder. It is soluble in water, slightly soluble\\nin methanol, very slightly soluble in ethanol and acetonitrile and insoluble in isopropanol.\\nEach 400 mg film-coated tablet of ISENTRESS for oral administration contains 434.4 mg\\nof raltegravir (as potassium salt), equivalent to 400 mg of raltegravir free phenol and the\\nfollowing inactive ingredients: calcium phosphate dibasic anhydrous, hypromellose 2208,\\nlactose monohydrate, magnesium stearate, micro...","Each 100 mg chewable tablet of ISENTRESS for oral administration contains 108.6 mg of\\nraltegravir (as potassium salt), equivalent to 100 mg of raltegravir free phenol and the\\nfollowing inactive ingredients: ammonium hydroxide, crospovidone, ethylcellulose 20 cP,\\nfructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic...","fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG\\n400, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol,\\nsucralose and yellow iron oxide.\\nEach packet of ISENTRESS for oral suspension 100 mg, contains 108.6 mg of raltegravir\\n(as potassium salt), equivalent to 100 mg of ralt...","monoammonium glycyrrhizinate, oleic acid, sorbitol, sucralose and sucrose.\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nRaltegravir is an HIV-1 antiviral drug \\n[see \\nMicrobiology (12.4)\\n] \\n.\\n12.2 Pharmacodynamics\\nIn a monotherapy study raltegravir (400 mg twice daily) demonstrated rapid antiviral\\nactivity with mean viral load reduction of 1.66 log \\ncopies/mL by Day 10.\\nIn the randomized, double-blind, placebo-controlled, dose-ranging trial, Protocol 005,\\nand Protocols 018 and 019, antiviral...","Peak raltegravir plasma concentrations were approximately 4-fold higher than the peak\\nconcentrations following a 400 mg dose. ISENTRESS did not appear to prolong the QTc\\ninterval for 12 hours postdose. After baseline and placebo adjustment, the maximum\\nmean QTc change was -0.4 msec (1-sided 95% upper Cl: 3.1 msec).\\n12.3 Pharmacokinetics\\nAdults\\nAbsorption\\nRaltegravir (film-coated tablet) is absorbed with a T \\nof approximately 3 hours\\npostdose in the fasted state. Raltegravir AUC and C \\n increase ...","There is little to no accumulation in AUC and C \\n. The average accumulation ratio for C\\n ranged from approximately 1.2 to 1.6.\\nThe absolute bioavailability of raltegravir has not been established. Based on a\\n10 \\nmax \\nmax\\n12hr\\nmax\\n12hr","formulation comparison study in healthy adult volunteers, the chewable tablet and oral\\nsuspension have higher oral bioavailability compared to the 400 mg film-coated tablet.\\nIn subjects who received 400 mg twice daily alone, raltegravir drug exposures were\\ncharacterized by a geometric mean AUC \\n of 14.3 \\u00b5M\\u2219hr and C \\n of 142 nM.\\nConsiderable variability was observed in the pharmacokinetics of raltegravir. For\\nobserved C \\nin Protocols 018 and 019, the coefficient of variation (CV) for inter-\\nsubje...","patients. The effect of consumption of low-, moderate- and high-fat meals on steady-\\nstate raltegravir pharmacokinetics was assessed in healthy volunteers administered the\\n400 mg film-coated tablet. Administration of multiple doses of raltegravir following a\\nmoderate-fat meal (600 Kcal, 21 g fat) did not affect raltegravir AUC to a clinically\\nmeaningful degree with an increase of 13% relative to fasting. Raltegravir C \\n was\\n66% higher and C \\n was 5% higher following a moderate-fat meal compared ...","was essentially unchanged. Food\\nappears to increase pharmacokinetic variability relative to fasting.\\nAdministration of the chewable tablet with a high fat meal led to an average 6% decrease\\nin AUC, 62% decrease in C \\n, and 188% increase in C \\n compared to administration\\nin the fasted state. Administration of the chewable tablet with a high fat meal does not\\naffect raltegravir pharmacokinetics to a clinically meaningful degree and the chewable\\ntablet can be administered without regard to food.\\nTh...","raltegravir was measured in the cerebrospinal fluid. In the study (n=18), the median\\ncerebrospinal fluid concentration was 5.8% (range 1 to 53.5%) of the corresponding\\nplasma concentration. This median proportion was approximately 3-fold lower than the\\nfree fraction of raltegravir in plasma. The clinical relevance of this finding is unknown.\\nMetabolism and Excretion\\nThe apparent terminal half-life of raltegravir is approximately 9 hours, with a shorter \\u03b1-\\nphase half-life (~1 hour) accounting for...","observed in preclinical species. Two components, namely raltegravir and raltegravir-\\nglucuronide, were detected in urine and accounted for approximately 9 and 23% of the\\ndose, respectively. The major circulating entity was raltegravir and represented\\n0-12hr\\n12hr\\n12hr \\n12hr\\nmax\\nmax\\n12hr\\nmax\\n12hr\\nmax\\n12hr","approximately 70% of the total radioactivity; the remaining radioactivity in plasma was\\naccounted for by raltegravir-glucuronide. Studies using isoform-selective chemical\\ninhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1\\nis the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the\\ndata indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-\\nmediated glucuronidation.\\nSpecial Populations\\nPediatric\\nTwo pediatric fo...","higher oral bioavailability compared to the chewable tablet. These observations resulted\\nin proposed pediatric doses targeting 6 mg/kg/dose for the chewable tablets and oral\\nsuspension. As displayed in Table 9, the doses recommended for HIV-infected infants,\\nchildren and adolescents 4 weeks to 18 years of age \\n[see \\nDosage and Administration\\n(2.3)\\n] \\nresulted in a pharmacokinetic profile of raltegravir similar to that observed in\\nadults receiving 400 mg twice daily.\\nOverall, dosing in pediatric ...","administered the 400 mg tablet formulation (233 nM) \\n[see \\nClinical Studies (14.3)\\n] \\n. As a\\nresult, the 400 mg film-coated tablet is the recommended dose in patients weighing at\\nleast 25 kg; however, the chewable tablet offers an alternative regimen in patients\\nweighing at least 25 kg who are unable to swallow the film-coated tablet \\n[see \\nDosage and\\nAdministration (2.3)\\n] \\n. In addition, pediatric patients weighing 11 to 25 kg who were\\nadministered the chewable tablets had the lowest trough co...","Film-coated\\ntablet\\n400 mg\\ntwice daily\\n18\\n14.1 \\n(121%)\\n233 ( \\n157%\\n)\\n\\u226525 kg\\nChewable\\ntablet\\nWeight\\nbased\\ndosing, see\\nTable 1\\n9\\n22.1 ( \\n36%\\n)\\n113 ( \\n80%\\n)\\n11 to\\nless\\nthan 25\\nChewable\\ntablet\\nWeight\\nbased\\ndosing, see\\n13\\n18.6 ( \\n68%\\n)\\n82 ( \\n123%)\\ntrough\\n*\\n\\u2020\\n0-12hr\\n\\u2020\\n12hr","*\\n\\u2020\\nkg\\nTable 2\\n3 to less\\nthan 20\\nkg\\nOral\\nsuspension\\nWeight\\nbased\\ndosing, see\\nTable 2\\n19\\n24.5 ( \\n43%\\n)\\n113 ( \\n69%\\n)\\nThe pharmacokinetics of raltegravir in infants under 4 weeks of age has not been\\nestablished.\\nAge\\nThe effect of age (18 years and older) on the pharmacokinetics of raltegravir was\\nevaluated in the composite analysis. No dosage adjustment is necessary.\\nRace\\nThe effect of race on the pharmacokinetics of raltegravir in adults was evaluated in the\\ncomposite analysis. No dosage adjustmen...","receiving raltegravir monotherapy with fasted administration. No dosage adjustment is\\nnecessary.\\nHepatic Impairment\\nRaltegravir is eliminated primarily by glucuronidation in the liver. A study of the\\npharmacokinetics of raltegravir was performed in adult subjects with moderate hepatic\\nimpairment. Additionally, hepatic impairment was evaluated in the composite\\npharmacokinetic analysis. There were no clinically important pharmacokinetic differences\\nbetween subjects with moderate hepatic impairment...","pharmacokinetics of raltegravir was performed in adult subjects with severe renal\\nimpairment. Additionally, renal impairment was evaluated in the composite\\npharmacokinetic analysis. There were no clinically important pharmacokinetic differences\\nbetween subjects with severe renal impairment and healthy subjects. No dosage\\nadjustment is necessary. Because the extent to which ISENTRESS may be dialyzable is\\nunknown, dosing before a dialysis session should be avoided.\\nUGT1A1 Polymorphism\\nThere is no ...","with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96,\\n2.09).\\nDrug Interactions\\n [see \\nDrug Interactions (7)\\n]\\nTable 10: Effect of Other Agents on the Pharmacokinetics of Raltegravir in\\nAdults\\nCoadministered\\nDrug\\nCoadministered\\nDrug\\nDose/Schedule\\nRaltegravir \\nDose/Schedule\\nRatio (90% Confidence\\nInterval) of Raltegravir\\nPharmacokinetic Parameters\\nwith/without Coadministered\\nDrug; \\nNo Effect = 1.00\\nn\\nC \\nAUC\\nC \\naluminum and\\nmagnesium\\nhydroxide antacid\\n20 mL single\\ndose gi...","0.43 \\n(0.34,\\n0.55)\\n20 mL single\\ndose given 4\\nhours before\\nraltegravir\\n17\\n0.78 \\n(0.55,\\n1.10)\\n0.81 \\n(0.63,\\n1.05)\\n0.40 \\n(0.31,\\n0.52)\\n20 mL single\\ndose given 4\\nhours after\\nraltegravir\\n18\\n0.70 \\n(0.48,\\n1.04)\\n0.68 \\n(0.50,\\n0.92)\\n0.38 \\n(0.30,\\n0.49)\\n20 mL single\\ndose given 6\\nhours before\\nraltegravir\\n16\\n0.90 \\n(0.58,\\n1.40)\\n0.87 \\n(0.64,\\n1.18)\\n0.50 \\n(0.39,\\n0.65)\\n20 mL single\\ndose given 6\\nhours after\\nraltegravir\\n16\\n0.90 \\n(0.58,\\n1.41)\\n0.89 \\n(0.64,\\n1.22)\\n0.51 \\n(0.40,\\n0.64)\\natazanavir\\n400 mg daily\\n100 mg single\\nd...","boceprevir\\n800 mg three\\ntimes daily\\n400 mg single\\ndose\\n22\\n(0.91-\\n1.36)\\n(0.88-\\n1.22)\\n(0.45-\\n1.23)\\ncalcium carbonate\\nantacid\\n3000 mg single\\ndose given with\\nraltegravir\\n400 mg twice\\ndaily\\n24\\n0.48 \\n(0.36,\\n0.63)\\n0.45 \\n(0.35,\\n0.57)\\n0.68 \\n(0.53,\\n0.87)\\nefavirenz\\n600 mg daily\\n400 mg single\\ndose\\n9\\n0.64\\n(0.41,\\n0.98)\\n0.64\\n(0.52,\\n0.80)\\n0.79\\n(0.49,\\n1.28)\\netravirine\\n200 mg twice\\ndaily\\n400 mg twice\\ndaily\\n19\\n0.89\\n(0.68,\\n1.15)\\n0.90\\n(0.68,\\n1.18)\\n0.66\\n(0.34,\\n1.26)\\nomeprazole\\n20 mg daily\\n400 mg single\\ndose\\n14 \\n(10\\nf...","1.27 \\n(0.94,\\n1.71)\\n0.47 \\n(0.36,\\n0.61)\\nritonavir\\n100 mg twice\\ndaily\\n400 mg single\\ndose\\n10\\n0.76\\n(0.55,\\n1.04)\\n0.84\\n(0.70,\\n1.01)\\n0.99\\n(0.70,\\n1.40)\\ntenofovir\\n300 mg daily\\n400 mg twice\\ndaily\\n9\\n1.64\\n(1.16,\\n2.32)\\n1.49\\n(1.15,\\n1.94)\\n1.03\\n(0.73,\\n1.45)\\ntipranavir/ritonavir\\n500 mg/200 mg\\ntwice daily\\n400 mg twice\\ndaily\\n15 \\n(14\\nfor C\\n)\\n0.82\\n(0.46,\\n1.46)\\n0.76\\n(0.49,\\n1.19)\\n0.45\\n(0.31,\\n0.66)\\n12.4 Microbiology\\nMechanism of Action\\nRaltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzy...","infection. Raltegravir did not significantly inhibit human phosphoryltransferases including\\nDNA polymerases \\u03b1, \\u03b2, and \\u03b3.\\nAntiviral Activity in Cell Culture\\nRaltegravir at concentrations of 31 \\u00b1 20 nM resulted in 95% inhibition (EC \\n) of viral\\nmin","Raltegravir at concentrations of 31 \\u00b1 20 nM resulted in 95% inhibition (EC \\n) of viral\\nspread (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures\\ninfected with the cell-line adapted HIV-1 variant H9IIIB. In addition, 5 clinical isolates of\\nHIV-1 subtype B had EC \\n values ranging from 9 to 19 nM in cultures of mitogen-\\nactivated human peripheral blood mononuclear cells. In a single-cycle infection assay,\\nraltegravir inhibited infection of 23 HIV-1 isolates represen...","activity was observed when human T-lymphoid cells infected with the H9IIIB variant of\\nHIV-1 were incubated with raltegravir in combination with non-nucleoside reverse\\ntranscriptase inhibitors (delavirdine, efavirenz, or nevirapine); nucleoside analog reverse\\ntranscriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, tenofovir, or\\nzidovudine); protease inhibitors (amprenavir, atazanavir, indinavir, lopinavir, nelfinavir,\\nritonavir, or saquinavir); or the entry inhibitor enfuvirtide.\\nR...","Q148 (changed to H, K, or R) or N155 (changed to H) plus one or more additional\\nsubstitutions (i.e., L74M, E92Q, Q95K/R, T97A, E138A/K, G140A/S, V151I, G163R,\\nH183P, Y226C/D/F/H, S230R, and D232N). E92Q and F121C are occasionally seen in the\\nabsence of substitutions at Y143, Q148, or N155 in raltegravir-treatment failure\\nsubjects.\\nTreatment-Na\\u00efve Adult Subjects:\\n By Week 240 in the STARTMRK trial, the primary\\nraltegravir resistance-associated substitutions were observed in 4 (2 with Y143H/R and\\n...","and N155H, was observed in 76 of the 112 virologic failure subjects with evaluable\\ngenotypic data from paired baseline and raltegravir treatment-failure isolates. The\\nemergence of the primary raltegravir resistance-associated substitutions was observed\\ncumulatively in 70 subjects by Week 48 and 78 subjects by Week 96, 15.2% and 17% of\\nthe raltegravir recipients, respectively. Some (n=58) of those HIV-1 isolates harboring\\none or more of the primary raltegravir resistance-associated substitutions ...","(INSTIs). Amino acid substitutions in HIV-1 integrase conferring resistance to raltegravir\\ngenerally also confer resistance to elvitegravir. Substitutions at amino acid Y143 confer\\ngreater reductions in susceptibility to raltegravir than to elvitegravir, and the E92Q\\nsubstitution confers greater reductions in susceptibility to elvitegravir than to raltegravir.\\nViruses harboring a substitution at amino acid Q148, along with one or more other\\nraltegravir resistance substitutions, may also have cli...","dolutegravir.\\n13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\nCarcinogenicity studies of raltegravir in mice did not show any carcinogenic potential. At\\nthe highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic\\nexposure was 1.8-fold (females) or 1.2-fold (males) greater than the AUC (54 \\u00b5M\\u2219hr) at\\nthe 400-mg twice daily human dose. Treatment-related squamous cell carcinoma of\\nnose/nasopharynx was observed in female rats dosed with 6...","150 mg/kg/day (males) and 50 mg/kg/day (females) and the systemic exposure in rats\\nwas 1.7-fold (males) to 1.4-fold (females) greater than the AUC (54 \\u03bcM\\u2219hr) at the 400-\\nmg twice daily human dose.\\nNo evidence of mutagenicity or genotoxicity was observed in \\nin vitro\\n microbial\\nmutagenesis (Ames) tests, \\nin vitro\\n alkaline elution assays for DNA breakage, and \\nin vitro\\nand \\nin vivo\\n chromosomal aberration studies.\\nNo effect on fertility was seen in male and female rats at doses up to 600 mg/kg/da...","antiretroviral treatment-na\\u00efve HIV-1 infected adult subjects and 96-week data from 2\\nrandomized, double-blind, placebo-controlled studies, BENCHMRK 1 and BENCHMRK 2\\n(Protocols 018 and 019), in antiretroviral treatment-experienced HIV-1 infected adult\\nsubjects.\\n14.1 \\nTreatment-Na\\u00efve Adult Subjects\\nSTARTMRK (Protocol 021) is a Phase 3 study to evaluate the safety and antiretroviral\\nactivity of ISENTRESS 400 mg twice daily + emtricitabine (+) tenofovir versus efavirenz\\n600 mg at bedtime plus emtric...","Protocol 021\\n400 mg Twice\\nDaily\\n600 mg At\\nBedtime\\n(N = 281)\\n(N = 282)\\nGender\\n  Male\\n81%\\n82%\\n  Female\\n19%\\n18%\\nRace\\n  White\\n41%\\n44%\\n  Black\\n12%\\n8%\\n  Asian\\n13%\\n11%\\n  Hispanic\\n21%\\n24%\\n  Native American\\n&lt;1%\\n&lt;1%\\n  Multiracial\\n12%\\n13%\\nRegion\\n  Latin America\\n35%\\n34%\\n  Southeast Asia\\n12%\\n10%\\n  North America\\n29%\\n32%\\n  EU/Australia\\n23%\\n23%\\nAge (years)\\n  18-64\\n99%\\n99%\\n  \\u226565\\n1%\\n1%\\n  Mean (SD)\\n38 (9)\\n37 (10)\\n  Median (min, max)\\n37 (19 to 67)\\n36 (19 to 71)\\nCD4+ Cell Count (cells/microL)\\n  Mean (SD)\\n219 (124)\\n2...","Yes\\n19%\\n21%\\nViral Subtype\\n  Clade B\\n78%\\n82%\\n  Non-Clade B \\n21%\\n17%\\nBaseline Plasma HIV-1 RNA\\n  \\u2264100,000 copies/mL\\n45%\\n49%\\n  &gt;100,000 copies/mL\\n55%\\n51%\\nBaseline CD4+ Cell Counts\\n  \\u226450 cells/mm \\n10%\\n11%\\n  &gt;50 cells/mm \\n and \\u2264200 cells/mm \\n37%\\n37%\\n  &gt;200 cells/mm \\n53%\\n51%\\nHepatitis Status\\n10\\n*\\n\\u2020\\n3\\n3\\n3\\n3\\n\\u2021","Notes: \\nISENTRESS and Efavirenz were administered with emtricitabine (+) tenofovir \\nN = Number of subjects in each group.\\n*\\n\\u2020\\n\\u2021\\n  Hepatitis B or C Positive \\n6%\\n6%\\nWeek 240 outcomes from Protocol 021 are shown in Table 12.\\nTable 12: Virologic Outcomes of Randomized Treatment\\nof Protocol 021 at 240 Weeks\\nISENTRESS\\n400 mg \\nTwice\\nDaily \\n(N = 281)\\nEfavirenz \\n600 mg \\nAt\\nBedtime \\n(N = 282)\\nDifference \\n(ISENTRESS \\u2013\\nEfavirenz) (CI)\\n*\\n\\u2020\\n\\u2021\\nSubjects with\\nHIV-1 RNA less\\nthan 50\\ncopies/mL\\n66%\\n60%\\n6.6% \\n(-1.4%...","6%\\n2%\\n \\nThe mean changes in CD4 count from baseline were 295 cells/mm \\n in the group\\nreceiving ISENTRESS 400 mg twice daily and 236 cells/mm \\n in the group receiving\\nEfavirenz 600 mg at bedtime.\\nIncludes additional subjects identified as having a history of AIDS.\\nNon-Clade B Subtypes (# of subjects): Clade A (4), A/C (1), A/G (2), A1 (1), AE (29), AG\\n(12), BF (6), C (37), D (2), F (2), F1 (5), G (2), Complex (3).\\nEvidence of hepatitis B surface antigen or evidence of HCV RNA by polymerase chain\\n...","from Day 1 through the Week 240 window if this resulted in no virologic\\ndata on treatment during Week 240 visit window.\\nOther includes: withdrew consent, loss to follow-up, moved etc., if the\\nviral load at the time of discontinuation was &lt;50 copies/mL.\\n*\\n\\u2020\\n\\u2021\\n3\\n3","14.2 Treatment-Experienced Adult Subjects\\nBENCHMRK 1 and BENCHMRK 2 are Phase 3 studies to evaluate the safety and\\nantiretroviral activity of ISENTRESS 400 mg twice daily in combination with an optimized\\nbackground therapy (OBT), versus OBT alone, in HIV-1-infected subjects, 16 years or\\nolder, with documented resistance to at least 1 drug in each of 3 classes (NNRTIs,\\nNRTIs, PIs) of antiretroviral therapies. Randomization was stratified by degree of\\nresistance to PI (1PI vs. &gt;1PI) and the use of...","Table 13: Baseline Characteristics\\nRandomized\\nStudies \\nProtocol 018 and\\n019\\nISENTRESS 400 mg\\nTwice Daily + OBT\\nPlacebo + OBT\\n(N = 462)\\n(N = 237)\\nGender\\nMale\\n88%\\n89%\\nFemale\\n12%\\n11%\\nRace\\nWhite\\n65%\\n73%\\nBlack\\n14%\\n11%\\nAsian\\n3%\\n3%\\nHispanic\\n11%\\n8%\\nOthers\\n6%\\n5%\\nAge (years)\\nMedian (min, max)\\n45 (16 to 74)\\n45 (17 to 70)\\nCD4+ Cell Count\\nMedian (min, max),\\ncells/mm \\n119 (1 to 792)\\n123 (0 to 759)\\n\\u226450 cells/mm \\n32%\\n33%\\n&gt;50 and \\u2264200\\ncells/mm \\n37%\\n36%\\nPlasma HIV-1 RNA\\nMedian (min, max),\\nlog \\n copies/mL\\n4.8 (2 t...","*\\nvirus\\n83%\\n84%\\nHepatitis B virus only\\n8%\\n3%\\nHepatitis C virus only\\n8%\\n12%\\nCo-infection of\\nHepatitis B and C\\nvirus\\n1%\\n1%\\nStratum\\nEnfuvirtide in OBT\\n38%\\n38%\\nResistant to \\u22652 PI\\n97%\\n95%\\nTable 14 compares the characteristics of optimized background therapy at baseline in\\nthe group receiving ISENTRESS 400 mg twice daily and subjects in the control group.\\nTable 14: Characteristics of Optimized Background\\nTherapy at Baseline\\nRandomized Studies \\nProtocol 018 and 019\\nISENTRESS\\n400 mg Twice\\nDaily + OBT\\nPl...","30%\\n2\\n31%\\n28%\\n3 or more\\n18%\\n20%\\nGenotypic Sensitivity Score\\n(GSS) \\n0\\n25%\\n27%\\n1\\n38%\\n40%\\n2\\n24%\\n21%\\n3 or more\\n11%\\n10%\\nHepatitis B virus surface antigen positive or hepatitis C virus antibody\\npositive.\\nDarunavir use in OBT in darunavir-na\\u00efve subjects was counted as one\\nactive PI.\\nThe Phenotypic Sensitivity Score (PSS) and the Genotypic Sensitivity\\nScore (GSS) were defined as the total oral ARTs in OBT to which a\\nsubject&#x27;s viral isolate showed phenotypic sensitivity and genotypic\\nsensitivity, respect...","Week 96 outcomes for the 699 subjects randomized and treated with the\\nrecommended dose of ISENTRESS 400 mg twice daily or placebo in the pooled\\nBENCHMRK 1 and 2 studies are shown in Table 15.\\nTable 15: Virologic Outcomes of Randomized Treatment\\nof Protocols 018 and 019 at 96 Weeks (Pooled Analysis)\\nISENTRESS \\n400 mg Twice\\nDaily + OBT \\n(N = 462)\\nPlacebo + OBT \\n(N = 237)\\n*\\n\\u2020\\n\\u2021\\nSubjects with HIV-1\\nRNA less than 50\\ncopies/mL\\n55%\\n27%\\nVirologic Failure \\n35%\\n66%\\nNo virologic data at\\nWeek 96 Window\\nReas...","for the control group.\\nTreatment-emergent CDC Category C events occurred in 4% of the group receiving\\nISENTRESS 400 mg twice daily and 5% of the control group.\\nVirologic responses at Week 96 by baseline genotypic and phenotypic sensitivity score\\nare shown in Table 16.\\nTable 16: Virologic Response at 96 Week Window by Baseline\\nGenotypic/Phenotypic Sensitivity Score\\nPercent with HIV-1 RNA \\ndarunavir use in OBT in darunavir-na\\u00efve subjects was counted as one\\nactive drug in OBT.\\nIncludes subjects who...","Includes subjects who discontinued due to AE or Death at any time point\\nfrom Day 1 through the Week 96 window if this resulted in no virologic\\ndata on treatment during the Week 96 window.\\nOther includes: withdrew consent, loss to follow-up, moved etc., if the\\nviral load at the time of discontinuation was &lt;50 copies/mL.\\n*\\n\\u2020\\n\\u2021\\n3\\n3","&lt;50 copies/mL \\nAt Week 96\\nn\\nISENTRESS \\n400 mg \\nTwice Daily +\\nOBT \\n(N = 462) \\nn\\nPlacebo +\\nOBT \\n(N = 237)\\n*\\nPhenotypic Sensitivity Score (PSS) \\n0\\n67\\n43\\n43\\n5\\n1\\n144\\n58\\n71\\n23\\n2\\n142\\n61\\n66\\n32\\n3 or more\\n85\\n48\\n48\\n42\\nGenotypic Sensitivity Score (GSS) \\n0\\n116\\n39\\n65\\n5\\n1\\n177\\n62\\n95\\n26\\n2\\n111\\n61\\n49\\n53\\n3 or more\\n51\\n49\\n23\\n35\\nSwitch of Suppressed Subjects from Lopinavir (+) Ritonavir to Raltegravir\\nThe SWITCHMRK 1 &amp; 2 Phase 3 studies evaluated HIV-1 infected subjects receiving\\nsuppressive therapy (HIV-1 RNA &lt;50 cop...","ritonavir with ISENTRESS 400 mg twice daily (n=174 and n=176, respectively). The\\nprimary virology endpoint was the proportion of subjects with HIV-1 RNA less than 50\\ncopies/mL at Week 24 with a prespecified non-inferiority margin of -12% for each study;\\nand the frequency of adverse events up to 24 weeks.\\nSubjects with a prior history of virological failure were not excluded and the number of\\nprevious antiretroviral therapies was not limited.\\nThese studies were terminated after the primary effica...","laboratory adverse events occurred at similar frequencies in the treatment groups.\\n14.3 Pediatric Subjects\\n2 to 18 Years of Age\\nIMPAACT P1066 is a Phase I/II open label multicenter trial to evaluate the\\npharmacokinetic profile, safety, tolerability, and efficacy of raltegravir in HIV infected\\nThe Phenotypic Sensitivity Score (PSS) and the Genotypic Sensitivity Score (GSS) were\\ndefined as the total oral ARTs in OBT to which a subject&#x27;s viral isolate showed\\nphenotypic sensitivity and genotypic sen...","children. This study enrolled 126 treatment experienced children and adolescents 2 to\\n18 years of age. Subjects were stratified by age, enrolling adolescents first and then\\nsuccessively younger children. Subjects were enrolled into cohorts according to age and\\nreceived the following formulations: Cohort I (12 to less than 18 years old), 400 mg film-\\ncoated tablet; Cohort IIa (6 to less than 12 years old), 400 mg film-coated tablet; Cohort\\nIIb (6 to less than 12 years old), chewable tablet; Cohor...","concentration as seen in adults, and acceptable short term safety. After dose selection,\\nadditional subjects were enrolled for evaluation of long term safety, tolerability and\\nefficacy. Of the 126 subjects, 96 received the recommended dose of ISENTRESS \\n[see\\nDosage and Administration (2.3)\\n] \\n.\\nThese 96 subjects had a median age of 13 (range 2 to 18) years, were 51% Female,\\n34% Caucasian, and 59% Black. At baseline, mean plasma HIV-1 RNA was 4.3 log \\ncopies/mL, median CD4 cell count was 481 cell...","Ninety-three (97%) subjects 2 to 18 years of age completed 24 weeks of treatment (3\\ndiscontinued due to non-compliance). At Week 24, 54% achieved HIV RNA &lt;50\\ncopies/mL; 66% achieved HIV RNA &lt;400 copies/mL. The mean CD4 count (percent)\\nincrease from baseline to Week 24 was 119 cells/mm \\n (3.8%).\\n4 Weeks to Less Than \\n2 Years of Age\\nIMPAACT P1066 also enrolled HIV-infected, infants and toddlers 4 weeks to less than 2\\nyears of age (Cohorts IV and V) who had received prior antiretroviral therapy eit...","optimized background regimen.\\nThe 26 subjects had a median age of 28 weeks (range: 4 -100), were 35% female, 85%\\nBlack and 8% Caucasian. At baseline, mean plasma HIV-1 RNA was 5.7 log \\n copies/mL\\n(range: 3.1 \\u2013 7), median CD4 cell count was 1400 cells/mm \\n (range: 131 \\u2013 3648) and\\nmedian CD4% was 18.6% (range: 3.3 \\u2013 39.3). Overall, 69% had baseline plasma HIV-1\\nRNA exceeding 100,000 copies/mL and 23% had a CDC HIV clinical classification of\\ncategory B or C. None of the 26 patients were completely ...","analyses, respectively. All 26 treated subjects were included for safety analyses.\\nAt Week 24, 39% achieved HIV RNA &lt;50 copies/mL and 61% achieved HIV RNA &lt;400\\ncopies/mL. The mean CD4 count (percent) increase from baseline to Week 24 was 500\\ncells/mm \\n(7.5%).\\nAt Week 48, 44% achieved HIV RNA &lt;50 copies/mL and 61% achieved HIV RNA &lt;400\\n10\\n3\\n3\\n10\\n3\\n3","copies/mL. The mean CD4 count (percent) increase from baseline to Week 48 was 492\\ncells/mm \\n(7.8%).\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with \\"227\\" on one\\nside. They are supplied as follows:\\nNDC\\n 68071-2113-6 \\nbottles of 6\\nStorage and Handling\\n400 mg Film-coated Tablets, Chewable Tablets and For Oral Suspension\\nStore at 20-25\\u00b0C (68-77\\u00b0F); excursions permitted to 15-30\\u00b0C (59-86\\u00b0F). See USP\\nControlled Room Temperature.\\nChewable Ta...","Instructions for Use).\\nGeneral Information\\nInstruct patients to reread patient labeling each time the prescription is renewed.\\nPatients should remain under the care of a physician when using ISENTRESS. Instruct\\npatients to inform their physician or pharmacist if they develop any unusual symptom,\\nor if any known symptom persists or worsens.\\nISENTRESS is not a cure for HIV-1 infection and patients may continue to experience\\nillnesses associated with HIV-1 infection such as opportunistic infections...","Do not share needles or other injection equipment.\\nDo not share personal items that can have blood or body fluids on them, like\\ntoothbrushes and razor blades.\\nDo not have any kind of sex without protection. Always practice safe sex by using a\\nlatex or polyurethane condom to lower the chance of sexual contact with semen,\\nvaginal secretions, or blood.\\nDo not breastfeed. Mothers with HIV-1 should not breastfeed because HIV-1 can be\\npassed to the baby in the breast milk. Also, it is unknown if ISENT...","General Dosing Instructions\\nInstruct patients that if they miss a dose of ISENTRESS, they should take it as soon as\\nthey remember. If they do not remember until it is time for the next dose, instruct them\\nto skip the missed dose and go back to the regular schedule. Instruct patients not to\\ndouble their next dose or take more than the prescribed dose.\\nFilm-Coated Tablets and Chewable Tablets\\nInform patients that the chewable tablet forms can be chewed or swallowed whole, but\\nthe film-coated table...","minutes of mixing.\\nSevere and Potentially Life-threatening Rash\\nInform patients that severe and potentially life-threatening rash has been reported.\\nAdvise patients to immediately contact their healthcare provider if they develop rash.\\nInstruct patients to immediately stop taking ISENTRESS and other suspect agents, and\\nseek medical attention if they develop a rash associated with any of the following\\nsymptoms as it may be a sign of a more serious reaction such as Stevens-Johnson\\nsyndrome, toxic ...","symptoms of liver problems (e.g., yellowing of the skin or whites of the eyes, dark or tea\\ncolored urine, pale colored stools/bowel movements, nausea, vomiting, loss of appetite,\\nor pain, aching or sensitivity on the right side below the ribs). Inform patients that if\\nsevere rash occurs, their physician will closely monitor them, order laboratory tests and\\ninitiate appropriate therapy.\\nRhabdomyolysis\\nBefore patients begin ISENTRESS, ask them if they have a history of rhabdomyolysis,\\nmyopathy or ...","Phenylketonuria\\nAlert patients with phenylketonuria that ISENTRESS Chewable Tablets contain\\nphenylalanine \\n[see \\nWarnings and Precautions (5.3)\\n].\\nDrug Interactions\\nInstruct patients to avoid taking aluminum and/or magnesium containing antacids during\\ntreatment with ISENTRESS \\n[see \\nDrug Interactions (7.2)\\n] \\n.\\nDistributed by: \\nMerck Sharp &amp; Dohme Corp., a subsidiary of \\nMerck &amp; Co., Inc.\\n \\nWhitehouse Station, NJ 08889, USA","Whitehouse Station, NJ 08889, USA\\nFor patent information: www.merck.com/product/patent/home.html\\nCopyright \\u00a9 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of \\nMerck &amp; Co., Inc.\\n \\nAll rights reserved.\\nuspi-mk0518-mf-1502r030\\nPatient Information\\nISENTRESS\\n (\\neye \\nsen\\n tris \\n) \\n(raltegravir) \\nfilm-coated tablets\\n \\nISENTRESS\\n (\\neye \\nsen\\n tris \\n) \\n(raltegravir) \\nchewable tablets\\n \\nISENTRESS\\n (\\neye \\nsen\\n tris \\n) \\n(raltegravir) \\nfor oral suspension\\nRead this Patient Information before you start taking I...","treat Human Immunodeficiency Virus-1 (HIV-1) infection in people 4 weeks of age and\\nolder. HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).\\nIt is not known if ISENTRESS is safe and effective in babies under 4 weeks of age.\\nWhen used with other HIV medicines to treat HIV-1 infection, ISENTRESS may\\nhelp:\\nreduce the amount of HIV in your blood. This is called \\"viral load\\".\\nincrease the number of white blood cells called CD4+ (T) cells in your blood, which\\nhelp fight off othe...","You must stay on continuous HIV therapy to control HIV-1 infection and decrease HIV-\\nrelated illnesses.\\nAvoid doing things that can spread HIV-1 infection to others.\\nDo not share or re-use needles or other injection equipment.\\nDo not share personal items that can have blood or body fluids on them, like\\ntoothbrushes and razor blades.\\nDo not have any kind of sex without protection. Always practice safe sex by using a\\nlatex or polyurethane condom to lower the chance of sexual contact with any body\\n...","Ask your doctor if you have any questions on how to prevent passing HIV to other\\npeople.\\nWhat should I tell my doctor before taking ISENTRESS?\\nBefore you take ISENTRESS, tell your doctor if you:\\nhave liver problems\\nhave a history of a muscle disorder called rhabdomyolysis or myopathy\\nhave increased levels of creatine kinase in your blood\\nhave phenylketonuria (PKU). ISENTRESS chewable tablets contain phenylalanine as\\npart of the artificial sweetener, aspartame. The artificial sweetener may be har...","about the health of you and your baby. Talk to your doctor about how you can take\\npart in this registry.\\nare breastfeeding or plan to breastfeed. \\nDo not breastfeed if you take\\nISENTRESS.\\nYou should not breastfeed if you have HIV-1 because of the risk of passing HIV-1\\nto your baby.\\nTalk with your doctor about the best way to feed your baby.\\nTell your doctor about all the medicines you take, including,\\n prescription and\\nover-the-counter medicines, vitamins, and herbal supplements. Some medicines ...","healthcare provider can tell you if it is safe to take ISENTRESS with other medicines.\\nHow should I take ISENTRESS?\\nTake ISENTRESS exactly as prescribed by your doctor.\\nDo not\\n change your dose of ISENTRESS or stop your treatment without talking with\\nyour doctor first.\\nStay under the care of your doctor while taking ISENTRESS.\\nISENTRESS film-coated tablets must be swallowed whole.\\nISENTRESS chewable tablets may be chewed or swallowed whole.\\nISENTRESS for oral suspension should be given to your c...","Do not switch between the film-coated tablet, the chewable tablet, or the\\noral suspension without talking with your doctor first.\\nDo not\\n run out of ISENTRESS. Get a refill of your ISENTRESS from your doctor or\\npharmacy before you run out.\\nIf you miss a dose, take it as soon as you remember. If you do not remember until it","is time for your next dose, skip the missed dose and go back to your regular\\nschedule. Do not double your next dose or take more ISENTRESS than prescribed.\\nIf you take too much ISENTRESS, call your doctor or go to the nearest hospital\\nemergency room right away.\\nWhat are the possible side effects of ISENTRESS?\\nISENTRESS can cause serious side effects including:\\nSerious skin reactions and allergic reactions. \\nSome people who take\\nISENTRESS develop serious skin reactions and allergic reactions that...","redness or swelling of the eyes\\nswelling of the mouth or face\\nproblems breathing\\nSometimes allergic reactions can affect body organs, such as your liver. Call your doctor\\nright away if you have any of the following signs or symptoms of liver problems:\\nyellowing of your skin or whites of your eyes\\ndark or tea colored urine\\npale colored stools (bowel movements)\\nnausea or vomiting\\nloss of appetite\\npain, aching, or tenderness on the right side of your stomach area\\nChanges in your immune system (Immu...","The most common side effects of ISENTRESS include:\\ntrouble sleeping\\nheadache\\ndizziness\\nnausea\\ntiredness\\nLess common side effects of ISENTRESS include:\\ndepression\\nhepatitis\\ngenital herpes\\nherpes zoster including shingles\\nkidney failure","kidney stones\\nindigestion or stomach area pain\\nvomiting\\nsuicidal thoughts and actions\\nweakness\\nTell your doctor right away if you get unexplained muscle pain, tenderness, or weakness\\nwhile taking ISENTRESS. These may be signs of a rare serious muscle problem that can\\nlead to kidney problems.\\nTell your doctor if you have any side effect that bothers you or that does not go away.\\nThese are not all the possible side effects of ISENTRESS. For more information, ask your\\ndoctor or pharmacist.\\nCall you...","Chewable Tablets:\\nStore ISENTRESS chewable \\ntablets at room temperature between 68\\u00b0F to 77\\u00b0F (20\\u00b0C\\nto 25\\u00b0C).\\nStore ISENTRESS chewable tablets in the original package with the bottle tightly\\nclosed.\\nKeep the drying agent (desiccant) in the bottle to protect from moisture.\\nFor Oral Suspension:\\nStore ISENTRESS for oral \\nsuspension at room temperature between 68\\u00b0F to 77\\u00b0F\\n(20\\u00b0C to 25\\u00b0C).\\nStore \\nin the original container. Do not open the foil packet until ready for \\nuse.\\nKeep ISENTRESS and all medici...","symptoms you have. It may harm them.\\nYou can ask your doctor or pharmacist for information about ISENTRESS that is written\\nfor health professionals.\\nFor more information go to www.ISENTRESS.com or call 1-800-622-4477.\\nWhat are the ingredients in ISENTRESS?\\nISENTRESS film-coated tablets:\\nActive ingredient: \\nraltegravir","Inactive ingredients:\\n calcium phosphate dibasic anhydrous, hypromellose 2208,\\nlactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 407\\n(contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate.\\nThe film coating contains:\\n black iron oxide, polyethylene glycol 3350, polyvinyl\\nalcohol, red iron oxide, talc and titanium dioxide.\\nISENTRESS chewable tablets:\\nActive ingredient: \\nraltegravir\\nInactive ingredients:\\n ammonium hydroxide, crospovidone, ethy...","sucralose and yellow iron oxide. The 100 mg chewable tablet also contains red iron\\noxide.\\nISENTRESS for oral suspension:\\nActive ingredient: \\nraltegravir\\nInactive ingredients: \\nammonium hydroxide, banana with other natural flavors,\\ncarboxymethylcellulose sodium, crospovidone, ethylcellulose 20 cP, fructose,\\nhydroxypropyl cellulose, hypromellose 2910/6cP, macrogol/PEG 400, magnesium\\nstearate, maltodextrin, mannitol, medium chain triglycerides, microcrystalline cellulose,\\nmonoammonium glycyrrhizina...","Copyright \\u00a9 2007, 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\nMerck &amp; Co.,\\nInc.\\n \\nAll rights reserved.\\nusppi-mk0518-mf-1502r026\\nInstructions for Use\\nISENTRESS \\n (eye \\nsen\\n tris) \\n(raltegravir) \\nfor oral suspension\\nRead this Instructions for Use before you mix and give a dose of ISENTRESS for oral\\nsuspension to your child for the first time, and each time you get a refill. There may be\\nnew information. These instructions will help you to correctly mix and give a dose of\\nISENTRESS for oral su...","more information about ISENTRESS.\\nYour doctor will decide the right dose based on your child&#x27;s weight.\\nAsk your doctor or pharmacist if you have any questions about how to mix or give\\nISENTRESS for oral suspension to your child.\\nEach ISENTRESS for oral suspension kit contains the following supplies (see\\nFigure A\\n):\\n2 reusable mixing cups with attached lids\\n2 reusable 5 mL dosing syringes\\n60 foil packets containing ISENTRESS for oral suspension\\nFor each dose of ISENTRESS for oral suspension you w...","Step 2. \\nFill the dosing syringe. Start with the plunger pushed all the way inside the\\nbarrel of the syringe. Insert the tip of the syringe into the water and pull back on the\\nplunger to the 5 mL marking on the barrel of the syringe (see \\nFigure C\\n).\\nStep 3. \\nPour out remaining water from mixing cup (see \\nFigure D\\n).","Step 4. \\nAdd the 5 mL of water from the dosing syringe back into the mixing cup by\\npressing down on the plunger (see \\nFigure E\\n).\\nStep 5. \\nOpen 1 foil packet. There is a notch that you can use to tear open the foil\\npacket, or you may use scissors to cut along the dotted line. Pour entire contents into\\nmixing cup (see \\nFigure F\\n).","Step 6. \\nClose the attached lid to seal the mixing cup (see \\nFigure G\\n). It will snap shut.\\nStep 7. \\nSwirl the mixing cup to mix using a gentle circular motion for 30-60 seconds\\n(see \\nFigure H\\n). \\nDo not\\n turn the mixing cup upside down. The liquid will be cloudy.\\nStep 8. \\nOpen the mixing cup. Put the tip of the syringe into the liquid and \\npull back\\nthe plunger to the mL marking that matches your child&#x27;s prescribed dose\\n(see \\nFigure I\\n). Your child&#x27;s dose may be different from the one shown in ...","How should I give a dose of ISENTRESS for oral suspension?\\nStep 9.\\n Place the tip of the dosing syringe in your child&#x27;s mouth and turn it toward\\neither cheek. Gently push down on the plunger to give the medicine (see \\nFigure J\\n). Give\\nthe dose of ISENTRESS oral suspension to your child within 30 minutes of mixing. If you\\nare not able to give your child&#x27;s dose within 30 minutes of mixing, pour the unused\\nmedicine into the trash. You will need to mix a new dose.\\nHow should I dispose of leftover IS...","Step 11. \\nRemove plunger from the barrel of the dosing syringe. Hand wash the dosing\\nsyringe and mixing cup with warm water and dish soap. Rinse with water and air dry\\n(see \\nFigure L\\n).\\nHow should I store ISENTRESS for oral suspension?\\nStore ISENTRESS for oral suspension at room temperature between 68\\u00b0F to 77\\u00b0F\\n(20\\u00b0C to 25\\u00b0C).\\nStore in the original container. Do not open the foil packets until ready for use.\\nKeep ISENTRESS for oral suspension and all medicines out of the reach of\\nchildren.\\nFor m...","Merck Sharp &amp; Dohme Corp., a subsidiary of \\nMerck &amp; Co., Inc.\\n \\nWhitehouse Station, NJ 08889, USA\\nIssued December 2013\\nFor patent information: www.merck.com/product/patent/home.html\\nCopyright \\u00a9 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\nMerck &amp; Co., Inc. \\nAll rights reserved.\\nifu-mk0518-mf-1312r000\\nISENTRESS  \\nraltegravir tablet, film coated\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION\\nDRUG\\nItem Code\\n(Source)\\nNDC:68071-2113(NDC:0006-\\n0227)\\nRoute of Administration\\nORAL\\nActive Ingredi...","NuCare Pharmaceuticals,Inc.\\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLOXAMER 407\\n (UNII: TUF2IVW3M2)\\n \\nPOLYETHYLENE GLYCOL 3350\\n (UNII: G2M7P15E5P)\\n \\nPOLYVINYL ALCOHOL\\n (UNII: 532B59J990)\\n \\nFERRIC OXIDE RED\\n (UNII: 1K09F3G675)\\n \\nSODIUM STEARYL FUMARATE\\n (UNII: 7CV7WJK4UI)\\n \\nTALC\\n (UNII: 7SEV7J4R1U)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nProduct Characteristics\\nColor\\npink (pink)\\nScore\\nno score\\nShape\\nOVAL (oval-shaped)\\nSize\\n16mm\\nFlavor\\nImprint Code\\n227\\nContains\\n    \\nPackaging\\n#\\nItem C..."]],["color",{"type":"ndarray","array":["#9edae5","#9edae5","#999","#9edae5","#1f77b4","#999","#999","#999","#9edae5","#9edae5","#ffbb78","#9edae5","#9edae5","#999","#9edae5","#999","#9edae5","#1f77b4","#999","#17becf","#1f77b4","#9edae5","#9edae5","#999","#ffbb78","#17becf","#17becf","#17becf","#1f77b4","#999","#9edae5","#999","#999","#999","#9edae5","#9edae5","#9edae5","#17becf","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#bcbd22","#ffbb78","#999","#17becf","#ffbb78","#999","#999","#999","#999","#ff9896","#ff9896","#999","#999","#ff9896","#ff9896","#ff9896","#ff9896","#999","#ff9896","#999","#ff9896","#bcbd22","#9edae5","#999","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#d62728","#9edae5","#9edae5","#9edae5","#9edae5","#9edae5","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#999","#999","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#999","#999","#999","#9467bd","#9467bd","#9467bd","#9467bd","#999","#999","#999","#ff9896","#9467bd","#ff9896","#999","#9467bd","#9467bd","#999","#9467bd","#9467bd","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#dbdb8d","#dbdb8d","#999","#dbdb8d","#dbdb8d","#dbdb8d","#dbdb8d","#dbdb8d","#dbdb8d","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#bcbd22","#999","#999","#bcbd22","#d62728","#d62728","#d62728","#d62728","#d62728","#d62728","#1f77b4","#999","#1f77b4","#1f77b4","#1f77b4","#9edae5","#9edae5","#1f77b4","#1f77b4","#999","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#999","#999","#999","#999","#999","#1f77b4","#999","#999","#999","#999","#999","#ff7f0e","#c49c94","#f7b6d2","#e377c2","#f7b6d2","#999","#f7b6d2","#999","#98df8a","#999","#f7b6d2","#7f7f7f","#f7b6d2","#f7b6d2","#e377c2","#e377c2","#e377c2","#e377c2","#e377c2","#e377c2","#e377c2","#999","#999","#999","#999","#f7b6d2","#7f7f7f","#c49c94","#999","#7f7f7f","#f7b6d2","#f7b6d2","#7f7f7f","#8c564b","#8c564b","#999","#999","#8c564b","#999","#999","#999","#999","#999","#c7c7c7","#999","#999","#999","#c5b0d5","#c5b0d5","#c49c94","#999","#98df8a","#999","#f7b6d2","#999","#999","#d62728","#d62728","#d62728","#d62728","#98df8a","#98df8a","#f7b6d2","#ff7f0e","#98df8a","#ff7f0e","#ff7f0e","#98df8a","#98df8a","#999","#ff7f0e","#98df8a","#98df8a","#98df8a","#ff7f0e","#ff7f0e","#98df8a","#98df8a","#98df8a","#999","#98df8a","#98df8a","#98df8a","#98df8a","#98df8a","#999","#98df8a","#98df8a","#d62728","#c49c94","#8c564b","#8c564b","#8c564b","#8c564b","#8c564b","#8c564b","#8c564b","#999","#e377c2","#7f7f7f","#7f7f7f","#f7b6d2","#999","#7f7f7f","#999","#999","#999","#f7b6d2","#c49c94","#f7b6d2","#f7b6d2","#7f7f7f","#7f7f7f","#7f7f7f","#7f7f7f","#7f7f7f","#c49c94","#f7b6d2","#e377c2","#f7b6d2","#999","#17becf","#17becf","#c49c94","#c49c94","#999","#999","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#999","#2ca02c","#2ca02c","#999","#999","#999","#999","#999","#999","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#999","#1f77b4","#1f77b4","#c7c7c7","#c7c7c7","#999","#aec7e8","#d62728","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#17becf","#17becf","#c7c7c7","#d62728","#999","#c7c7c7","#c7c7c7","#999","#c5b0d5","#c5b0d5","#d62728","#999","#c7c7c7","#c7c7c7","#c7c7c7","#c5b0d5","#c5b0d5","#c7c7c7","#c7c7c7","#c7c7c7","#c7c7c7","#999","#c5b0d5","#c7c7c7","#c7c7c7","#999","#aec7e8","#999","#999","#d62728","#d62728","#d62728","#999","#d62728","#aec7e8","#d62728","#999","#1f77b4","#1f77b4","#1f77b4","#999","#aec7e8","#aec7e8","#999","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#999","#1f77b4","#1f77b4","#1f77b4","#aec7e8","#aec7e8","#aec7e8","#999","#999","#9467bd","#999","#999","#999","#999","#999","#999","#999","#999","#d62728","#d62728","#d62728","#d62728","#c5b0d5","#c5b0d5","#d62728","#d62728","#d62728","#c5b0d5","#c5b0d5","#d62728","#d62728","#d62728","#d62728","#d62728","#d62728","#aec7e8","#d62728","#d62728","#d62728","#d62728","#1f77b4","#999","#ff7f0e","#1f77b4","#17becf","#17becf","#999","#999","#98df8a","#f7b6d2","#999","#999","#1f77b4","#1f77b4","#999","#999","#999","#999","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#2ca02c","#2ca02c","#2ca02c","#1f77b4","#1f77b4","#999","#ff7f0e"],"shape":[460],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1306","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1307"}}},"glyph":{"type":"object","name":"Scatter","id":"p1302","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1303","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1304","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1273","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p1288","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p1289"},{"type":"object","name":"WheelZoomTool","id":"p1290","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1291","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1292","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1297"},{"type":"object","name":"SaveTool","id":"p1298"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1283","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1284","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1285"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1286"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1278","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1279","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1280"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1281"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1282","attributes":{"axis":{"id":"p1278"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1287","attributes":{"dimension":1,"axis":{"id":"p1283"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1308","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1309","attributes":{"label":{"type":"value","value":"APRETUDE Drug Information"},"renderers":[{"id":"p1305"}],"index":181}},{"type":"object","name":"LegendItem","id":"p1310","attributes":{"label":{"type":"value","value":"APRETUDE HIV-1 PrEP Injection Schedule"},"renderers":[{"id":"p1305"}],"index":183}},{"type":"object","name":"LegendItem","id":"p1311","attributes":{"label":{"type":"value","value":"APRETUDE for HIV-1 PrEP"},"renderers":[{"id":"p1305"}],"index":191}},{"type":"object","name":"LegendItem","id":"p1312","attributes":{"label":{"type":"value","value":"ATRIPLA Drug Information"},"renderers":[{"id":"p1305"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1313","attributes":{"label":{"type":"value","value":"ATRIPLA Warnings and Side Effects"},"renderers":[{"id":"p1305"}],"index":4}},{"type":"object","name":"LegendItem","id":"p1314","attributes":{"label":{"type":"value","value":"Antiretroviral Resistance"},"renderers":[{"id":"p1305"}],"index":129}},{"type":"object","name":"LegendItem","id":"p1315","attributes":{"label":{"type":"value","value":"Antiretroviral Therapy (ART) and Birth\\nDefects"},"renderers":[{"id":"p1305"}],"index":47}},{"type":"object","name":"LegendItem","id":"p1316","attributes":{"label":{"type":"value","value":"Antiretroviral Therapy Side Effects"},"renderers":[{"id":"p1305"}],"index":10}},{"type":"object","name":"LegendItem","id":"p1317","attributes":{"label":{"type":"value","value":"Cabotegravir Pharmacokinetics and\\nInteractions"},"renderers":[{"id":"p1305"}],"index":188}},{"type":"object","name":"LegendItem","id":"p1318","attributes":{"label":{"type":"value","value":"HIV Pre-Exposure Prophylaxis (PrEP) with\\nAPRETUDE"},"renderers":[{"id":"p1305"}],"index":182}},{"type":"object","name":"LegendItem","id":"p1319","attributes":{"label":{"type":"value","value":"HIV Prevention Trials"},"renderers":[{"id":"p1305"}],"index":213}},{"type":"object","name":"LegendItem","id":"p1320","attributes":{"label":{"type":"value","value":"HIV Treatment Side Effects"},"renderers":[{"id":"p1305"}],"index":223}},{"type":"object","name":"LegendItem","id":"p1321","attributes":{"label":{"type":"value","value":"HIV Treatment and Administration"},"renderers":[{"id":"p1305"}],"index":180}},{"type":"object","name":"LegendItem","id":"p1322","attributes":{"label":{"type":"value","value":"ISENTRESS Drug Information"},"renderers":[{"id":"p1305"}],"index":326}},{"type":"object","name":"LegendItem","id":"p1323","attributes":{"label":{"type":"value","value":"Medication Administration Instructions"},"renderers":[{"id":"p1305"}],"index":307}},{"type":"object","name":"LegendItem","id":"p1324","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p1305"}],"index":2}},{"type":"object","name":"LegendItem","id":"p1325","attributes":{"label":{"type":"value","value":"Pharmaceutical Trials"},"renderers":[{"id":"p1305"}],"index":81}},{"type":"object","name":"LegendItem","id":"p1326","attributes":{"label":{"type":"value","value":"Raltegravir Pharmacokinetics"},"renderers":[{"id":"p1305"}],"index":331}},{"type":"object","name":"LegendItem","id":"p1327","attributes":{"label":{"type":"value","value":"The provided document contains\\ninformation about drug-drug interactions\\ninvolving a medication called EFV\\n(Efavirenz). Here are some key points\\nregarding the interaction of EFV with\\nother drugs:  1. EFV can decrease the\\nplasma concentrations of certain calcium\\nchannel blockers, which may affect their\\nclinical response. Dose adjustments\\nshould be guided by clinical response.\\n2. The plasma concentrations of HMG-CoA\\nreductase inhibitors (statins) such as\\natorvastatin, pravastatin, and\\nsimvastatin decreased with EFV. Consult\\nthe Full Prescribing Information for the\\nstatins.  3. Methadone maintenance doses\\nbetween 35-100 mg daily for 14-21 days\\nmay be affected by EFV, with a potential\\ndecrease in methadone levels (by 25% to\\n59%).  4. Bupropion, a medication used\\nto treat depression and smoking\\ncessation, may also have its levels\\ndecreased when coadministered with EFV.\\nThe hydroxybupropion level may increase,\\nbut the clinical significance is not\\nknown.  5. Sertraline, an\\nantidepressant, may have its plasma\\nconcentrations decreased by EFV,\\npotentially leading to reduced\\nsertraline levels (by 29% to 40%).  6.\\nVoriconazole, an antifungal medication,\\nmay have its plasma concentrations\\ndecreased when coadministered with EFV.\\nThe clinical significance is not known.\\n7. Several antiviral medications\\ninteract with EFV in various ways:    -\\nBoceprevir, elbasvir/grazoprevir,\\nglecaprevir/pibrentasvir, simeprevir,\\nsofosbuvir/velpatasvir, and\\nsofosbuvir/velpatasvir/voxilaprevir may\\nhave their plasma concentrations\\naffected by EFV. The combination of\\nthese medications with EFV is either\\ncontraindicated or not recommended due\\nto potential loss of therapeutic effect\\nor increased risk of adverse reactions.\\n- Darunavir, when boosted with\\nritonavir, may increase tenofovir\\nlevels. Monitor patients for TDF-\\nassociated adverse reactions and\\ndiscontinue ATRIPLA in patients who\\ndevelop such reactions. Do not use once\\ndaily administration of\\nlopinavir/ritonavir when coadministered\\nwith EFV.    - Tenofovir levels may\\nincrease when coadministered with\\nlopinavir/ritonavir, which may lead to\\nincreased risk of adverse reactions. Do\\nnot use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for\\nall patients when coadministered with\\nEFV.    - When coadministered with\\nritonavir-boosted darunavir, tenofovir\\nlevels may increase, which may lead to\\nincreased risk of adverse reactions.\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions and discontinue ATRIPLA in\\npatients who develop such reactions.  8.\\nThe document also mentions that the\\npotential exists for reduction in plasma\\nconcentrations of other drugs\\nmetabolized by CYP3A, but specific\\nexamples are not provided. Dose\\nadjustments should be guided by clinical\\nresponse (refer to the full prescribing\\ninformation for the affected drug)."},"renderers":[{"id":"p1305"}],"index":56}},{"type":"object","name":"LegendItem","id":"p1328","attributes":{"label":{"type":"value","value":"The provided text appears to be a series\\nof tables and notes from clinical trials\\ncomparing the effects of two\\nantiretroviral drugs, ISENTRESS (400 mg\\ntwice daily) and Efavirenz (600 mg at\\nbedtime), on various parameters such as\\nviral load, liver function tests, lipid\\nlevels, and creatine phosphokinase.\\nKey findings include:     1. At 240\\nweeks, a higher percentage of subjects\\ntaking ISENTRESS had HIV-1 RNA less than\\n50 copies/mL compared to those taking\\nEfavirenz (66% vs 60%, respectively).\\n2. The incidence of ALT (\\u22655.0 x ULN) and\\nAST (\\u22655.0 x ULN) was similar in both\\ngroups (2% for ISENTRESS and 2% for\\nEfavirenz, and 3% for both drugs,\\nrespectively).     3. The incidence of\\ncreatine phosphokinase (\\u226510.0 x ULN) was\\nhigher in the ISENTRESS group compared\\nto the Efavirenz group (15% vs 14%,\\nrespectively).     4. The incidence of\\nlipase (\\u22653.0 x ULN) and creatinine (&gt;1.8\\nx ULN or increase to \\u22651.5 x baseline)\\nwas similar in both groups (3% for each\\nparameter in both groups).\\nAdditionally, changes from baseline to\\nMonth 15 in total cholesterol, HDL\\ncholesterol, LDL cholesterol,\\ntriglycerides, and total cholesterol to\\nHDL ratio were presented in another\\ntrial (HPTN 083 and HPTN 084), but the\\nspecific findings were not provided in\\nthe text.     Overall, these data\\nsuggest that ISENTRESS may be more\\neffective at reducing HIV-1 viral load\\ncompared to Efavirenz, but with a higher\\nincidence of creatine phosphokinase\\nelevations. The impact on liver function\\ntests and lipid levels appears to be\\nsimilar between the two drugs."},"renderers":[{"id":"p1305"}],"index":227}},{"type":"object","name":"LegendItem","id":"p1329","attributes":{"label":{"type":"value","value":"The provided text appears to be a table\\nof pharmacokinetic data for various\\nantiviral drugs, including protease\\ninhibitors (e.g., Atazanavir), integrase\\ninhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g.,\\nSofosbuvir/Velpatasvir). The table shows\\nthe changes in pharmacokinetic\\nparameters for each drug when\\ncoadministered with Efavirenz (EFV), a\\nnon-nucleoside reverse transcriptase\\ninhibitor.     The data includes the\\nmean percentage change of various\\npharmacokinetic parameters, such as AUC\\n(Area Under the Curve) and Cmax (Maximum\\nConcentration), for each drug when\\ncoadministered with EFV at different\\ndoses. Some drugs show increased\\nconcentrations (e.g.,\\nSofosbuvir/Velpatasvir), while others\\nshow decreased concentrations (e.g.,\\nTipranavir/Ritonavir).     The table\\nalso includes the dose of each drug and\\nEFV, as well as any additional\\ninformation such as meal requirements or\\nduration of administration. It is\\nimportant to note that all interaction\\ntrials were conducted in healthy\\nvolunteers.     This data can be useful\\nfor pharmacists, physicians, and other\\nhealthcare professionals when\\nprescribing these drugs to patients, as\\nit helps them understand potential drug\\ninteractions and adjust dosages\\naccordingly to ensure safe and effective\\ntreatment."},"renderers":[{"id":"p1305"}],"index":108}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p1399","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p1335","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1344","attributes":{"start":0.07415413856506348,"end":12.280063152313232}},"y_range":{"type":"object","name":"Range1d","id":"p1345","attributes":{"start":-1.5933003723621368,"end":10.915313482284546}},"x_scale":{"type":"object","name":"LinearScale","id":"p1346"},"y_scale":{"type":"object","name":"LinearScale","id":"p1347"},"title":{"type":"object","name":"Title","id":"p1342","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1374","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1331","attributes":{"selected":{"type":"object","name":"Selection","id":"p1332","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1333"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"5e/SQAY/RUA5KLVAZJ8UQAXuf0A="},"shape":[5],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"cnLsPxzazj+4FPRAOEf2P9UcBEE="},"shape":[5],"dtype":"float32","order":"little"}],["topic",["ATRIPLA Warnings and Side Effects","Others","APRETUDE for HIV-1 PrEP","The provided text appears to be a table of pharmacokinetic data for\\nvarious antiviral drugs, including protease inhibitors (e.g.,\\nAtazanavir), integrase inhibitors (e.g., Simeprevir), and NS5A\\ninhibitors (e.g., Sofosbuvir/Velpatasvir). The table shows the changes\\nin pharmacokinetic parameters for each drug when coadministered with\\nEfavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor.\\nThe data includes the mean percentage change of various\\npharmacokinetic parameters, such as AUC (Area Under the Curve) and\\nCmax (Maximum Concentration), for each drug when coadministered with\\nEFV at different doses. Some drugs show increased concentrations\\n(e.g., Sofosbuvir/Velpatasvir), while others show decreased\\nconcentrations (e.g., Tipranavir/Ritonavir).     The table also\\nincludes the dose of each drug and EFV, as well as any additional\\ninformation such as meal requirements or duration of administration.\\nIt is important to note that all interaction trials were conducted in\\nhealthy volunteers.     This data can be useful for pharmacists,\\nphysicians, and other healthcare professionals when prescribing these\\ndrugs to patients, as it helps them understand potential drug\\ninteractions and adjust dosages accordingly to ensure safe and\\neffective treatment.","APRETUDE HIV-1 PrEP Injection Schedule"]],["correctness",[false,true,false,false,true]],["questions",["For which condition should patients be closely monitored after discontinuing ATRIPLA?","Can you tell me which medications are known to interact with Efavirenz, specifically in terms of changes in pharmacokinetic parameters for coadministered drugs?","In what circumstances would an additional HIV testing be necessary for a person who has a history of injection drug use and is currently on methadone treatment?","In the context you provided, are there any drugs for which dosing instructions have been given?","How long before or after the initiation injection should APRETUDE be administered and what is the frequency of the intramuscular (Gluteal) injections during the continuation phase of treatment with APRETUD?"]],["agent_answer",["Patients should be closely monitored for hepatic function after discontinuing ATRIPLA, especially those who are coinfected with HIV-1 and HBV. This monitoring should include both clinical and laboratory follow-up for at least several months.","Based on the information provided:\\n\\nThe following medications are known to interact with Efavirenz **(EFV)** in terms of changes in pharmacokinetic parameters for coadministered drugs:\\n\\n1. **Atazanavir**  \\n   - When coadministered with EFV, there was a **decrease** in Atazanavir&#x27;s pharmacokinetic parameters:  \\n     - C\\u2098\\u2090\\u20b5 \\u2193 59%  \\n     - AUC \\u2193 74%  \\n     - C\\u2098\\u1d62\\u2099 \\u2193 93%  \\n\\n2. **Atazanavir/ritonavir**  \\n   - When combined with EFV, there was an **increase** in pharmacokinetic parameters for Atazanavir:  \\n     - C\\u2098\\u2090\\u20b5 \\u2191 14%  \\n     - AUC \\u2191 39%  \\n     - C\\u2098\\u1d62\\u2099 \\u2191 48%  \\n\\n3. **Lopinavir/ritonavir**  \\n   - EFV was studied in parallel with Lopinavir/ritonavir, though specific values were not shown. It is noted that there is an interaction, and further data may be necessary to determine the full significance.\\n\\nThese interactions show that Efavirenz has notable effects on the pharmacokinetics of coadministered drugs, depending on the combination (decreasing or increasing levels). This should be carefully considered in clinical practice to avoid subtherapeutic or toxic effects.","For a person with a history of injection drug use and currently on methadone treatment who is taking APRETUDE, additional HIV testing would be necessary in the following circumstances:\\n\\n1. Before each injection of APRETUDE, to confirm HIV-1 negative status.\\n2. Upon diagnosis of any other sexually transmitted infection (STI).\\n3. If there is a missed injection or a potential lapse in adherence, reassessing the risk of HIV-1 acquisition and testing may be warranted.\\n4. After discontinuation of APRETUDE, given the residual concentrations of cabotegravir that may remain in the systemic circulation for up to 12 months or longer.\\n\\nHealthcare providers should also emphasize adherence to the recommended dosing and testing schedule while providing counseling, especially for those who may need additional support in managing their health effectively.","Yes, in the context provided, dosing instructions have been given for ISENTRESS. Specifically:\\n\\n1. **ISENTRESS (raltegravir) film-coated tablets, chewable tablets, and oral suspension**:\\n   - For **patients who miss a dose**, they should take it as soon as they remember unless it is almost time for the next dose, in which case they should skip the missed dose and return to the regular schedule. Double-dosing is not recommended.\\n   - **Chewable tablets** can either be chewed or swallowed whole, whereas **film-coated tablets** must be swallowed whole.\\n   - For the **oral suspension**, parents and/or caregivers are instructed to administer it within 30 minutes of mixing and to read the Instructions for Use prior to administration, especially when given to pediatric patients.\\n\\nThese instructions are specific to ISENTRESS and ensure patients and caregivers use the medication safely and effectively.","APRETUDE can be administered up to 7 days before or after the initiation injection date. During the continuation phase of treatment, the frequency of intramuscular (Gluteal) injections is every 2 months."]],["reference_answer",["Patients who are coinfected with HIV-1 and HBV should be closely monitored for severe acute exacerbations of hepatitis, particularly for several months after stopping ATRIPLA.","The given context does not provide information about the shipping destination range.","Additional HIV testing is needed if an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent with acute HIV-1 infection develop following an exposure event.","The context provides dosing instructions for Indinavir, Lopinavir/ritonavir, Nelfinavir, and Ritonavir.","APRETUDE can be given up to 7 days before or after the initiation injection, and the continuation injection for APRETUDE is given every 2 months onwards after the initiation injection."]],["id",[152,107,212,109,197]],["content",["sides. Each bottle contains 30 tablets and silica gel desiccant, and is closed with a child-\\nresistant closure.\\nStore below 30 \\u00b0C (86 \\u00b0F).\\nKeep container tightly closed.\\nDispense only in original container.\\n17 PATIENT COUNSELING INFORMATION\\nAdvise the patient to read the approved patient labeling (Patient Information).\\nSevere Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV\\nInform patients that severe acute exacerbations of hepatitis B have been reported in\\npatients wh...","NA = not available\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\nCarbamazepine\\n200 mg qd \\u00d7 3\\ndays, 200 mg bid\\n\\u00d7 3 days, then\\n400 mg qd \\u00d7 15\\ndays\\n600 mg\\nqd \\u00d7 35\\ndays\\n14\\n\\u2193 21\\n(\\u2193 15 to\\n\\u2193 26)\\n\\u2193 36\\n(\\u2193 32 to\\n\\u2193 40)\\n\\u2193 47\\n(\\u2193 41 to\\n\\u2193 53)\\nDiltiazem\\n240 mg \\u00d7 14\\ndays\\n600 mg\\nqd \\u00d7 28\\ndays\\n12\\n\\u2191 16\\n(\\u2191 6 to \\u2191\\n26)\\n\\u2191 11\\n(\\u2191 5 to \\u2191\\n18)\\n\\u2191 13\\n(\\u2191 1 to \\u2191\\n26)\\nVoriconazole\\n400 mg po q12h\\n\\u00d7 1 day then 200\\nmg po q12h \\u00d7 8\\ndays\\n400 mg\\nqd \\u00d7 9\\ndays\\nNA\\n\\u2191 38\\n\\u2191 44\\nNA\\n300 mg po q12h\\ndays 2\\u20137\\n300 mg\\nqd \\u00d7 7\\ndays\\nNA\\n\\u2193 14\\n \\n(\\u2193 7 to \\u2193\\n21)\\n\\u2194\\nNA\\n400 mg po q12h\\ndays 2\\u20137\\n300 m...","consistent with acute HIV-1 infection (e.g., fever, fatigue, myalgia, skin rash).\\nIf recent (&lt;1 month) exposures to HIV-1 are suspected or clinical symptoms\\nconsistent with acute HIV-1 infection are present, use a test approved or cleared\\nby the FDA as an aid in the diagnosis of acute or primary HIV-1 infection.\\nIf an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent with\\nacute HIV-1 infection develop following an exposure event, additional HIV testing to\\ndetermine HIV sta...","meal\\n7\\u201320\\n300 mg\\nqd/ritonavir 100\\nmg qd d 1\\u201310\\n(pm), then 400\\nmg qd/ritonavir\\n100 mg qd d 11\\u2013\\n24 (pm)\\n(simultaneous\\nwith EFV)\\n600 mg qd\\nwith a light\\nsnack d\\n11\\u201324 (pm)\\n14\\n\\u2191 17\\n(\\u2191 8 to \\u2191\\n27)\\n\\u2194\\n\\u2193 42\\n(\\u2193 31 to\\n\\u2193 51)\\nIndinavir\\n1000 mg q8h \\u00d7\\n10 days\\n600 mg qd\\n\\u00d7 10 days\\n20\\nAfter morning dose\\n\\u2194\\n\\u2193 33\\n \\n(\\u2193 26 to\\n\\u2193 39)\\n\\u2193 39\\n \\n(\\u2193 24 to\\n\\u2193 51)\\nAfter afternoon dose\\n\\u2194\\n\\u2193 37\\n \\n(\\u2193 26 to\\n\\u2193 46)\\n\\u2193 52\\n \\n(\\u2193 47 to\\n\\u2193 57)\\nAfter evening dose\\n\\u2193 29\\n \\n(\\u2193 11 to\\n\\u2193 43)\\n\\u2193 46\\n \\n(\\u2193 37 to\\n\\u2193 54)\\n\\u2193 57\\n \\n(\\u2193 50 to\\n\\u2193 63)\\nLopinavir/ritona...","Should be administered on the last day of oral lead-in or within 3 days thereafter.\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\nis scheduled to receive the injections.\\nOral Lead-In \\n(at Least 28 Days)\\n(Month Prior \\nto Starting Injections)\\nIntramuscular (Gluteal)\\n \\nInitiation Injection \\n(Month 1 and Month 2)\\nIntramuscular (Gluteal)\\nContinuation Injection \\n(Month 4 and \\nEvery 2 Months\\nOnwards)\\nOral cabotegravir 30 mg by\\nmouth once daily for 28 days\\nAPRET..."]],["color",["#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#0a980a"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1375","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1376"}}},"glyph":{"type":"object","name":"Scatter","id":"p1371","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1372","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1373","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1389","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1380","attributes":{"selected":{"type":"object","name":"Selection","id":"p1381","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1382"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[460],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[460],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1390","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1391"}}},"glyph":{"type":"object","name":"Scatter","id":"p1386","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1387","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1388","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1343","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p1358"},{"type":"object","name":"WheelZoomTool","id":"p1359","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1360","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1361","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1366"},{"type":"object","name":"SaveTool","id":"p1367"},{"type":"object","name":"HoverTool","id":"p1334","attributes":{"renderers":[{"id":"p1374"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1353","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1354","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1355"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1356"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1348","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1349","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1350"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1351"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1352","attributes":{"axis":{"id":"p1348"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1357","attributes":{"dimension":1,"axis":{"id":"p1353"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1377","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1378","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p1374"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1379","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p1374"}],"index":1}}]}},{"type":"object","name":"LabelSet","id":"p1395","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p1392","attributes":{"selected":{"type":"object","name":"Selection","id":"p1393","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1394"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"utyVP+rYtj+DBk5AkOq8QBWiCEBm11BAYyOXQEUod0AumyFAMffBQIJvtUAE1KdAL6uBQH6RlEDg861ASZLVQKDFgkBrP0ZAY6LoQIv4uEAEi9lA"},"shape":[21],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"WRXIQD7Ni0AFPOBAyzBNQPm+BkGHKLFA6yaeQP21rT/qCwFAVx2fQEbYxEBjUedArtYBQXzx70BLZwBBBd+HQGf5PUBqX2RAlLNPQOegxj+VXsU/"},"shape":[21],"dtype":"float32","order":"little"}],["topic",["ISENTRESS Drug Information","Raltegravir Pharmacokinetics","HIV Treatment and Administration","Antiretroviral Therapy Side Effects","Medication Administration Instructions","Cabotegravir Pharmacokinetics and Interactions","Pharmaceutical Trials","The provided document contains information about drug-drug interactions involving a medication called EFV (Efavirenz). Here are some key points regarding the interaction of EFV with other drugs:\\n\\n1. EFV can decrease the plasma concentrations of certain calcium channel blockers, which may affect their clinical response. Dose adjustments should be guided by clinical response.\\n\\n2. The plasma concentrations of HMG-CoA reductase inhibitors (statins) such as atorvastatin, pravastatin, and simvastatin decreased with EFV. Consult the Full Prescribing Information for the statins.\\n\\n3. Methadone maintenance doses between 35-100 mg daily for 14-21 days may be affected by EFV, with a potential decrease in methadone levels (by 25% to 59%).\\n\\n4. Bupropion, a medication used to treat depression and smoking cessation, may also have its levels decreased when coadministered with EFV. The hydroxybupropion level may increase, but the clinical significance is not known.\\n\\n5. Sertraline, an antidepressant, may have its plasma concentrations decreased by EFV, potentially leading to reduced sertraline levels (by 29% to 40%).\\n\\n6. Voriconazole, an antifungal medication, may have its plasma concentrations decreased when coadministered with EFV. The clinical significance is not known.\\n\\n7. Several antiviral medications interact with EFV in various ways:\\n   - Boceprevir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, simeprevir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir may have their plasma concentrations affected by EFV. The combination of these medications with EFV is either contraindicated or not recommended due to potential loss of therapeutic effect or increased risk of adverse reactions.\\n   - Darunavir, when boosted with ritonavir, may increase tenofovir levels. Monitor patients for TDF-associated adverse reactions and discontinue ATRIPLA in patients who develop such reactions. Do not use once daily administration of lopinavir/ritonavir when coadministered with EFV.\\n   - Tenofovir levels may increase when coadministered with lopinavir/ritonavir, which may lead to increased risk of adverse reactions. Do not use once daily administration of lopinavir/ritonavir. Dose increase of lopinavir/ritonavir is recommended for all patients when coadministered with EFV.\\n   - When coadministered with ritonavir-boosted darunavir, tenofovir levels may increase, which may lead to increased risk of adverse reactions. Monitor patients receiving ATRIPLA concomitantly with ritonavir-boosted darunavir for TDF-associated adverse reactions and discontinue ATRIPLA in patients who develop such reactions.\\n\\n8. The document also mentions that the potential exists for reduction in plasma concentrations of other drugs metabolized by CYP3A, but specific examples are not provided. Dose adjustments should be guided by clinical response (refer to the full prescribing information for the affected drug).","The provided text appears to be a table of pharmacokinetic data for various antiviral drugs, including protease inhibitors (e.g., Atazanavir), integrase inhibitors (e.g., Simeprevir), and NS5A inhibitors (e.g., Sofosbuvir/Velpatasvir). The table shows the changes in pharmacokinetic parameters for each drug when coadministered with Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor.\\n\\n   The data includes the mean percentage change of various pharmacokinetic parameters, such as AUC (Area Under the Curve) and Cmax (Maximum Concentration), for each drug when coadministered with EFV at different doses. Some drugs show increased concentrations (e.g., Sofosbuvir/Velpatasvir), while others show decreased concentrations (e.g., Tipranavir/Ritonavir).\\n\\n   The table also includes the dose of each drug and EFV, as well as any additional information such as meal requirements or duration of administration. It is important to note that all interaction trials were conducted in healthy volunteers.\\n\\n   This data can be useful for pharmacists, physicians, and other healthcare professionals when prescribing these drugs to patients, as it helps them understand potential drug interactions and adjust dosages accordingly to ensure safe and effective treatment.","The provided text appears to be a series of tables and notes from clinical trials comparing the effects of two antiretroviral drugs, ISENTRESS (400 mg twice daily) and Efavirenz (600 mg at bedtime), on various parameters such as viral load, liver function tests, lipid levels, and creatine phosphokinase.\\n\\n   Key findings include:\\n\\n   1. At 240 weeks, a higher percentage of subjects taking ISENTRESS had HIV-1 RNA less than 50 copies/mL compared to those taking Efavirenz (66% vs 60%, respectively).\\n\\n   2. The incidence of ALT (\\u22655.0 x ULN) and AST (\\u22655.0 x ULN) was similar in both groups (2% for ISENTRESS and 2% for Efavirenz, and 3% for both drugs, respectively).\\n\\n   3. The incidence of creatine phosphokinase (\\u226510.0 x ULN) was higher in the ISENTRESS group compared to the Efavirenz group (15% vs 14%, respectively).\\n\\n   4. The incidence of lipase (\\u22653.0 x ULN) and creatinine (&gt;1.8 x ULN or increase to \\u22651.5 x baseline) was similar in both groups (3% for each parameter in both groups).\\n\\n   Additionally, changes from baseline to Month 15 in total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and total cholesterol to HDL ratio were presented in another trial (HPTN 083 and HPTN 084), but the specific findings were not provided in the text.\\n\\n   Overall, these data suggest that ISENTRESS may be more effective at reducing HIV-1 viral load compared to Efavirenz, but with a higher incidence of creatine phosphokinase elevations. The impact on liver function tests and lipid levels appears to be similar between the two drugs.","HIV Prevention Trials","APRETUDE Drug Information","APRETUDE HIV-1 PrEP Injection Schedule","HIV Pre-Exposure Prophylaxis (PrEP) with APRETUDE","APRETUDE for HIV-1 PrEP","HIV Treatment Side Effects","Antiretroviral Therapy (ART) and Birth Defects","Antiretroviral Resistance","Antiretroviral Therapy Side Effects","ATRIPLA Drug Information","ATRIPLA Warnings and Side Effects"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"2ef2386e-ee33-4b8c-8607-2fc0dc12e15d","roots":{"p1400":"a7ca47ce-8903-4e6b-b1a3-d20caf40d63a"},"root_ids":["p1400"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="a7ca47ce-8903-4e6b-b1a3-d20caf40d63a" data-root-id="p1400" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
